


Draft

Acute Exposure Guideline Levels (AEGLs)

for

Styrene
(CAS Reg. No. 100-42-5)



All individuals and organizations in attendance at the NAC/AEGL meeting on September, 16th – 18th, 2003, interested in submitting comments/information regarding the above chemical should send hard copies to

Tobin, Ph. D.

Designated Federal Officer

National Advisory Committee/AEGL

U.S. Environmental Protection Agency

Mail Stop: 7406 M

1200 Pennsylvania Avenue N.W

Washington, D.C. 20460

Phone: (202)564-8557; Fax: (202)564-8679;

E-Mail: TOBIN.PAUL@EPAMAIL.EPA.GOV

Acute Exposure Guideline Levels (AEGLs)

for Styrene

August 2003

Draft

Staff Scientist:

Jens-Uwe Voss (Toxicological Consultant)

Phone: +49 (7631) 798477 fax: +49 (7631) 798476 E-mail: jens-uwe.voss@t-online.de

Chemical Manager in German Toxicological Expert Group on AEGL:

Hans-Uwe Wolf (Universität Ulm)

Phone +49 (731) 502-3290 fax: +49 (731) 502-2309 E-mail: hans-uwe.wolf@medizin.uni-ulm.de

Industry Reviewer for German Toxicological Expert Group on AEGL:

Rudolf Jäckh (BASF AG)

Phone +49 (621) 6056716 fax: +49 (621) 6051734 E-mail: rudolf.jaekch@basf-ag.de

Chemical Reviewer:

N.N.

Phone +1 fax: +1 E-mail: @

PREFACE

Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic chemicals.

AEGLs represent threshold exposure limits for the general public and are applicable to emergency exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the recommended exposure levels are applicable to the general population including infants and children, and other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows:

AEGL-1 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure.

AEGL-2 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects, or an impaired ability to escape.

AEGL-3 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening health effects or death.

Airborne concentrations below the AEGL-1 represent exposure levels that could produce mild and progressively increasing odor, taste, and sensory irritation, or certain asymptomatic, non-sensory effects. With increasing airborne concentrations above each AEGL level, there is a progressive increase in the likelihood of occurrence and the severity of effects described for each corresponding AEGL level. Although the AEGL values represent threshold levels for the general public, including sensitive subpopulations, it is recognized that certain individuals, subject to unique or idiosyncratic responses, could experience the effects described at concentrations below the corresponding AEGL level.

TABLE OF CONTENTS

PREFACE	III
EXECUTIVE SUMMARY	VII
1 INTRODUCTION.....	1
2 HUMAN TOXICITY DATA.....	3
2.1 Acute Lethality	3
2.2 Nonlethal Toxicity	3
2.2.1 Case Reports	3
2.2.2 Occupational exposure.....	4
2.2.3 Experimental Studies	5
2.3 Developmental/Reproductive Toxicity.....	13
2.4 Genotoxicity.....	13
2.5 Carcinogenicity.....	14
2.6 Summary.....	14
3 ANIMAL TOXICITY DATA.....	16
3.1 Acute Lethality	16
3.1.1 Rats	17
3.1.2 Mice	21
3.1.3 Guinea pigs	23
3.1.4 Hamsters.....	23
3.2 Nonlethal Toxicity	23
3.2.1 Nonhuman primates	23
3.2.2 Rats	23
3.2.3 Mice	27
3.2.4 Guinea pigs	29
3.2.5 Rabbits	29
3.3 Developmental/Reproductive Toxicity.....	29
3.3.1 Rats	29
3.3.2 Mice	31
3.3.3 Rabbits	31
3.3.4 Hamsters.....	31
3.4 Genotoxicity.....	31
3.5 Carcinogenicity.....	33
3.6 Summary.....	37
4 SPECIAL CONSIDERATIONS.....	40
4.1 Toxicokinetics.....	40
4.2 Mechanism of Toxicity	47
4.3 Other relevant information.....	47
4.3.1 PBPK-Modelling.....	47
4.3.2 Species variability	48
4.3.3 Susceptible populations.....	48
4.3.4 Concurrent exposure issues.....	48
5 DATA ANALYSIS AND PROPOSED AEGL-1	49
5.1 Summary of Human Data Relevant to AEGL-1	49

5.2	Summary of Animal Data Relevant to AEGL-1	49
5.3	Derivation of AEGL-1	49
6	DATA ANALYSIS AND PROPOSED AEGL-2	50
6.1	Summary of Human Data Relevant to AEGL-2	50
6.2	Summary of Animal Data Relevant to AEGL-2	51
6.3	Derivation of AEGL-2	52
7	DATA ANALYSIS AND PROPOSED AEGL-3	54
7.1	Summary of Human Data Relevant to AEGL-3	54
7.2	Summary of Animal Data Relevant to AEGL-3	54
7.3	Derivation of AEGL-3	55
8	SUMMARY OF PROPOSED AEGLS	56
8.1	AEGL Values and Toxicity Endpoints	56
8.2	Comparison with Other Standards and Guidelines	58
8.3	Data Adequacy and Research Needs	60
9	REFERENCES	60
	APPENDIX A: DERIVATION OF AEGL VALUES	71
	APPENDIX B: DERIVATION OF EXPONENTIAL FUNCTION FOR TEMPORAL SCALING....	75
	APPENDIX C: BENCHMARK CALCULATIONS FOR STYRENE	77
	APPENDIX D: DERIVATION SUMMARY FOR STYRENE AEGLS	81
	APPENDIX E: DERIVATION OF THE LEVEL OF DISTINCT ODOR AWARENESS FOR STYRENE	85

LIST OF TABLES

TABLE 1: CHEMICAL AND PHYSICAL PROPERTIES	2
TABLE 2: SUMMARY OF ACUTE NON-LETHAL EFFECTS IN CONTROLLED HUMAN STUDIES FOLLOWING INHALATION OF STYRENE	9
TABLE 3: SUMMARY OF LETHAL EFFECTS IN ANIMALS AFTER ACUTE INHALATION EXPOSURE TO STYRENE.....	18
TABLE 4: SUMMARY OF ACUTE NON-LETHAL EFFECTS IN ANIMALS AFTER INHALATION EXPOSURE TO STYRENE.....	25
TABLE 5: SUMMARY OF RESULTS ON STUDIES OF CANCER IN RATS TREATED WITH STYRENE *	34
TABLE 6: SUMMARY OF RESULTS ON STUDIES OF CANCER IN MICE TREATED WITH STYRENE *	36

TABLE 7: EXPOSURE CONCENTRATIONS AND BLOOD LEVEL OF STYRENE IN HUMANS AND RATS.....	43
TABLE 8: AEGL-1 VALUES FOR STYRENE	50
TABLE 9: AEGL-2 VALUES FOR STYRENE	54
TABLE 10: AEGL-3 VALUES FOR STYRENE	56
TABLE 11: SUMMARY/RELATIONSHIP OF PROPOSED AEGL VALUES ^a	56
TABLE 12: EXTANT STANDARDS AND GUIDELINES FOR STYRENE	58

LIST OF FIGURES

FIGURE 1: SYMPTOM RATINGS AT OR AFTER ACUTE EXPOSURE OF HUMANS TO STYRENE	8
FIGURE 2: CONCENTRATION-RESPONSE CURVE FOR ACUTE LETHALITY FOLLOWING INHALATION OF STYRENE IN RATS	17
FIGURE 3: STYRENE CONCENTRATION IN ARTERIAL BLOOD OF HUMANS DURING AND AFTER A 2-HOUR EXPOSURE TO 69 PPM STYRENE IN AIR	41
FIGURE 4: OBSERVED (CIRCLES) AND SIMULATED CONCENTRATIONS OF STYRENE IN ARTERIALIZED CAPILLARY BLOOD FROM TWO HUMAN VOLUNTEERS	41
FIGURE 5: STYRENE CONCENTRATION IN BLOOD OF RATS DURING A 5-HOUR EXPOSURE TO DIFFERENT CONCENTRATIONS OF STYRENE IN AIR	42
FIGURE 6: PATHWAYS FOR THE METABOLISM OF STYRENE IN HUMANS AND RODENTS.....	46
FIGURE 7: CATEGORICAL REPRESENTATION OF STYRENE INHALATION DATA.....	57

EXECUTIVE SUMMARY

Styrene is a colorless or slightly yellow, viscous liquid, soluble in ethanol, benzene and petroleum ether and slightly soluble in water. Owing to its volatility, low flash point, and the range of explosive limits in air (lower: 1.1 %, upper: 6.3 % v/v), styrene poses an acute fire and explosion hazard. Due to its tendency to polymerize at room temperature in the presence of oxygen and to oxidize on exposure to light and air, styrene is normally stabilized by the addition of < 0.006 - 0.01% w/w tertiary butylcatechol (4-tert-butylbenzene-1,2-diol) as an inhibitor. Styrene is one of the most important monomers in industry worldwide. It is predominantly used for the production of polymers (polystyrene and copolymers of styrene with acrylonitrile and/or butadiene). Worldwide production reached 17 945 thousand tonnes in 1998.

In humans, the effects associated with acute exposure to styrene are irritation of eyes and mucous membranes and central nervous system (CNS) depression. In contrast to observations made in animal studies (see below), no pulmonary effects were described in controlled studies during or after single or subacute exposures. Also, limited data in humans provide no evidence that (occupational) styrene exposure causes lesions of the nasal epithelia or decrements in olfactory function (Dalton et al. 2003; Ödkvist et al. 1985). No data were available indicating reproductive or developmental effects of styrene in humans following acute exposure. Epidemiological studies revealed no sound evidence for an association between repeated occupational exposure to styrene and reproductive or developmental effects. Genotoxicity (chromosomal aberrations (CA), sister chromatid exchange (SCE), micronuclei) was observed in human cells *in vitro*. *In vivo*, no data were available with respect to genotoxicity following acute exposure of humans to styrene. In epidemiological studies on workers, evidence between occupational exposure to styrene and genotoxic effects (CA, SCE, gene mutations, DNA single-strand breaks) including formation of DNA-adduct were observed. With respect to carcinogenicity in humans, in its latest evaluation IARC (2002) concluded that the increased risks for cancers in epidemiological studies were small and statistically unstable, that the findings were not very robust, and chance, bias or confounding could not be ruled out.

Animal studies were mostly carried out with rats and mice, limited data are available for guinea pigs, hamsters and an unspecified species of monkeys. As in humans, irritation and CNS effects are also observed in animals following acute inhalation exposure. In mice, RD₅₀ values for sensory irritation of 156 ppm (3 minutes of exposure), 586 ppm (5 minutes), and 980 ppm (10 minutes) were reported (Alarie 1973; Bos et al. 1992; de Ceaurriz et al. 1981). Signs indicating irritation, e.g., closed eyes, salivation, rubbing of paws and chin, were also reported in toxicity studies with rats at concentrations as low as 200 ppm (Cruzan et al. 1997b, 1998). Immediate irritation in rats was noted at 1300 ppm (Spencer et al. 1942). CNS-depression in rats and mice was observed at higher concentrations. Rats lost consciousness at 2000 ppm after 5 hours of exposure (Withey and Collins 1979) and showed reduced attention at 6-hour exposures to 1500 ppm (Jarry et al. 2002). In mice, signs of CNS depression during a 4-hour exposure were staggered gait at 1420 ppm and apathy and finally narcosis at higher concentrations of 2983 and 3766 ppm (BASF 1979a). In rats, death was observed when animals were exposed for 4 hours to 4814 ppm and higher concentrations (BASF 1979b). Death was mostly rapid due to CNS depression but some delayed deaths with signs of pulmonary lesions were observed in rats at high concentrations causing severe CNS effects. Mice were much more sensitive than rats (and, based on a limited number of data, guinea pigs and monkeys). Death of mice was observed following a single 6-hour exposure to 250 ppm (Sumner et al. 1997) or 500 ppm (Morgan et al. 1993c). Also, at these concentrations, respiratory toxicity with lesions of the respiratory and olfactory epithelia in the nasal passages and of the bronchioles were observed in mice but not in rats.

With respect to developmental or reproductive effects, no embryo-/fetotoxicity or malformations were observed in rats after a single oral treatment on the 11th or 17th day of gestation,

respectively. In mice, decreased postnatal survival was observed after single oral administration of a maternally toxic dose on day 17 of gestation, while no effect was noted at a lower dose. Following repeated exposure of rats through gestation day 6 – 20 to 300 ppm, an increased neonatal death rate and delayed postnatal development was observed compared to pair-fed controls. Fetotoxicity was also seen in hamsters exposed to 1000 ppm 6 hours/day from gestation day 6 -18, but not at 750 ppm. In other studies with repeated oral or inhalation exposure of rats, mice, and rabbits, no significant developmental effects were observed. Styrene is genotoxic *in vitro*, provided there is sufficient activation to styrene oxide (SO), and *in vivo*. Data from laboratory animals indicate that styrene exposure may lead to the formation of DNA-adducts, sister chromatid exchange, and chromosomal aberrations. With respect to carcinogenicity, no clear effect was observed in rats. In mice, an increase of lung tumors was observed. IARC (2002) recently has re-evaluated the data on carcinogenicity of styrene and concluded that there is “limited evidence” in experimental animals for the carcinogenicity of styrene. In the overall evaluation, it was concluded that styrene is “possibly carcinogenic to humans (Group 2B)” (IARC 2002). Styrene is being reassessed under the IRIS Program of the US-EPA, no quantitative carcinogenicity assessment for lifetime exposure is currently proposed (US EPA 1998). US-EPA’s Office of Research and Development has updated previous assessments on the carcinogenic potential of styrene and concluded that styrene is appropriately classified as a Group C, possible human carcinogen (US EPA 2003).

Styrene has a pungent, slightly sweetish odor and is irritating to eyes and mucous membranes at higher concentrations. The derivation of the level of distinct odor awareness (LOA) was based on results from human studies presented in the report of Van Doorn et al. (2002) and follows the guidance as described in the same report. The LOA represents the concentration above which it is predicted that more than half of the exposed population will experience at least a distinct odor intensity, while about 10 % of the population will experience a strong odor intensity. The LOA should help chemical emergency responders in assessing the public awareness of the exposure due to odor perception. For styrene, the calculated level of distinct odor awareness (LOA) is 0.54 ppm.

The AEGL-1 derivation is based on irritating effects of styrene in humans. In a study on psychological reactions related to chemosensory irritation, ratings for odor and annoyance increased similarly with increasing styrene concentrations ranging from 0.5 – 40 ppm, while there was only a marginal increase for irritation. Effects sizes comparing the ratings between exposure to 20 ppm and pre-exposure were higher for odor, irritation, and annoyance. Effects sizes were also higher compared to “clean air only”-exposure. However, the ratings for irritation indicated only marginal effects in this respect (Seeber et al. 2002). No increase in irritation or headaches compared to control was noted at 20 ppm in a further study (Hake et al. 1983). Subjective signs and symptoms of irritation and CNS effects were not negatively influenced during a 6-hour exposure at 25 ppm or 50 ppm or at 50 ppm with 4 peak exposures of 15 minutes at 100 ppm (Ska et al. 2003). At 50 ppm, a further study indicated a slight increase in subjective symptoms ratings for eye and nose irritation, headache, and fatigue (Oltamare et al. 1974). At 100 ppm, Oltamare et al. (1974) further reported that signs of irritation and of mild subjective CNS effects (headaches, fatigue, poor concentration, sleepiness) were felt more often than at 50 ppm. Complaints of mild eye and throat irritation at 99 ppm in one test but not in another at 116 ppm were reported by Stewart et al. (1968). Complaints of eye and nose irritation were frequent at about 200 ppm (Oltamare et al. 1974; Stewart et al. 1968).

A concentration of 20 ppm (Seeber et al. 2003) was selected to derive AEGL-1. Because this concentration represents a NOAEL for local (as well as CNS) effects and in other studies effects at 50 ppm and 100 ppm were only weak or absent, an intraspecies factor of 1 is applied. The value of 20 ppm was used for all timepoints since slight irritation and subjective discomfort that were reported at higher concentrations did not increase within several hours of exposure.

As explained in section 4.1, 4.3.2, 6.2, and 7.2, the AEGL-2 and AEGL-3 values will not be based on data from studies with mice. The derivation of AEGL-2 is based on human studies. Irritation and CNS effects have to be considered for the derivation of AEGL-2. Nasal and mild eye irritation were reported by volunteers exposed to 376 ppm (Stewart et al. 1968). In their study of styrene exposed workers, Götell et al. (1972) reported that they themselves suffered from immediate lacrymation and irritation of the nasopharynx when exposed to 300 – 400 ppm, and concentrations of 500 – 800 ppm caused irritation intolerable to the investigators within 1 or 2 minutes. Strong eye and nasal irritation was also reported by volunteers exposed to concentrations \geq 600 ppm (Carpenter et al. 1944; Wolf et al. 1956).

With respect to effects on the CNS, a 6-hour exposure at 50 ppm with 4 repeated 15-minute peaks at 100 ppm had no negative influence on performance to neuropsychological tests (Ska et al. 2003). At 99 ppm, intermittent difficulties in performing a modified Romberg test were observed in 3/6 subjects exposed for 7 hours with a 30-minute break in between. Other tests on coordination and on manual dexterity were normal, and no effects were noted at the end of exposure. No CNS effects were seen in another experiment with 116 ppm exposure for 2 hours or 216 ppm for 1 hour in the same study (Stewart et al. 1968). Headaches, but no effects on equilibrium and cognitive function tests were noted in male and female volunteers at repeated exposures to 100 and 125 ppm for at least one hour (Hake et al. 1983). Oltramare et al. (1974) noted that slight difficulties in balance performance at 50 – 200 ppm (1.5 hours), but there was no concentration-response, and slight difficulties in balance performance at 200 ppm (1 hour), but the variation of data was large. No effects on simple and choice reaction time was seen following exposure to 250 ppm for 30 minutes. However, when the concentration was raised to 350 ppm for 30 minutes directly afterwards, both simple and choice reaction time were increased (Gamberale and Hultengren 1974). More pronounced effects were observed during exposure to 376 ppm for one hour: One subject complained of nausea that persisted one hour after the end of exposure, 2 subjects had a feeling of being inebriated, 3 of 5 subjects exposed were unable to normally perform a modified Romberg test, and also 3 subjects had significant decrements in other tests of coordination and manual dexterity (Stewart et al. 1968). In a toxicokinetic study, 2 subjects were exposed to 386 ppm styrene for 2 hours while performing light physical exercise of 50 W (Löf and Johanson 1993). In that study, no information was presented as to the presence or absence of subjective or objective signs of intoxication or irritation. However, it may reasonably be assumed that no severe CNS effects will have occurred in such a study. At higher concentrations, the irritation becomes very strong (see above), and only one controlled study was located that was conducted at this level (Carpenter et al. 1944). In this study, 2 subjects exposed to 800 ppm for 4 hours suffered from listlessness, drowsiness, impairment of balance, and, after cessation of exposure, muscular weakness and unsteadiness with inertia and depression. A “steadiness test” measuring manual dexterity indicated a marked decreased of performance compared to pre-exposure level. Besides CNS-depression, the subjects complained of eye and throat irritation.

The AEGL-2 is based on the CNS effects observed in humans following exposure to 376 ppm for 1 hour: nausea in one subject; feeling of being inebriated in two, and inability to normally perform the modified Romberg test and significant decrements in other tests of coordination and manual dexterity in three of five subjects (Stewart et al. 1968). The effects described address a level of CNS depression that seems still below a level for an impairment of the ability to escape and therefore a concentration of 376 ppm is considered a NOAEL. However, this concentration also is close to concentrations causing intolerable irritation in humans that may limit the ability to escape and thus are above AEGL-2.

Generally, for volatile substances with CNS-depressant effects an intraspecies factor of 3 is applied to account for sensitive individuals because the effective concentration range does not differ more than 2-3fold between individuals. In case of styrene, it must be taken into account that physical activity has a marked effect on the uptake of styrene and its level in blood. In the studies used to derive AEGL-2, the subjects were at rest. In controlled studies, the observed increase of styrene in arterial blood at exposure to about 150 ppm styrene was approximately 3fold when the physical activity was increased from

rest to light exercise (50 W), 5fold at moderate exercise (100 W), and 10fold at heavy exercise (150 W) (Astrand 1975). Therefore, it could be argued that an intraspecies uncertainty factor of 10 to account for sensitive subgroups would be necessary to protect individuals at heavy physical exercise. Application of a factor of 10 would lead to a 1-hour AEGL-2 of 38 ppm and similar values at longer time periods. On the other hand, the following two points which indicate that a factor of 3 is justified, are believed to outweigh the above rationale. Firstly, due to physiological limitations, heavy physical exercise (150 W) cannot be performed continuously for longer periods of time. Therefore, it is unrealistic to consider an exposure scenario with heavy exercise for one or several hours. In contrast, light exercise (50 W) may be performed over a longer period of time. In this case, the increase of the styrene concentration in blood will be about 3fold which is within the range of an uncertainty factor of three. Secondly, an AEGL-2 value in the range of 38 ppm as mentioned above would be in conflict with styrene exposure data at occupational workplaces. At workplaces, such concentrations are or were frequently observed (IARC 2002) without workers showing signs of CNS depression that would have limited their ability to escape.

Therefore, an intraspecies uncertainty factor of 3 is considered adequate to protect sensitive subgroups including groups exposed to styrene during longer periods of light exercise. This leads to a value of 130 ppm as AEGL-2 for 1 hour.

This experimentally derived exposure value was scaled to shorter periods of time using the equation $c^n \times t = k$ (Ten Berge et al. 1986). As outlined in NRC (2001), a default of $n = 3$ for shorter periods of time (30 minutes and 10 minutes) was applied, due to the lack of suitable experimental data for deriving the concentration exponent. The “n” value of 1.2 used for calculations of AEGL-3 (see below) was not used for AEGL-2 for following reasons: Firstly, the exponent was derived from lethality studies in which delayed mortality was observed that was not related to narcotic effects on the CNS (which are relevant for AEGL-2) but probably to pulmonary lesions observed at these very high concentrations (in addition to CNS effects which are the major cause of death). Secondly, toxicokinetics at high exposure concentrations over several hours of exposures (as in the lethality studies) is different from that at lower concentrations for shorter time periods.

Toxicokinetic studies with humans exposed to styrene concentrations at 70 – 200 ppm show that most of the increase of the styrene concentration in blood is seen during the first 30 minutes of exposure and that there is no or very little increase at 1 – 3 hours at these concentrations. Therefore, no additional extrapolation is necessary and the AEGL-2 of 130 ppm derived for 1 hour is applied to longer periods of time.

The AEGL-3 values are derived from a lethality study with rats (BASF 1979b). In rats, exposure to high concentrations of styrene leads to progressive CNS depression with narcosis and, finally, death. Delayed deaths with pulmonary lesions were also described in acute studies with rats but only at concentrations leading to severe or lethal CNS effects. In humans, the acute effects on the CNS are also well known. However, no reports were identified describing lethal intoxication of humans following styrene exposure. Therefore, it is not known if the pulmonary lesions observed in rats may also occur in humans exposed to life-threatening or potentially lethal concentrations of styrene.

For a conservative approach, data from studies with rats taking into account delayed deaths with pulmonary lesions were taken to derive AEGL-3. From the data of the 4-hour exposure study of BASF (1979b), a benchmark calculation was performed with the lethality data using different models. A $BMDL_{05}$ for female rats of 3409 ppm (rounded to 3400 ppm) was used as a starting point to derive AEGL-3.

A total uncertainty factor of 10 was applied. This total factor may formally be split up into an interspecies factor of 3 and an intraspecies factor also of 3. For volatile solvents like styrene with a CNS-

depressant effect, an interspecies uncertainty factor of 3 has been applied in the derivation of AEGL for several substances. This is based on the similarity of effects manifested in rodents compared to humans. In case of styrene, limited data indicate no gross differences in the concentration of styrene in blood between rats and humans. According to a toxicokinetic model, at concentrations exceeding 200 ppm styrene in air, the non-steady-state concentration of styrene in blood of humans (calculated for 6 hours of exposure) will always be lower than that in blood of rats since (Ramsey and Andersen 1984). Styrene levels in human blood were in accordance with this model up to 376 ppm in air, however, no experimental human data are available for validation at higher concentrations.

An intraspecies uncertainty factor of 3 was applied to account for sensitive individuals since the threshold for CNS impairment is not expected to vary much among individuals. As in case of the derivation of AEGL-2, an intraspecies uncertainty factor of 3 is considered adequate to protect sensitive subgroups including groups exposed to styrene during longer periods of light exercise.

The experimentally derived exposure values were scaled to AEGL time frames using the equation $c^n \times t = k$ (Ten Berge et al. 1986). An exponent of $n = 1.2$ which was used for extrapolation to all time points was derived from the 4-hour and 6-hour LC₅₀ for rats obtained by BASF (1979b) and Bonnet et al..

Individual cases of respiratory sensitization to styrene were described. Taking into account the wide use of styrene both in industry and in do-it-yourself products, sensitization seems to be an exceptionally rare event. Although the risk of sensitization following a single exposure at AEGL is considered negligible, individuals already sensitized to styrene may not be able to tolerate styrene concentrations that are without effect in non-sensitized individuals and may not be protected by the AEGL developed for styrene in this TSD.

SUMMARY TABLE OF AEGL VALUES FOR STYRENE ^a						
Classification	10-Minute	30-Minute	1-Hour	4-Hour	8-Hour	Endpoint (Reference)
AEGL-1 (Nondisabling)	20 ppm (85 mg/m ³)	20 ppm (85 mg/m ³)	20 ppm (85 mg/m ³)	20 ppm (85 mg/m ³)	20 ppm (85 mg/m ³)	NOAEL for slight irritation (Seeber et al. 2002)
AEGL-2 (Disabling)	230 ppm (980 mg/m ³)	160 ppm (680 mg/m ³)	130 ppm (550 mg/m ³)	130 ppm (550 mg/m ³)	130 ppm (550 mg/m ³)	CNS effects in humans (Gamberale and Hultengren 1974; Stewart et al. 1968)
AEGL-3 (Lethality)	4800 ppm * (20,450 mg/m ³)	1900 ppm * (8090 mg/m ³)	1100 ppm (4690 mg/m ³)	340 ppm (1450 mg/m ³)	190 ppm (810 mg/m ³)	No lethality in rats (BASF 1979b)

a: Since liquid styrene is an eye irritant, eye contact must be avoided.

*: The lower explosive limit (LEL) of styrene in air is 1.1 % (11,000 ppm). The AEGL-3 value of 4800 ppm (20,450 mg/m³) for 10 minutes and the AEGL-3 value of 1900 ppm (8090 mg/m³) are higher than 1/10 of the LEL. Therefore, safety considerations against hazard of explosion must be taken into account.

References

BASF. 10-12-1979b. Bericht über die Bestimmung der akuten Inhalationstoxizität LC₅₀ von Styrol als Dampf bei 4stündiger Exposition an Sprague-Dawley-Ratten. Unveröffentlichte Untersuchung. [Report on the determination of the acute inhalation toxicity LC₅₀ of styrene as vapor at a 4-hour exposure in Sprague-Dawley rats. Unpublished study.] BASF AG, Ludwigshafen, Germany. [In German].

Gamberale, F. and M. Hultengren. 1974. Exposure to styrene. II. Psychological functions. *Work Environment and Health* 11: 86-93.

IARC. 2002. Some Traditional Herbal Medicines, some Mycotoxins, Naphthalene and Styrene. Summary of Data Reported and Evaluation. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans* 82, p. 437-550. IARC (International Agency for Research on Cancer), WHO (World Health Organization), Lyon, France.

Seeber, A., C. van Thriel, K. Haumann, E. Kiesswetter, M. Blaszkewicz, and K. Golka. 2002. Psychological reactions related to chemosensory irritation. *Int. Arch Occup. Environ Health* 75: 314-325.

Stewart, R.D., H.C. Dodd, E.D. Baretta, and A.W. Schaffer. 1968. Human exposure to styrene vapor. *Archives of Environmental Health* 16: 656-662.

US EPA. 2003. Technology Transfer Network Air Toxics Website. Styrene. Air Toxics Website. U.S. Environmental Protection Agency, Washington, DC. <http://www.epa.gov/ttn/atw/htlhf/styrene.htm>.

van Doorn, R., M.W. Ruijten, and T. van Harreveld. 2002. Guidance for the Application of Odor in Chemical Emergency Response. Version 2.1; August, 29., 2002. Presented at the NAC/AEGL-Meeting September 2002, Washington DC.

1 1 INTRODUCTION

2 Styrene is a colorless or slightly yellow, viscous liquid. It is slightly soluble in water, soluble in
3 ethanol and very soluble in benzene and petroleum ether. Due to its tendency to polymerize at room
4 temperature in the presence of oxygen and to oxidize on exposure to light and air, styrene is normally
5 stabilized by the addition of < 0.006 - 0.01% w/w tertiary butylcatechol (4-tert-butylbenzene-1,2-diol) as
6 an inhibitor (WHO 1983).

7 Pure styrene has a pungent, slightly sweetish odor. However, oxidation may lead to the
8 formation of peroxides, certain aldehydes and ketones giving a sharp, penetrating, disagreeable odor.
9 When emitted into the air, its half-time is estimated to be about 2 hours, and chemical transformation
10 products include benzaldehyde and formaldehyde, both of which are odorous air pollutants (WHO 2000).

11 Styrene is one of the most important monomers in industry worldwide. The first step in its
12 industrial production is the catalytic alkylation of benzene with ethylene leading to ethylbenzene. In the
13 second step, ethylbenzene is dehydrogenated to styrene. In an alternative process, styrene is formed as a
14 co-product in the synthesis of propylene oxide from ethylbenzene and propene via ethylbenzene hydro-
15 peroxide and 1-phenylethanol (WHO 1983). Purified products typically are 99.7% to greater than 99.9%
16 w/w styrene with less than 0.1 % ethylbenzene, cumene, phenylpropene, phenyl acetate and p-xylene.

17 Styrene is predominantly used for the production of polymers (polystyrene, copolymers of
18 styrene with acrylonitrile and/or butadiene) that find wide application in latex paints and coatings,
19 synthetic rubbers, polyesters and styrene-alkyd coatings. Styrene is a HPV (high production volume)
20 chemical with a worldwide production of 17 945 thousand tonnes in 1998. Small amounts of styrene can
21 be found in gum exudate from the damaged trunk of certain trees, probably being produced by
22 decomposition of cinnamic acid derivatives that are present in such exudates in large quantities. Styrene
23 also occurs in many agricultural products and foods, however, it is not clear whether styrene is naturally
24 produced within plants (IARC 2002).

25 Owing to its volatility, low flash point, and the range of explosive limits in air (lower: 1.1 %,
26 upper: 6.3 % v/v), styrene poses an acute fire and explosion hazard. Chemical and physical properties of
27 styrene are presented in Table 1.

TABLE 1: CHEMICAL AND PHYSICAL PROPERTIES		
Parameter	Data	Reference
Synonyms	Vinylbenzene, phenylethene, ethenylbenzene, cinnamene	WHO 1983
Chemical formula	C ₈ H ₈	
Molecular weight	104.14 g/mol	WHO 1983
CAS Reg. No.	100-42-5	ATSDR 1992
Physical state	Liquid at room temperature	Weast 1973
Solubility	300 mg/l in water (at 20 °C), soluble in alcohol, ether, acetone, miscible with benzene and petrol ether	Weast 1973; WHO 1983
Vapor pressure	3.1 hPa (at 10 °C), 6.67 hPa (at 20 °C), 8.67 hPa (at 25 °C), 13.3 hPa (at 35 °C)	ATSDR 1992; NIOSH 1983; WHO 1983
Vapor density (air = 1)	3.6	
Liquid density (g/cm ³)	0.9060 (at 20 °C)	Weast 1973
Melting point	-30.63 °C	Weast 1973
Boiling point	145.2 °C (at 1013 hPa)	Weast 1973
Explosive limits in air	1.1 – 6.3 %	ATSDR 1992
Flash point (closed cup)	31 °C	ATSDR 1992
Autoignition temperature	490 °C	ATSDR 1992
Conversion factors (at 25 °C)	1 ppm = 4.26 mg/m ³ 1 mg/m ³ = 0.234 ppm	Calculated according to NRC 2001

1 2 **HUMAN TOXICITY DATA**

2 **2.1 Acute Lethality**

3 No reports of lethal intoxication following styrene exposure were located in the literature.

4 **2.2 Nonlethal Toxicity**

5 **2.2.1 Case Reports**

6 The investigators of a field study on styrene exposure of workers noted that they could not
7 withstand styrene concentrations of 500 – 800 ppm for more than 1 – 2 minutes, whereas the workers
8 exposed to this level complained of only minor to moderate irritation of eyes and nasopharynx. The
9 authors further report that they themselves (five unadapted persons) suffered from lacrymation and
10 irritation of the nasopharynx at about 300 – 400 ppm (Götell et al. 1972).

11 By degassing the tank of a ship on a river, styrene was blown into the surrounding air without
12 sufficient dilution. 15 employees of a nearby power plant and 3 river police men who were exposed to an
13 unknown concentration of styrene complained of immediate eye irritation and tickle in the throat,
14 dizziness, headache and nausea (Hahn et al. 2000).

15 After using a polyester resin canoe building kit, a 36-year old man twice suffered from
16 neurologic symptoms (MacFarlane et al. 1984). The work had been carried out in an unventilated shed for
17 about 4 – 5 hours during which styrene evaporated from the construction kit. The man developed severe
18 postural hypotension, neurological signs (slurred speech, nystagmus, limb ataxia) and conjunctivitis.

19 Moscato et al. (1987) described two cases of workers employed in plastics factories that had
20 bronchial asthma or runny nose, dry irritating cough and chest tightness. They were exposed to styrene
21 and ethyl benzene and one of them to polyester resin. However, specific inhalation challenges revealed an
22 immediate bronchospastic response only after provoked inhalation exposure to styrene (15 ppm for 15
23 minutes). In both subjects, symptoms completely disappeared after changing their job. A further case of
24 asthma in a subject occupationally exposed to styrene and showing a positive reaction to styrene in a
25 provoked exposure test was reported by Hayes et al. (1991). A case of skin dermatitis following dermal
26 exposure to styrene was reported by Sjöborg et al. (1982), skin patch tests revealed a strong reaction to
27 styrene and a cross-reaction to vinyl toluene, but a weak one to benzoyl peroxide (used in hardeners for
28 styrene-based plastics) and no reaction to styrene polymerization inhibitors and typical styrene impurities.

29 ***Non-inhalation exposure***

30 Repair of a water tank led to contamination of tap water with styrene and subsequent oral and
31 inhalation exposure (Arnedo-Pena et al. 2003). Residents of 27 apartments in two buildings using the
32 contaminated water were contacted. A questionnaire on subjective symptoms was administered to 84 out
33 of 93 persons living in affected apartments at the time of the accident. Styrene measured in samples of
34 water collected two days after the accident reached concentrations up to 900 µg/L. Symptoms were
35 reported by 46 persons, most frequently irritation of the throat (26%), nose (19%), eyes (18%) and skin
36 (14%). General gastrointestinal symptoms were observed with 11% reporting abdominal pain and 7%
37 diarrhea. The factors most strongly associated with symptoms were drinking tap water, exposure to vapors
38 from the basement and eating foods prepared with tap water. All residents in the ground floor reported
39 symptoms.

1 2.2.2 Occupational exposure

2 A great number of studies on workers with occupational exposure to styrene in different
3 workplaces have been carried out. These studies have been repeatedly reviewed and summarized (ACGIH
4 1997; ATSDR 1992; Cohen et al. 2002; DFG 1987; Government Canada 1993; IARC 2002; OEHHA
5 1999; Sherrington and Routledge 2001; US EPA 1998; WHO 1983; WHO 2000). Workers are exposed to
6 styrene in a number of industries, e.g. in the production of styrene and styrene polymers. In the fabrication
7 of reinforced-polyester plastics composites, 8-hour average samples in breathing zones often exceed
8 styrene concentrations of 100 ppm (IARC 2002). Here, the highest exposure concentrations were observed
9 in chopper gun operators where 8-hour mean concentrations in personal breathing zone of 564 mg/m³
10 (range 307 – 938 mg/m³) (132 ppm; range 72 – 219 ppm) were measured (Truchon et al. 1992). In
11 previous studies on workers in the manufacture of reinforced plastics, 8-hours TWA concentrations in the
12 breathing zone of up to 292 ppm were reported, with peaks of about 1500 ppm during shorter periods of
13 work for about 5 – 10 minutes (Götell et al. 1972).

14 In workers exposed to styrene, central and peripheral nervous systems effects have been
15 observed. Especially, reversible decrease in color discrimination has been described in many studies.
16 Decrements of auditory function (threshold for hearing at high frequencies, hearing acuity) was also
17 observed in several smaller cross-sectional studies, however, in the largest study on workers in the glass
18 fibre-reinforced plastics industry, no evidence was observed that exposure to styrene had an effect on
19 hearing acuity when both lifetime styrene exposure and noise were taken into account. Studies of effects
20 on the immune and hematopoietic system, liver, and kidney did not reveal consistent changes (IARC
21 2002). Generally, in these studies effects on workers with long-term exposure to styrene were
22 investigated. A detailed description of the findings from these studies is beyond the scope of this
23 document because they do not provide data that can be used for the derivation of AEGL. Therefore, only
24 studies are described here in which effects following acute occupational exposure to styrene were
25 investigated.

26 Acute behavioral effects and symptoms of exposure to styrene were investigated in a cross-
27 sectional study (Edling and Ekberg 1985). 12 workers (mean age 30 years) with a mean exposure to
28 styrene of 2.5 years took part in the study. Neuropsychiatric symptoms (questionnaire) and a reaction time
29 test were conducted after an exposure free interval of at least 24 hours before and after the morning and
30 the afternoon shift. A reference group of 10 non-exposed men was available for the morning shift. The
31 mean 8-hour TWA of breathing zone personal samples was 43 ± 28 mg/m³ (10 ± 6.5 ppm) in the morning
32 shift and 54 ± 37 mg/m³ (13 ± 9 ppm) in the afternoon shift. No significant differences in neuropsychiatric
33 symptoms and reaction time were observed between pre- and postshift evaluations and between exposed
34 and controls.

35 Acute (and chronic) effects of styrene on the nervous system were investigated in a further
36 cross-sectional study (Triebig et al. 1989). A total of 36 workers from companies handling polyester resin
37 materials for 1 – 16 (median: 7) years and two control groups were each examined on a Monday. One
38 control group formed to compare acute effects consisted of 20 men from two companies with no exposure
39 to neurotoxic chemicals. To compare chronic effects, a second control group was formed by "one to one
40 matching" with respect to age, socio-economic status, and pre-exposure intelligence level. Ambient air
41 monitoring using active sampling (short time) and passive samplers (long time) showed styrene in air of
42 3 – 251 ppm (median: 18 ppm) and 140 – 600 ppm during lamination of the inside of boats. Clinical
43 examination revealed no signs or symptoms of peripheral neuropathy or encephalopathy. Acute eye
44 irritation was noted after exposure to about 200 ppm or more. Neurobehavioural tests showed neither
45 significant differences in acute effects between the two groups nor between pre- and postshift testing nor
46 significant differences in relevant neurobehavioural variables between the styrene workers and controls.

1 Limited data on the effects of styrene vapors on the nasal mucosa are available from a cross-
2 sectional study (Ödkvist et al. 1985). 11 ship builders (mean age 39 years, range 26 – 57 years) exposed to
3 styrene for a mean of 7 years (range 1 – 16 years) took part in the study. Air levels in the plant were in the
4 range of 200 – 250 mg/m³ (47 – 59 ppm) (no details reported). 25 men matched for age and smoking
5 habits and without industrial exposure served as controls. Nasal biopsies were taken from the mucosa of
6 the inferior turbinates, and morphological findings were graded according to a scoring system evaluating
7 histological characteristics. No statistically significant differences between the mean scores of both groups
8 were found.

9 **2.2.3 Experimental Studies**

10 Two male subjects were exposed to 800 ppm styrene for 4 hours in a 4000 cubic ft. room
11 (about 110 m³) in which fans were arranged to produce rapid and thorough mixing of the air (Carpenter et
12 al. 1944). Styrene was evaporated at room temperature from large wicks in air stream and the vapor
13 concentration was monitored (using an “interferometer” developed for the iodometric determination of
14 organic vapors) and controlled manually. Psycho-motor response was followed by means of a “steadiness”
15 test. The test was performed by the subject holding at arm’s length a small wire in a hole drilled in a
16 copper strip. The number of contacts and the time the wire was in contact with the periphery of the hole
17 was recorded during a 3-minute period. Exposure to styrene caused immediate eye and throat irritation,
18 increased nasal mucous secretion, pronounced and persistent metallic taste, and CNS depression with
19 listlessness, drowsiness, impairment of balance, and, after termination of exposure, muscular weakness
20 and unsteadiness that were accompanied by inertia and depression. In the steadiness test, the contact time
21 was 630 % of the day’s normal value. There was apparently no control without exposure so it cannot
22 completely be ruled out that some of the effects described might not be related to the styrene exposure but
23 to the experimental conditions. However, this seems unlikely since the styrene concentration was very
24 high and the effects noted were very pronounced. Furthermore, during exposure to lower concentrations of
25 other chemicals (butadiene, toluene) in the same experiment, weaker or no effects were observed.

26 An unspecified number of humans were exposed to a range of analytically determined con-
27 centrations of styrene in an enclosed, tightly sealed room (Wolf et al. 1956). The subjects quickly entered
28 the room and noted their reactions with respect to odor, eye irritation, and nasal irritation. Probably, there
29 was no unexposed control, but experimental details (esp., number of subjects, duration of exposure) were
30 not reported by the authors. At 60 ppm, there was a “detectable odor but no irritation”. 100 ppm were
31 “tolerated without excessive discomfort” though the odor was “strong”. An “objectionably strong odor”
32 was felt between 200 and 400 ppm, while 600 ppm or more caused strong eye and nasal irritation.

33 In a toxicokinetic study, two volunteers were exposed to styrene at concentrations up to
34 386 ppm for 2 hours while performing light physical exercise of 50 W (Löf and Johanson 1993, see
35 section 4.1). No information was presented with respect to subjective or objective signs of intoxication or
36 irritation, but it may reasonably be assumed that no severe effects will have occurred in such a study.

37 Local irritation and effects on the nervous system were studied by Stewart et al. (1968). The
38 study was conducted with a group of 9 healthy male technical employees (32 – 55 years old) with no
39 known exposure to styrene for at least a year. In 5 experiments, a number of 1 – 5 subjects were exposed
40 for 1, 2 or (with a 30-minute break at half-time) 7 hours in an exposure chamber of about 50 m³ to
41 analytically (infrared analysis and gas chromatography) confirmed styrene concentrations of 51.4 ppm
42 (1 hour), 99.4 ppm (7 hours), 116.7 ppm (2 hours), 216.1 ppm (1 hour), and 376 ppm (1 hour). During
43 exposure, subjective and objective responses of each individual were recorded every 15 minutes. A
44 neurological examination was performed every 15 minutes during exposures lasting up to 2 hours and
45 every hour at longer lasting exposures. This examination included a modified Romberg test (balancing on
46 one foot with eyes closed and both arms at a side), heel and toe, and finger to nose test. Additionally a

1 manual dexterity and a Flannigan coordination test were performed the morning and afternoon during the
2 7-hour exposure and after 30 minutes during the 1-hour exposure to 216 and 376 ppm.

3 No untoward subjective symptoms or objective signs of illness were recorded during a 1-hour
4 exposure to 51 ppm (3 subjects) or during a 2-hour exposure to 117 ppm (1 subject). The odor was strong,
5 but not judged to be objectionable. At 216 ppm (3 subjects), the odor was initially strong, and one subject
6 noted nasal irritation after 20 minutes. No signs of CNS effects were observed during the 1-hour exposure.

7 Effects were seen at 376 ppm (5 subjects). Three of the subjects previously exposed to 216 ppm
8 reported they were able to discern that they were now exposed to a higher concentration. "Mild" eye
9 irritation occurred within 3 minutes. All subjects complained of nasal irritation within 15 minutes and one
10 of them of a burning sensation of the skin of his face. Neurological alterations also were seen at this
11 concentration. After 25 minutes, one subject, after 60 minutes two subjects were unable to normally
12 perform the modified Romberg test. After 50 minutes, significant decrements were found in 3 of 5
13 subjects in other tests of coordination and manual dexterity. Furthermore, nausea after 45 minutes in one
14 subject (persisting one hour post exposure), and feeling of being inebriated (2 subjects) and headache (one
15 subject) after one hour were reported.

16 Exposure to 99 ppm for 2 x 3.5 hours caused complaints of mild eye and throat irritation in 3 of
17 6 subjects after 20 – 30 minutes which later subsided. 3 of 6 subjects reported intermittent difficulties in
18 performing the Romberg test one or two times at the eight trials of this test during exposure. Tests of
19 coordination and manual dexterity were normal. At the end of exposure, there were no reports of
20 subjective symptoms. Throughout the study, clinical and laboratory data were normal and not altered
21 compared to preexposure (Stewart et al. 1968).

22 Effects of styrene on psychological functions were studied in 12 healthy male volunteers (age
23 21 – 31 years) (Gamberale and Hultengren 1974). They were exposed in groups of six to either air
24 (control) or to nominal but analytically (gas chromatography) monitored concentrations of 50, 150, 250
25 and 350 ppm styrene via mouthpiece in four continuous 30-minute periods. After each 30-minute period,
26 the concentration of styrene was raised to the next higher level without interruption of exposure. In a
27 second set of experiments, the control group was exposed to styrene and vice versa. Performance tests
28 were carried out during each period of exposure. Care was taken that the volunteers were unaware of the
29 exposure status by introducing menthol into the inhaled air, breathing through a mouthpiece only, and use
30 of nose clips. Additionally, control experiments were initiated with a relatively strong smell of styrene in
31 the mouthpiece and ended with a short exposure to styrene after completion of the final test. All subjects
32 believed that they had been exposed on both trial days. Local irritation was almost completely absent
33 because the subjects were exposed via mouthpiece so that eyes and nose were spared from direct
34 exposure. Nevertheless, compared to control exposure, subjects felt slight discomfort (feeling of tension
35 and being affected) after exposure to styrene. In the performance tests, the performance level in the two
36 perceptual tests (Identical Numbers and Spokes), was affected by training, both under control and
37 exposure conditions. In both tests, the training effect in exposure to styrene was somewhat less
38 pronounced than in control conditions, especially at the two higher concentrations. This could indicate that
39 training was less effective under styrene exposure, however, the differences between the mean
40 performance values for control and styrene exposure were not significantly different in any case. There
41 was a clear effect of styrene on reaction time. The reaction time was significantly impaired in two tests
42 (simple and choice reaction time) at 350 ppm but not at lower concentrations.

43 In a further study, 6 volunteers were exposed to analytically (Beckman hydrocarbon analyzer)
44 monitored concentrations of styrene in room of about 15 m³ (Oltramare et al. 1974). 3 of the 6 volunteers
45 had been exposed occupationally to styrene but not during the last 1 days prior to the experiment.
46 Altogether, 42 exposure sessions were held each lasting 1 – 3 hours and usually exposing one or two

1 subjects at a time. 2 subjects were exposed to styrene once at 300 ppm, all were exposed once or twice to
2 100 and 200 ppm, and most were exposed at 3 – 5 ppm (“odor-blinded” control) and 50 ppm.

3 Psychomotor functions of the three subjects with previous occupational exposed to styrene
4 were studied in sessions each lasting 90 minutes. Volunteers were individually exposed. All were exposed
5 to 3 – 5 ppm first, then to 50 (only two subjects), 100, or 200 pm in random order, and finally to 3 – 5
6 ppm again. Reaction time was determined before, 1 hour after start, and 30 minutes after termination of
7 exposure. Simple reaction time was about the same as pre-exposure at 3 – 5 ppm but was lengthened by
8 12 – 37 % at 50, 100, and 200 ppm during exposure. 30 minutes after exposure, reaction time at 200 ppm
9 was still increased by 11 – 35 %. Similar results were obtained in an audiovisual reaction test. However,
10 there was no concentration response trend. In a multiple stimulus reaction test, no effect on performance
11 was seen at 50 ppm. As the ability to perform this test improved with repeated trials, both during each
12 session and from session to session, the authors comment that an effect of styrene at 50 ppm might have
13 been masked. A decrement of about 2 % at 100 ppm and of 10 % at 200 ppm during and after exposure
14 were seen (Oltromare et al. 1974).

15 Difficulties in balance performance were also studied by Oltromare et al. (1974) in 3 of 6
16 subjects. Statistically significant differences in a modified Romberg-test on a swaying platform were ob-
17 served after 1-hour exposure to 200 ppm compared to control. No difference was seen when results from
18 control and the 100-ppm group were compared. The authors noted that – due to the small sample size and
19 the large variation of data – the results should be confirmed before definite conclusions are drawn.

20 Also, the 6 volunteers were asked to note the occurrence of 12 subjective symptoms (irritation:
21 lips, nose, eyes; gastralgia, CNS effects: nausea, dizziness, headaches, sleepiness, poor concentration,
22 intoxication, fatigue, malaise) during and after the exposure (**FIGURE 1**). A total of 55 individual
23 responses were available for analysis from all of the exposure sessions. For each of the 12 symptoms, the
24 number of positive responses was presented as numerator and the total number of exposures at this
25 concentration as the denominator of a ratio. Since a given subject could have been exposed more than
26 once at a given concentration, it is not evident if multiple positive responses for each individual symptom
27 mean that several subjects experienced a symptom or that one subject experienced that symptom at several
28 occasions. Also, it cannot be deduced from the data which symptoms were reported by the 3 previously
29 exposed workers. However, the authors state that the workers reported irritation at 3 – 5 ppm, and the
30 authors considered that this may have been due to chronic inflammation from working with styrene. On
31 the other hand, the symptoms noted for CNS effects were consistently fewer for the subjects with previous
32 exposure. For the parameters indicating CNS effects and also for gastralgia, there was a clear increase in
33 positive symptom reports at 100 ppm and higher concentrations. The authors reported that at 50 ppm
34 about half of the subjects experienced what was described as a prenarctic discomfort. For irritation, an
35 increase in symptom reports seems evident only for eye irritation at 200 ppm, and, less so, for irritation of
36 the lips at 200 ppm (Oltromare et al. 1974).

Symptom		Styrene ppm				
		3-5	50	100	200	300
Irritation						
Lips	D	0/10	0/6	1/13	2/12	0/2
	P	0/10	0/6	0/13	1/12	0/2
Eyes	D	1/10	4/6	4/13	7/12	2/2
	P	0/10	0/6	1/13	2/12	0/2
Nose	D	4/10	3/6	7/13	5/12	1/2
	P	2/10	1/6	3/13	2/12	0/2
Gastralgia	D	0/10	0/6	3/13	5/12	1/2
	P	0/10	0/10	1/13	2/12	0/2
Nausea	D	0/10	0/6	5/13	4/12	2/2
	P	0/10	0/6	1/13	2/12	0/2
Dizziness	D	1/10	1/6	0/13	3/12	0/2
	P	0/10	1/6	0/13	2/12	0/2
Headaches	D	1/10	3/6	10/13	10/12	2/2
	P	0/10	2/6	8/13	9/12	0/2
Sleepiness	D	3/10	2/6	12/13	12/12	2/2
	P	1/10	1/6	4/13	11/12	2/2
Poor concentration	D	1/10	4/6	9/13	11/12	2/2
	P	0/10	2/6	4/13	9/12	2/2
Intoxication	D	0/10	1/6	2/13	6/12	1/2
	P	0/10	1/6	1/13	3/12	0/2
Fatigue	D	2/10	4/6	10/13	9/12	2/2
	P	2/10	4/6	9/13	9/12	2/2
Malaise	D	0/10	1/6	7/13	7/12	2/2
	P	0/10	0/6	1/13	0/12	0/2

D = occurrences during exposure
P = persistence after exposure

1

2 **FIGURE 1: SYMPTOM RATINGS AT OR AFTER ACUTE EXPOSURE OF HUMANS TO** 3 **STYRENE**

4 (Table adopted from Oltramare et al. 1974)

5 Vestibulo-oculomotor disturbances were studied by Ödkvist et al.(1982). 10 healthy non-
6 smoking volunteers (5 man, 5 women, age 20 – 30 years) inhaled styrene via mouth-tube at an analytically
7 confirmed concentration between 87 and 139 ppm (fluctuating < 2 % during each individual exposure)
8 during light exercise (50 W) for one hour. Vestibulo-oculomotor tests (swing test, optovestibular test,
9 visual suppression test, optokinetic test, saccade test, slow pursuit moving test) were performed before,
10 during and 1 hour after exposure. Each individual served as its own control. There were no effects on any
11 test except the saccade test in which 8 of 10 subjects showed an enhanced maximum speed of the saccade
12 during exposure. The authors conclude that the results suggest an effect of styrene on the vestibulo-ocular
13 system by blocking inhibitory mechanisms in the CNS.

14 Pierce et al. (1998) exposed 4 healthy male non-smoking volunteers (26 – 30 years old, no
15 known history of solvent exposure) in a 13.8 m³ chamber to analytically (infrared spectrophotometry)
16 confirmed concentrations of 15 – 99 ppm styrene in different exposure scenarios. No changes were

1 observed in a digit recognition test performed after 35 minutes of exposures and in electroencephalogram
 2 performed after each 100-minute exposure.

3

TABLE 2: SUMMARY OF ACUTE NON-LETHAL EFFECTS IN CONTROLLED HUMAN STUDIES FOLLOWING INHALATION OF STYRENE

Exposure duration	Concentration ppm (mg/m ³)	Effects and remarks	Reference
1 – 2 minutes	500 – 800 ppm 300 – 400 ppm	Intolerable irritation of previously non-exposed subjects; lacrymation, irritation of nasopharynx	Götell et al. 1972
4 hours	800	Immediate eye and throat irritation, CNS depression with listlessness, drowsiness, impairment of balance, and, after termination of exposure, muscular weakness and unsteadiness with inertia and depression	Carpenter et al. 1944
Not reported	60 ppm 100 ppm 200 – 400 ppm ≥ 600 ppm	Rapid onset of effects: “detectable odor but no irritation” “tolerated without excessive discomfort”, “strong” odor “objectionably strong odor” strong eye and nasal irritation	Wolf et al. 1956
4 x 30 minutes with stepwise increasing concentration	50 ppm 150 ppm 250 ppm 350 ppm	Exposure via mouthpiece (avoiding eye irritation); slight increase of simple and choice reaction time at 350 ppm	Gamberale and Hultengren 1974
1 hour	87 – 139 ppm	No effect on vestibulo-oculomotor parameters except saccade test where 8 of 10 subjects showed an enhanced maximum speed of the saccade	Ödkvist et al. 1982
35 minutes 100 minutes	15 – 99 ppm 15 – 99 ppm	No changes in digit recognition test No changes in electroencephalogram	Pierce et al. 1998
1 hour 2 hours 20 minutes 1 hour 3 minutes 15 minutes 25 min. – 1 hour 2 x 3.5 hours (with 30 minutes break)	51 ppm 117 ppm 216 ppm 216 ppm 376 ppm 376 ppm 376 ppm 99 ppm	No subjective symptoms or objective signs of illness; strong, but not objectionable odor Odor initially strong, nasal irritation No signs of CNS effects “Mild” eye irritation Nasal irritation CNS effects: difficulties in balance performance tests, decrements in manual dexterity test, nausea, inebriation, headaches Complaints of mild eye and throat irritation after 20 – 30 minutes, subsiding later; intermittent difficulties in performing Romberg test in 3/6 subjects. No subjective symptoms or signs of CNS effects at the end of exposure. Clinical and laboratory data normal.	Stewart et al. 1968

TABLE 2: SUMMARY OF ACUTE NON-LETHAL EFFECTS IN CONTROLLED HUMAN STUDIES FOLLOWING INHALATION OF STYRENE

Exposure duration	Concentration ppm (mg/m ³)	Effects and remarks	Reference
1 – 3 hours	50, 100, 200 ppm	Rating scores for subjective symptoms of CNS effects (headaches, sleepiness, nausea, fatigue, poor concentration) ↑ in rating score at ≥ 100 ppm Scores for irritation at 50 ppm also ↑, but no evident concentration response	Oltramare et al. 1974
1 hour	200 ppm	Slight difficulties in balance performance, but large variation of data	
1.5 hours	50, 100, 200 ppm	Possibly slight increase in reaction time, but no dose-response	
6 hours	25 – 50 (with/without 4 peaks 15 min 100 ppm)	Neither performance to neuropsychological tests nor subjective signs and symptoms of irritation or CNS effects negatively influenced	Ska et al. 2003; Vyskocil et al. 2002a
1 - 7.5 hours	0 ppm 20 ppm 75 – 125 ppm* 100 ppm 125 ppm	Men: 3 days at 20 ppm, 4 days at 100 ppm, 4 days at 75 – 125 ppm (average 100 ppm), 5 days at 125 ppm, 7 days at 0 ppm Women: 4 days at 100 ppm, 2 days at 0 ppm No CNS effects in equilibrium and cognitive testing Subjective symptoms (exposure times not reported): Irritation (eyes, nose, throat) Headache: Men/ Women Men/ Women 13 %/ 8 % 3 %/ 0 % 17 % 0 % 20 % 0 % 33 %/ 32 % 13 %/ 35 % 45 % 12 %	Hake et al. 1983
3 – 4 hours	20 ppm 0.5 – 40 ppm (peak)	Ratings for odor, annoyance and, marginally, for irritation increase with concentration; ratings of irritation verbally labelled as “hardly at all”	Seeber et al. 2002

1 *: fluctuating exposure concentration, average 100 ppm.

2 Acute effects of styrene on the CNS were also studied in a total group of healthy male
3 volunteers (20 – 50 years old, smokers and non-smokers) not previously exposed to styrene and with no
4 documented exposure to neurotoxicants during the study (Ska et al. 2003; Vyskocil et al. 2002a; 2002b).
5 The volunteers were exposed to styrene at rest to 5 different scenarios that lasted 6 hours each: a)
6 continuously to 106 mg/m³ (25 ppm), b) variable exposure with a mean of 25 ppm and four 15-minutes
7 peak exposures up to 213 mg/m³ (50 ppm), c) exposure to 1 ppm, control), d) exposure to 50 ppm, e)
8 mean exposure to 50 ppm with four 15-minutes peaks up to 426 mg/m³ (100 ppm). The sequence of
9 exposures was c-a-b-c-d-e. Exposure was carried out in an 18 m³ chamber and the styrene concentration
10 was monitored by gas chromatography and infrared analysis. Before and after exposure, the volunteers
11 were submitted to a battery of test proposed by the World Health Organization to detect neurotoxic effects
12 of chemicals: sensory tests (visual: Lanthony D-15 and vision contrast test, olfactory: smell test),
13 neuropsychological tests (reaction time, attention, memory, psychomotricity), and self-evaluation
14 questionnaires for mood (seven-category response scale) and symptoms (four-point scale for 17 items
15 regarding irritation and CNS effects) in a test-retest design. The testings were performed before exposure
16 (Base-line) and within 1 hour after the end of exposure. Initially, 42 subjects took part in the study.
17 However, only data from subjects who had taken part in all scenarios were retained for further analyses.

1 Missing data were due to absence of subjects at a given scenario or to factual problems during testing.
2 Therefore, complete data were available for 24 subjects. The different exposure scenarios negatively
3 influenced neither the performance to any test nor the subjective signs and symptoms.

4 Psychological reactions related to chemosensory irritation during exposure to a number of
5 chemicals including styrene were investigated by Seeber et al. (2002). Exposure studies were conducted in
6 a ventilated room of 28 m³ (air exchange about 250 m³/h) with continuous control of the concentration of
7 the test substance (deviations < 3 %). In all experiments, 4 young healthy male volunteers who had no
8 knowledge of the experimental conditions, were investigated simultaneously. The concentrations of
9 styrene were 20 ppm for 3 hours or 0,5 ppm periods for 50 minutes followed by 40 ppm peaks for 30
10 minutes during a total 4 hours. At control and at 20 ppm each, a total number of 16 volunteers were
11 exposed, at 0.5/40 ppm, the total number of volunteers was 24. Ratings for irritation, odor and annoyance
12 were assessed and mean values were calculated from 2 – 5 repeated ratings for a given exposure level
13 (total observations 16 – 246). For odor and annoyance, ratings increased similarly with increasing styrene
14 concentration while there was only a marginal report for irritation. Thus, annoyance was more closely
15 associated with odor than with irritation. Effect sizes comparing the ratings during exposure to 20 ppm
16 and during the pre-exposure test were higher for odor, irritation and annoyance. Effect sizes were also
17 higher compared to “clean air only”-exposure. However, the ratings for irritation (in case of styrene and
18 all other solvents investigated) reached only levels verbally labelled “hardly at all”.

19 ***Studies with repeated inhalation exposure***

20 In a study conducted for and summarized by NIOSH (1983), 10 men were exposed in groups of
21 2 – 4 for 1, 3, or 7.5 hours/day to 0, 20, 100, or 125 ppm styrene (Hake et al. 1983). 8 women were
22 exposed in groups of 1 – 4 at 0 or 100 ppm. For men, there were 3 days of exposure at 20 ppm, 4 days at
23 100 ppm, 4 days at 100 ppm with concentrations fluctuating between 75 and 125 ppm, 5 days at 125 ppm,
24 and 7 days at 0 ppm. For women, there were 4 days at 100 ppm and 2 days at 0 ppm. In control exposures,
25 the chamber was odorized with 10 ppm styrene upon entry of the subjects after which exposure was
26 reduced to 0 ppm within 10 minutes. Each subject was exposed to more than one concentration, non-
27 exposure weekends or control exposures were interspersed with exposure to styrene.

28 There were no deleterious effects on equilibrium as measured by Romberg- and heel-to-toe
29 tests. Some changes in visual evoked response and amplitude of electroencephalogram (EEG) were
30 observed in 3 of 6 subjects studied that – according to the authors – were consistent with CNS-depression.
31 However, the changes were neither consistent between subjects nor in magnitude within subjects.
32 Furthermore, there was no significant variance in cognitive testing scores related to styrene exposure.
33 Respiratory parameters generally showed no effects of styrene exposure; however, the authors observed
34 decrements in maximal expiration values in subjects repeatedly exposed to 100 ppm for 7.5 hours (no
35 details reported).

36 With respect to subjective symptoms noted on a checklist during exposure, the overall data
37 indicated some dose-response for irritation (eyes, nose, and throat) and headaches. For men, the reported
38 incidences of irritation were 13 % (0 ppm), 17 % (20 ppm); 20 % (100 ppm), 33 % (100 ppm fluctuating),
39 45 % (125 ppm); for headaches, incidences were 3 %, 0 %, 0 %, 13 %, 12 %. For women, the incidence of
40 irritation was 8 % (0 ppm) ad 32 % (100 ppm), for headaches, incidences were 0 % and 35 %. There was
41 no specific indication as to which exposure time the various subjective responses were elicited at a given
42 exposure concentration (Hake et al. 1983).

1 *Odor perception*

2 The odor of styrene has been described as solventy, rubbery, and plasticity (Leonardos et al.
3 1969; Ruth 1986) and also as strongly metallic (Gamberale and Hultengren 1974). A wide range of odor
4 thresholds is reported in the literature. This wide range may be due to different degrees of purities of the
5 test substances used, the presence or absence of polymerization inhibitors, different methodology used,
6 different bases used (median, mean, range), individual variability or an adaptation to odor perception
7 following repetitive exposure.

8 The olfactory function and the styrene odor detection threshold were compared between a
9 group of workers exposed to styrene at least 4 years (reinforced-plastics industry, current mean personal
10 air sampling concentrations of styrene about 11 – 66 ppm) and a group of age- and gender-matched naïve
11 controls (Dalton et al. 2003). Absolute odor threshold concentration values were not presented in the
12 study. The styrene odor detection threshold for workers was on average 32-fold higher than for controls.
13 Furthermore, when the results were stratified by age, the most pronounced increase in odor threshold was
14 observed in workers who were in their 5th or 6th decade, while duration of exposure was not related to the
15 effect. No differences were found between workers and controls with respect to the odor threshold for an
16 olfactory standard, phenylethyl alcohol, and for the ability to identify a variety of 20 different aroma
17 compounds in an odor identification test. The results do not provide evidence that styrene is an olfactory
18 toxicant in humans.

19 Van Doorn et al. (2002) present results of odor threshold determinations for styrene that were
20 a) measured by olfactometry methods considered compatible with a precursor of the NVN2820 and
21 EN13725 method or b) were measured by TNO in the Netherlands using a precursor of the NVN2820 and
22 EN 13725 methods, with a mean n-butanol threshold of 25 ppb. Results of both were converted to the
23 reference agreed in EN13725 of 400 ppb n-butanol by using a factor of $40:25 = 1.6$. Thereby, odor
24 thresholds of 0.049 ppm and 0.025 ppm, respectively, were obtained. Taking into account the threshold
25 value of 0.033 ppm obtained by the Japanese method (see below Hoshika et al. 1993), Van Doorn et al.
26 (2002) calculated a mean odor threshold of 0.0345 ppm for styrene.

27 A comparison of odor threshold values determined by different methods in Japan (triangle
28 olfactometer method, odor room, 20 trained male perfumers 30 – 45 years old) and in the Netherlands
29 (olfactometer, 4 men, 4 women 18 – 40 years old), showed that the “barely perceptible or detectable odor
30 thresholds” of 0.033 ppm and 0.016 ppm, respectively, are quite similar (Hoshika et al. 1993). The
31 Japanese “triangle olfactometer method” produces an n-butanol threshold of 38 ppb that is compatible
32 with the value (40 ppb) of the method according to EN13725 (Van Doorn et al. 2002).

33 In accordance with these data, WHO (1983) reported an odor perception threshold of 0.05 –
34 0.08 ppm. In other older studies and compilations, substantially higher values were reported. Odor
35 thresholds ranging from 0.1 – 201 ppm (0.43 – 860 mg/m³) for styrene (inhibited) and from 0.047 –
36 201 ppm (0.2021 – 860 mg/m³) for styrene (uninhibited) were reported by Ruth (1986). Based on 10
37 original literature references which were not explicitly reported, a geometric mean odor threshold of
38 0.32 ppm styrene (standard error 2.0 ppm) was calculated (Amoore and Hautala 1983).

39 The odor recognition threshold was determined for 53 odorant chemicals including styrene
40 under controlled laboratory conditions using a standardized and defined procedure (Leonardos et al.
41 1969). The odor threshold represents that concentration at which all four trained panelists could positively
42 recognize the odor. Different threshold values were obtained for styrene without inhibitor (0.047 ppm) or
43 with inhibitor (0.10 ppm) and for inhibited styrene additionally purified by gas-liquid chromatography
44 (0.21 ppm). The chemical nature of the inhibitor was not reported.

1 **2.3 Developmental/Reproductive Toxicity**

2 No data regarding developmental or reproductive toxicity in humans following single exposure
3 to styrene have been found in the available literature.

4 ***Studies with repeated inhalation exposure***

5 The epidemiological data have been extensively reviewed recently (Brown et al. 2000; IARC
6 2002). In case reports, malformations in children of styrene-exposed mothers and spontaneous abortion in
7 female workers occupationally exposed to styrene were described. However, these observations could not
8 be confirmed in epidemiological studies. According to the reviews mentioned above, there is no sound
9 evidence for an association between workplace exposure to styrene and spontaneous abortions,
10 malformations or decreased male fecundity.

11 **2.4 Genotoxicity**

12 Genotoxicity studies have been extensively evaluated and summarized in a number of reviews
13 (ATSDR 1992; Bonassi et al. 1996; Cohen et al. 2002; IARC 1994; IARC 2002; Vodicka et al. 2002;
14 WHO 1983; WHO 2000). Since a detailed description of the findings from these studies is beyond the
15 scope of this TSD, findings as described in these reviews are summarized.

16 In *in vitro* systems with human cells, styrene induced chromosomal aberrations (CA), sister
17 chromatid exchanges (SCE), micronuclei, and hypoploidy in whole-blood cultures in the absence of
18 exogenous metabolic activation system were observed. CA and SCE were also observed in lymphocyte
19 cultures in the absence of exogenous metabolic activation system.

20 *In vivo*, no data regarding genotoxic effects in humans following single exposure to styrene
21 have been found in the available literature.

22 ***Studies with repeated inhalation exposure***

23 A number of cytogenetic studies have been conducted on workers with occupational exposure
24 to styrene, especially in the reinforced plastics industry. The workers in the individual studies had been
25 exposed between less than one year and about 30 years to widely differing concentrations of styrene as
26 estimated from air sample or monitoring or biological monitoring of urinary styrene metabolites. The
27 number of workers included in individual studies mostly was less than 50. With respect to chromosomal
28 aberrations, the majority of studies revealed a significant increase in CA (including gaps), and dose-
29 responses were observed in several studies. A cross-studies evaluation found a positive association among
30 studies between the level of styrene exposure and the frequency of CA. Fewer studies have looked at sister
31 chromatid exchange (SCE), and the percentage of positive studies was smaller than the percentage of
32 positive studies of CA. However, two regression analyses revealed significant associations between
33 styrene in air or urinary mandelic acid excretion and SCE frequency. There is less evidence of an
34 association between styrene exposure and the frequency of micronuclei, and in a cross-studies evaluation,
35 no such association could be found. Other studies in workers have provided evidence that occupational
36 exposure to exposure may lead to a several-fold increase in the formation of DNA-adducts (*O*⁶-
37 deoxyguanosine and *N*7-deoxyguanosine adducts), DNA single-strand breaks, and gene mutations at the
38 HPRT and the glycophorin A locus.

39 Recently, physiological modeling of the relative contributions of styrene-7,8-oxide (SO)
40 derived from direct inhalation and from styrene metabolism to the systemic dose in humans has been
41 performed. From these calculations, it has been suggested that SO which is present in the air at workplaces

1 in the reinforced plastics industry could present a greater hazard of cytogenetic damage than inhalation of
2 styrene (Tornero-Velez and Rappaport 2001).

3 **2.5 Carcinogenicity**

4 No data regarding the development of cancer in humans following single exposure have been
5 found in the available literature.

6 ***Studies with repeated inhalation exposure***

7 The cancer epidemiology data have been reviewed recently (Cohen et al. 2002; IARC 2002).

8 Retrospective cohort mortality studies and nested case-control studies were conducted in three
9 types of industry: in the production of styrene monomer and polystyrene, of glass-fibre reinforced plastics,
10 and of styrene-butadiene rubber.

11 Because workers in the reinforced plastics industry have higher styrene exposure and less
12 potential for exposure to other substances than the other cohorts studied, the most informative data with
13 regard to an association between styrene exposure and cancer come from studies of these cohorts. In three
14 studies in such cohorts, an excess of lung or respiratory cancer was found. However, the excess occurred
15 in those groups of workers with lower exposure. An excess of lymphatic and hematopoietic (LH) cancers
16 was observed in some epidemiological studies in the reinforced plastics industry, but not in others. Such
17 an association also was found in two studies of workers in styrene production, but exposure was poorly
18 documented and may have been also to other chemicals beside styrene. Studies in workers of the styrene-
19 butadiene rubber production also found a small excess of leukemia mortality. However, these findings are
20 difficult to evaluate because of the high correlation between exposure to styrene and butadiene (Cohen et
21 al. 2002).

22 Reports of increased risks of other cancers (rectal, pancreatic, nervous system) are also reported
23 in some studies. Mostly, the numbers of cases are small, and these findings are not supported from data of
24 larger cohort studies.

25 **2.6 Summary**

26 A great number of studies on workers with occupational exposure to styrene in different
27 workplaces have been carried out. These studies have been repeatedly reviewed and summarized (ACGIH
28 1997; ATSDR 1992; Cohen et al. 2002; DFG 1987; Government Canada 1993; IARC 2002; OEHHA
29 1999; Sherrington and Routledge 2001; US EPA 1998; WHO 1983; WHO 2000). The highest exposure
30 occurs in the fabrication of reinforced-polyester plastics composites, where 8-hour average samples in
31 breathing zones often exceeded 100 ppm styrene (IARC 2002). In older studies on workers in the
32 manufacture of reinforced plastics, 8-hours TWA concentrations in the breathing zone of up to 292 ppm
33 were reported, with peaks of about 1500 ppm during shorter periods of work for about 5 – 10 minutes
34 (Götell et al. 1972).

35 In workers with chronic exposure to styrene, effects on the central and peripheral nervous
36 systems that were described in many studies include a reversible decrease in color discrimination.
37 Decrements of auditory function was also observed, though findings made in several smaller cross-
38 sectional studies could not be confirmed in the largest study. Studies of effects on the immune and
39 hematopoietic system, liver, and kidney did not reveal consistent changes (IARC 2002).

40 No reports of lethal intoxication following styrene exposure were located in the literature.

1 Pure styrene has a pungent, slightly sweetish odor. A wide range of odor thresholds has been
2 reported. Van Doorn et al. (2002) presented results of odor threshold determinations for styrene and
3 calculated an n-butanol corrected mean odor threshold of 0.0345 ppm for styrene.

4 Styrene is irritating to eyes and the respiratory tract. In a number of controlled studies with
5 human volunteers, irritation and effects on the CNS were investigated.

6 In a study on psychological reactions related to chemosensory irritation, ratings for odor and
7 annoyance increased similarly with increasing styrene concentrations ranging from 20 – 40 ppm, while
8 there was only a marginal increase for irritation. Effects sizes comparing the ratings between exposure to
9 20 ppm and pre-exposure were higher for odor, irritation, and annoyance. Effects sizes were also higher
10 compared to “clean air only”-exposure. However, the ratings for irritation reached only levels verbally
11 labelled as “hardly at all” (Seeber et al. 2002). No increase in irritation or headaches compared to control
12 was noted at 20 ppm in a further study (Hake et al. 1983). At 50 ppm, one study indicated a marginal
13 increase in subjective symptoms ratings for eye and nose irritation, headache, and fatigue (Oltamare et al.
14 1974). In that study, signs of irritation and of mild subjective CNS effects (headaches, fatigue, poor
15 concentration, sleepiness) were reported more often at 100 ppm. Complaints of mild eye and throat
16 irritation at 100 ppm in one test but not in another were reported by Stewart et al. (1968). In a recent
17 study, subjective signs and symptoms during 6-hour exposure to 25 – 50 ppm styrene with 4 peaks of
18 15 minutes at 100 ppm indicated no irritation (Vyskocil et al. 2002a,b). At about 200 ppm, most subjects
19 noted irritation of eye and nose (Oltamare et al. 1974; Stewart et al. 1968) and the severity increased with
20 a further increase in concentration to 376 ppm. In their study on styrene-exposed workers, Götell et al.
21 (1972) noted that they themselves suffered from immediate lacrymation at 300 – 400 ppm and could not
22 withstand 500 – 800 ppm for more than 1 – 2 minutes although the workers tolerated such concentrations.
23 In two further studies with controlled exposure of volunteers, concentrations \geq 600 ppm caused strong
24 eye, nasal, and throat irritation (Carpenter et al. 1944; Wolf et al. 1956).

25 No lesions of the nasal mucosa were observed in a cross-sectional study on styrene-exposed
26 workers. Furthermore, the ability to detect and identify different odors in a controlled odor test was not
27 affected in workers with long-term exposure to styrene. These limited data provide some evidence that –
28 in contrast to rats and especially mice – styrene does not seem to be an olfactory or upper respiratory tract
29 toxicant in humans. Support for this conclusion also comes from toxicokinetic studies *in vitro* in which the
30 metabolic capacity of nasal epithelia from humans, rats, and mice was compared (see section 4.1, page
31 46).

32 With respect to CNS effects, one study reported higher ratings of headaches, poor con-
33 centration, and fatigue at 50 ppm compared to „odor-blinded“ control exposed to 3 – 5 ppm (Oltamare et
34 al. 1974). In another study, headaches did not occur when subjects were repeatedly exposed to fluctuating
35 concentrations of 75 – 125 ppm (average: 100 ppm), but were reported at 125 ppm (Hake et al. 1983).
36 Pierce et al. (1998) found no changes in a digit recognition test after 35 minutes of exposure and in
37 electroencephalogram after 100 minutes of exposure to 15 – 99 ppm styrene in different exposure
38 scenarios. At 100 ppm, intermittent difficulties in performing a modified Romberg test were observed in
39 3/6 subjects exposed for 7 hours with a 30-minute break in between. Other tests on coordination and on
40 manual dexterity were normal, and no effects were noted at the end of exposure. In the same study, no
41 CNS effects were seen in another experiment with 100 ppm exposure for 2 hours or 216 ppm for 1 hour
42 (Stewart et al. 1968). Also, exposure for 6 hours at 50 ppm with 4 peaks of 15 minutes at 100 ppm had no
43 negative influence on performance to neuropsychological tests (Vyskocil et al. 2002a,b). No effects on
44 equilibrium and cognitive function tests were noted in male and female volunteers at repeated exposures
45 to 100 and 125 ppm for at least one hour (Hake et al. 1983). Oltamare et al. (1974) noted that slight
46 difficulties in balance performance at 50 – 200 ppm (1.5 hours), but there was no concentration-response,
47 and slight difficulties in balance performance at 200 ppm (1 hour), but the variation of data was large. No

1 effects on simple and choice reaction time was seen following exposure to 250 ppm for 30 minutes.
2 However, when the concentration was raised to 350 ppm for 30 minutes directly afterwards, both simple
3 and choice reaction time were increased (Gamberale and Hultengren 1974). More pronounced effects were
4 observed during exposure to 376 ppm for one hour: one subject complained of nausea that persisted one
5 hour after the end of exposure, 2 had a feeling of being inebriated, and 3 of 5 subjects exposed were
6 unable to normally perform the modified Romberg test and also 3 subjects (unclear, if the same 3 subjects)
7 had significant decrements in other tests of coordination and manual dexterity (Stewart et al. 1968). Only
8 one controlled study was located in which CNS effects were followed at a higher concentration than 376
9 ppm. In that study, two subjects exposed to 800 ppm for 4 hours reported that they suffered from
10 listlessness, impairment of balance, drowsiness, and, after termination of exposure, from muscular
11 weakness and unsteadiness with inertia and depression. CNS-depression was also indicated by a marked
12 decrease in performance in a “steadiness test” (measuring manual dexterity) (Carpenter et al. 1944).

13 No data are available indicating reproductive or developmental toxicity of styrene in
14 humans after acute exposure.

15 In *in vitro* systems with human cells, styrene induced chromosomal aberrations (CA), sister
16 chromatid exchanges (SCE), micronuclei, and hypoploidy. No data regarding genotoxic effects in humans
17 following single exposure to styrene are available. Epidemiological studies provide evidence for genetic
18 effects (chromosomal aberrations, mutations, DNA-adducts) in occupationally exposed workers.

19 With respect to carcinogenicity, IARC (2002) concluded that the increased risks for cancers of
20 the lymphatic and hematopoietic system are small, statistically unstable and often based on subgroup
21 analyses, the findings are not very robust and that it cannot be ruled out that the observations are the
22 results of chance, bias or confounding. Cohen et al. (2002) conclude that, although the balance of
23 epidemiologic studies do not suggest a causal association between styrene and any human cancer, because
24 of the limited power of these studies, the inconclusive results do not rule out the possibility that the
25 observed increase of lung tumors in mice are of relevance to humans.

26 In its latest evaluation, IARC (2002) concluded that there is “*limited evidence* in humans for
27 the carcinogenicity of styrene” and, taking into account the results from animal carcinogenicity studies
28 (see 3.5), that styrene is “*possibly carcinogenic to humans (Group 2B)*” (IARC 2002). US-EPA’s Office
29 of Research and Development has also updated previous assessments on the carcinogenic potential of
30 styrene and concluded that styrene is appropriately classified as a Group C, possible human carcinogen
31 (US EPA 2003).

32 Based on the body burden of styrene-7,8-epoxide or its adducts with hemoglobin and DNA,
33 and taking into account the results from carcinogenicity studies with styrene in animals, a cancer risk has
34 been estimated in the range of 1.7 – 7.5 per 100,000 persons exposed for 40 years to 20 ppm styrene,
35 8 hours/day, 5 days/week, 48 weeks/year (Greim 2003).

36 **3 ANIMAL TOXICITY DATA**


37 **3.1 Acute Lethality**

38 Data on acute lethality after inhalation exposure to styrene are available for rats, mice, and
39 guinea pigs (TABLE 3). Non-lethal effects observed in these studies are described in section 3.2.2.

1 3.1.1 Rats

2 Female and male Sprague-Dawley rats (10 of each sex/group; 20 of each sex at the highest
 3 concentration) were exposed to analytically (gas chromatography) determined concentrations of 2983,
 4 3766, 4814, 5911, 6621, 7218 and 8407 ppm styrene in a 180 L dynamic exposure chamber for 4 hours
 5 (BASF 1979b). Survival of animals was followed for 14 days after the exposure. No deaths were observed
 6 at 2983 and 3766 ppm. At the other concentrations, deaths were observed up to three days after exposure.
 7 No differences in LC_{50} between female and male rats were observed. A combined LC_{50} of 6410 ppm (95
 8 % conf. limit 6025 – 6769 ppm) for male and female rats was determined. Necropsy revealed acute
 9 dilation and congestive hyperemia in the heart, enlarged lung, and centrilobular liver changes with fatty
 10 degeneration. Other, non-lethal effects are described in section 3.2.2.

11 The LC_{50} values were determined for a number of benzene derivatives in male Sprague-Dawley
 12 rats (Bonnet et al. 1982a). Groups of 12 rats each were exposed (as more precisely described in Gradiski
 13 et al.(1978)) in 170 L dynamic exposure chambers to analytically (gas chromatography) confirmed vapor
 14 concentrations of styrene for 6 hours. Animals were observed for 14 days after the end of exposure. The 6-
 15 hour LC_{50} for styrene was 4618 ppm (95 % confidence interval 4399 – 4894 ppm). Death was preceded by
 16 somnolence, tremors, and muscular seizures but no lacrymation was observed. From the figure presented
 17 in the publication, it can be estimated that 90 % of the animals died (LC_{90}) at about 5000 ppm and 10 %
 18 died (LC_{10}) at about 3300 ppm (FIGURE 2) indicating a steep concentration-response curve. The authors
 19 also reported the occurrence of delayed deaths (more than 24 hours after the end of exposure) and that
 20 surviving animals showed growth retardation between day 7 and 14 post exposure. However, no detailed
 21 data were presented.



22 **FIGURE 2: CONCENTRATION-RESPONSE CURVE FOR ACUTE LETHALITY FOLLOWING**
 23 **INHALATION OF STYRENE IN RATS**

24 (Figure from Bonnet et al. 1982a)

TABLE 3: SUMMARY OF LETHAL EFFECTS IN ANIMALS AFTER ACUTE INHALATION EXPOSURE TO STYRENE				
Species, sex, strain	Concentration in ppm	Exposure Duration	Effect/Remarks	Reference
Rat , f, m, S-D	6410 6310 6480	4 hours	LC ₅₀ , female and male LC ₅₀ , females only LC ₅₀ , males only	BASF 1979b
Rat, f, m, S-D	8407 7218 6621 5911 4814 3766 2983	4 hours	18/20 f, 20/20 m, 38/40 m + f died 5/10 f, 8/10 m, 13/20 m + f died 6/10 f, 3/10 m, 9/20 m + f died 6/10 f, 1/10 m, 7/20 m + f died 1/10 f, 2/10 m, 3/20 m + f died 0/10 f, 0/10 m, 0/20 m + f died 0/10 f, 0/10 m, 0/20 m + f died	BASF 1979b
Rat, nd, nd	1300 2000 2500 5000 10,000	30 hours > 40 hours 16 hours > 30 hours 8 hours 21 hours 2 hours 8 hours 1 hour 3 hours	LC ₀ LC ₁₀₀ LC ₀ LC ₁₀₀ LC ₀ LC ₁₀₀ LC ₀ LC ₁₀₀ LC ₀ LC ₁₀₀	Spencer et al. 1942
Rat (18 f; 15 m)	5100	1 hour	No death during exposure	Niklasson et al. 1993
Rat, nd, nd	2270 (9.7 mg/l) 2761 (11.8 mg/l) 3276 (14.0 mg/l)	4 hours 4 hours 4 hours	LC ₁₆ LC ₅₀ LC ₈₄	Shugaev 1969
Rat, nd, nd	2700	4 hours	LC ₅₀ ; abstract only	Jaeger et al. 1974
Rat, f, m, CD	1500	6 hours	0/20 died after repeated (subchronic) exposure	Cruzan et al. 1997b
Rat, f, m, CD	1000	6 hours	0/70 died after repeated (chronic) exposure	Cruzan et al. 1998
Rat, m, S-D	~ 5000 4618 ~ 3300	6 hours 6 hours 6 hours	LC ₉₀ estimated from figure LC ₅₀ LC ₁₀ estimated from figure	Bonnet et al. 1982a
Rat, f, S-D	7769 (33.2 mg/l)	4 hours 8 hours	0/10 animals died 4/10 animals died	Lundberg et al. 1986
Mouse , f, m, NMRI	1600 1840 1370	4 hours	LC ₅₀ , female and male LC ₅₀ , females only LC ₅₀ , males only	BASF 1979a
Mouse, f, m, NMRI	3766 2983 1528 1420 864	4 hours	10/10 f, 10/10 m died 7/10 f, 9/10 m died 3/10 f, 8/10 m died 4/10 f, 6/10 m died 1/10 f, 0/10 m died	BASF 1979a

TABLE 3: SUMMARY OF LETHAL EFFECTS IN ANIMALS AFTER ACUTE INHALATION EXPOSURE TO STYRENE				
Species, sex, strain	Concentration in ppm	Exposure Duration	Effect/Remarks	Reference
	680		0/10 f, 0/10 m died	
Mouse, f, OF1	2429	6 hours	LC ₅₀	Bonnet et al. 1979b; 1982a
Mouse, nd, nd	4142 (17.7 mg/l) 4914 (21.0 mg/l) 5873 (25.1 mg/l)	2 hours 2 hours 2 hours	LC ₁₆ LC ₅₀ LC ₈₄	Shugaev 1969
Mouse	2223 (9.5 mg/l)	4 hours	LC ₅₀ (no details reported)	Izmerov et al. 1982
Mouse, B6C3F1, 65 f, 23-27 m	500 250	6 hours 6 hours	5 m, 0 f died after one exposure no death after one exposure	Morgan et al. 1993c
Mouse, B6C3F1, 5 m	500 250	6 hours 6 hours	4/5 found moribund and sacrificed, no death/moribund after one exposure	Morgan et al. 1993c
Mouse, B6C3F1, 36 f, 36 m	500 250	6 hours 6 hours	6/36 m, 1/36 f died after one exposure no death after one exposure	Morgan et al. 1993a
Mouse, B6-C3F1, 30 m	500	6 hours	2/30 died after one exposure	Mahler et al. 1999
Mouse, B6-C3F1, 20 f, 20 m	500	6 hours	no death after one exposure	Cruzan et al. 1997b
Mouse, CD-1, 20 f, 20 m	500 250	6 hours	1/20 m died after one exposure no death after one exposure	Cruzan et al. 1997b
Mouse, B6-C3F1, 39 m	250	6 hours	4/39 died after one exposure	Sumner et al. 1997
Mouse, CD-1, 30 m	250	6 hours	0/39 died after one exposure	Sumner et al. 1997
Guinea pig, nd, nd	1300 2000 2500 5000 10,000	16 hours 40 hours 7 hours 30 hours 6 hours 14 hours 3 hours 8 hours 1 hour 3 hours	LC ₀ LC ₁₀₀ LC ₀ LC ₁₀₀ LC ₀ LC ₁₀₀ LC ₀ LC ₁₀₀ LC ₀ LC ₁₀₀	Spencer et al. 1942

1 f: female; m: male; nd: no data; S-D: Sprague-Dawley.

2

1 A total number of 405 rats (sex, strain and number of animals per exposure group not reported)
2 were exposed to styrene concentrations ranging from 1300 ppm to 10,000 ppm for one hour to up to more
3 than 30 hours (Spencer et al. 1942). After the exposure the animals were observed for 2 – 4 weeks. No
4 LC₅₀ but only LC₀ and LC₁₀₀ were reported in the study. The highest concentration that could be reached
5 without observed condensation of the chemical out of the atmosphere was 10,000 ppm¹. At this
6 concentration, no deaths were observed after one hour of exposure, but all rats exposed for 3 hours died.
7 At 5000 ppm, no animal died after exposure for 2 hours but all animals exposed for 8 hours died. At
8 2500 ppm, all animals survived an 8-hour exposure and death of all animals only was observed when the
9 exposure lasted 21 hours. All animals survived 16 hours of exposure to 2000 ppm. Immediate deaths
10 during or shortly after the end of exposure were due to the effect of styrene on the CNS (see 3.2.2).
11 However, there were also delayed deaths with pulmonary edema and hemorrhages that were considered to
12 develop as a result of the acute irritating effect of styrene on the lung.

13 Shugaev (1969) exposed rats (strain, sex and number of animals not reported) to analytically
14 (gas chromatography) controlled styrene vapor concentrations for 4 hours in dynamic flow exposure
15 chambers. A LC₅₀ of 11.8 mg/l (95 % confidence interval 10.3 – 13.5 mg/l) (2761 ppm; 95 % confidence
16 interval 2410 – 3159 ppm) was calculated. It was also reported that animals “often” died after the
17 exposure. It is further reported that these animals were not used for the determination of lethal brain
18 styrene concentrations but it is not clear if data for animals dying after the end of exposure were included
19 in the determination of the LC values.

20 Groups of ten female Sprague-Dawley rats were exposed to analytically (infrared analysis)
21 confirmed styrene vapor concentrations for 4 or 8 hours, respectively (Lundberg et al. 1986). Deaths were
22 counted 24 hours after the start of exposure. At 33,200 mg/m³ (7769 ppm), a concentration that
23 corresponded to approximately saturated styrene vapor in air at 25 °C (see footnote 1), no deaths were
24 seen after a 4-hour exposure but four of ten animals died within 24 hours after an 8-hour exposure. No
25 LC₅₀ could be determined.

26 According to an abstract (Jaeger et al. 1974), a 4-hour LC₅₀ of 2700 ppm was estimated for fed
27 and fasted rats. It is further reported that styrene caused death by pulmonary irritation and edema, but no
28 further details were presented (strain, no. of animals and dose group, treatment with inducers, inhalation
29 exposure conditions, occurrence of CNS effects).

30 No deaths occurred in CD (Sprague-Dawley) rats exposed 6 hours/day, 5 days/week to
31 1500 ppm for 13 weeks (Cruzan et al. 2001a) or to 1000 ppm for 104 weeks (Cruzan et al. 1998). Acute
32 non-lethal (irritation) effects observed in these studies are described in section 3.2.2.

33 ***Studies with non-inhalation exposure***

34 The oral toxicity of styrene was determined in a total number of 57 young adult white rats
35 raised from a stock obtained from the Wistar institute. Styrene was given by gavage, but it is not clear
36 whether the compound was given undiluted or as an olive-oil or corn-oil solution emulsified with an
37 aqueous solution of gum arabic. The oral toxicity was low as indicated by an LD₅₀ of 5.0 g/kg b.w. (Wolf et
38 al. 1956). In accordance with these data, in another study no death of rats was observed after oral
39 administration of 1600 mg/kg b.w. but all rats died after treatment with 8000 mg/kg b.w. (Spencer et al.
40 1942).

¹ [Note: from the vapor pressure data – see **TABLE 1** – a saturated vapor concentration of 6580 ppm at 20 °C and of 8560 ppm at 25 °C can be calculated].

1 Groups of six female Sprague-Dawley rats were treated i.p. with styrene (Lundberg et al.
2 1986). Deaths were counted 24 hours and 14 days after the injection. The reported LD₅₀ of
3 898 mg/kg b.w. and the 95 % confidence limits (768 – 1051 mg/kg b.w.) were identical at both time
4 points indicating that there were no delayed deaths after intraperitoneal administration of styrene.

5 **3.1.2 Mice**

6 Bonnet et al. (1979) studied the toxicity of styrene in female OF1 mice. Groups of at least 20
7 mice were exposed by whole body exposure in 170 L dynamic exposure chambers (as more precisely
8 described in Gradiski et al. (1978) to analytically (gas chromatography) confirmed vapor concentrations
9 of styrene for 6 hours. Animals were observed for 14 days after the end of exposure. The 6-hour LC₅₀ for
10 styrene was 2429 ppm (95 % confidence intervals 2352 – 2530 ppm). The authors reported the occurrence
11 of delayed deaths on the 5th to 10th day after exposure but no detailed data were presented.

12 Shugaev (1969) exposed mice (strain, sex and number of animals not reported) to analytically
13 controlled styrene vapor concentrations for 2 hours in dynamic flow exposure chambers. A LC₅₀ of
14 21.0 mg/l (95 % confidence interval 17.8 – 24.8 mg/l) (2761 ppm; 95 % confidence interval 4165 –
15 5803 ppm) was calculated. It was also reported that animals “often” did not die during, but after the
16 exposure.

17 BASF (1979) conducted an acute inhalation toxicity study with NMRI mice. 10 female and 10
18 male mice per dose group were exposed “whole body” to analytically (gas chromatography) determined
19 concentrations of 680, 864, 1420, 1528, 2983 or 3766 ppm styrene for 4 hours in a 180 L dynamic
20 exposure chamber. Survival of animals was followed for 14 days after the exposure. No deaths were
21 observed at 680 ppm. At the other concentrations, deaths were observed 1 – 4 days after the exposure. The
22 concentration-response curve was steeper for male mice, and males seemed more sensitive than females.
23 LC₅₀ of 1370 ppm (95 % conf. limit 1087 – 1653 ppm) for male mice and of 1840 ppm (1486 –
24 2359 ppm) for female mice were determined. Necropsy revealed acute dilation and congestive
25 hyperemia in the heart, enlarged lung, and centrilobular liver changes. Other, non-lethal effects are
26 described in section 3.2.3.

27 Without presenting further details, a 4-hour LC₅₀ of 9500 mg/m³ (2223 ppm) for mice is
28 reported by Izmerov et al. (1982).

29 In a study to evaluate toxic effects of short-term exposure to B6C3F1 mice, 23 – 27 male and
30 65 female animals (8 weeks old) per group were exposed to analytically confirmed concentrations of 0,
31 125, 250, or 500 ppm styrene (99.9 % pure) for 6 hours/day (starting at 7 AM) for up to 14 days (Morgan
32 et al. 1993c). Each animal was exposed individually in Hazleton 2000 chambers and the styrene
33 concentration was measured every minute by infrared spectrophotometry. After one exposure day, 5 males
34 exposed to 500 ppm died. Mortality and morbidity were delayed after exposure and typically animals were
35 found dead or moribund the morning after the exposure day. In an additional experiment in the same study
36 conducted only with male mice, 4 of 5 animals died after one 6-hour exposure at 500 ppm. No deaths were
37 observed after one exposure in male mice at lower concentrations or at any concentration in female mice.

38 In a further study of the same group (Mahler et al. 1999), 2/30 male, 8-week old B6C3F1 mice
39 were found dead one day after a single 6-hour exposure to 500 ppm styrene. Death was attributed to
40 massive hepatic necrosis. In another study, death of 4/39 male B6C3F1 mice was observed following one
41 exposure to 250 ppm for 6 hours (Sumner et al. 1997).

42 Sex differences in susceptibility of B6C3F1 mice were further investigated (Morgan et al.
43 1993a). 36 animals (8 weeks old) per sex and dose were exposed as described above to 0, 125, 250, or

1 500 ppm styrene. At 500 ppm, six male and one female mice were found dead or were terminated
2 moribund after one exposure. No deaths occurred after one exposure to 250 ppm or 125 ppm. Necropsy of
3 dead or moribund mice revealed that the liver of these animals was engorged with blood, and microscopic
4 examination showed severe congestion and necrosis in the liver of these animals.

5 In a subacute toxicity study with CD-1 and B6C3F1 mice, one of 20 male CD-1 mice exposed
6 to 500 ppm died after one 6-hour exposure (Cruzan et al. 1997b).

7 Data on lethality following repeated short-term exposure in Morgan et al. (1993a), Morgan et
8 al. (1993c) and Cruzan et al. (1997) are summarized below (*“studies with repeated exposure”*).

9 ***Studies with repeated inhalation exposure***

10 In a developmental toxicity study, 2 of 6 pregnant BMR/T6T6 mice exposed to 500 ppm
11 6 hours/day from the 6th day of gestation on died before the intended end of the exposure phase on day 16.
12 At 750 ppm, 3 of 5 mice died. Surviving dams carried a high number of dead and resorbed fetuses
13 (Kankaanpää et al. 1980, see 3.3.2).

14 B6C3F1 mice were exposed up to 14 consecutive days to styrene as described above (see 3.1.2,
15 Morgan et al. 1993c). No animals died at 0 and 125 ppm styrene. The highest mortality was observed at
16 250 ppm where 7 males and 2 females died after two exposures and a total of 11 males and 6 females after
17 14 days. At 500 ppm, no deaths occurred in females, 7 males died after 2 exposures and a total of 8 males
18 died during the 14-day exposure.

19 In a second study investigating sex-related differences in susceptibility of B6C3F1 mice to
20 styrene, animals were exposed up to 3 consecutive days to styrene as described above (see 3.1.2, Morgan
21 et al. 1993a). No control mice or mice exposed to 125 ppm died. At 250 ppm, 2 males and 3 females died
22 or were terminated moribund after 2 exposures. At 500 ppm, 6 males and one female died after one
23 exposure but no additional deaths occurred after subsequent exposures.

24 The susceptibility of different strains of mice to styrene inhalation exposure was studied
25 (Morgan et al. 1993b). 8 week old B6C3F1, C57BL/6, Swiss and DBA/2 mice (20 of each sex and strain
26 at each dose group) were exposed to styrene (99.9 % pure) at nominal but analytically confirmed
27 concentrations of 0, 125, 250, or 500 ppm in Hazleton 2000 chambers for 6 hours/day for 4 consecutive
28 days. No animals of any strain died at 0 and 125 ppm. Both strain and sex differences in mortality (or
29 sacrifice in moribund condition) were observed. The highest mortality occurred in Swiss mice and both
30 sexes proved similarly susceptible (male: 10/20 died at 500 ppm, female: 3/20 at 250 ppm, 8/20 at 500
31 ppm died). Overall mortality in B6C3F1 mice was comparable to that in Swiss mice but there was a clear
32 sex-specific effect with mortality in male B6C3F1 mice (14/20 at 250 ppm, 3/20 at 500 ppm died) being
33 much higher than in females (1/20 at 250 ppm). Mortality in C57/BL6 mice also differed between males
34 (7/20 at 250 ppm, 1/20 at 500 ppm) and females (1/20 at 250 ppm and 500 ppm each). Mortality in male
35 B6C3F1 and C57BL/6 mice at 250 ppm was higher than at 500 ppm. No mortality was observed in male
36 and female DBA/2 mice.

37 Sex-related differences in mortality were also observed in B6C3F1 and CD-1 mice in another
38 subacute study in which mice (20 per sex and dose group) were exposed in 0.75 m³ inhalation chambers to
39 analytically confirmed concentrations of 0, 15, 60, 250 or 500 ppm styrene for 6 hours/day, 5 days/week
40 for 14 days (Cruzan et al. 1997b). No deaths were observed at 15 and 60 ppm. Remarkably, the
41 concentration-response was non-linear in female mice of both strains as mortality after two weeks clearly
42 was higher at 250 ppm (7 CD-1, 10 B6C3F1) than at 500 ppm (2 CD-1, 0 B6C3F1). This was not

1 observed in male mice of both strains where mortality increased with increasing concentration: One male
2 of each strain died at 250 ppm, 7 male CD-1 and 8 B6C3F1 males died at 500 ppm.

3 In a further study by Morgan et al. (1995), 8 week old male and female B6C3F1 and Swiss
4 mice were exposed to 0, 150 or 200 ppm styrene as described above for 6 hours/day on 4 consecutive
5 days. One female Swiss mouse died after four exposures to 200 ppm, necropsy revealed centrilobular
6 hepatocellular necrosis in this mouse. No deaths were observed in male Swiss or in B6C3F1 mice of both
7 sexes.

8 **3.1.3 Guinea pigs**

9 A total number of 410 guinea pigs (sex, strain and number of animals per exposure group not
10 reported) were exposed to styrene concentrations ranging from 1300 ppm to 10,000 ppm for one hour to
11 40 hours (Spencer et al. 1942). After the exposure the animals were observed for 2 – 4 weeks. No LC₅₀ but
12 only LC₀ and LC₁₀₀ were reported in the study. The highest concentration that could be reached without
13 condensation of the chemical out of the atmosphere was 10,000 ppm. At this concentration, no deaths
14 were observed after one hour of exposure, but all guinea pigs exposed for 3 hours died. At 5000 ppm, no
15 animal died after exposure for 3 hours but all animals exposed for 8 hours died. At 2500 ppm, all animals
16 survived a 6-hour exposure and death of all animals only was observed when the exposure lasted 14 hours.
17 All animals survived 7 hours of exposure to 2000 ppm but all animals died when exposure at this
18 concentration was extended to 30 hours. Immediate deaths during or shortly after the end of exposure
19 were due to the effect of styrene on the CNS. However, there were also delayed deaths with pulmonary
20 edema and hemorrhages that were considered to develop as a result of the acute irritating effect of styrene
21 on the lung.

22 **3.1.4 Hamsters**

23 *Studies with non-inhalation exposure*

24 Groups of 23 male Syrian hamsters were treated with 0, 450 or 600 mg/kg b.w. styrene in corn
25 oil by gavage (Parkki 1978). 3 of the animals that had received 600 mg/kg b.w. styrene died within 24
26 hours after administration. No deaths occurred at 450 mg/kg b.w.

27 **3.2 Nonlethal Toxicity**

28 **3.2.1 Nonhuman primates**

29 *Studies with repeated inhalation exposure*

30 Spencer et al. (1942) exposed 4 monkeys (two of each sex, species not specified) to 1300 ppm
31 styrene 7 – 8 hours/day, 5 days/week. Male monkeys received 142 exposures during 7 months, females
32 262 – 264 exposures over a period of 12 months. Additionally, there were at least 3 control monkeys. No
33 further experimental details were reported. There were no signs of irritation or intoxication. Furthermore,
34 the animals were reported to be in excellent condition and to show no gross or microscopic pathological
35 lesions (at least lung, liver, kidney, spleen, pancreas, adrenals were examined). Blood examination
36 revealed no differences between the four exposed and three control monkeys.

37 **3.2.2 Rats**

38 Female and male Sprague-Dawley rats (10 of each sex/group; 20 of each sex at the highest
39 concentration) were exposed to 2983, 3766, 4814, 5911, 6621, 7218 and 8407 ppm styrene for 4 hours

1 (BASF 1979b 3.1.1). Styrene was irritating to eyes and respiratory tract as indicated by closed eyes, eye
2 and nasal secretion, salivation, and dyspnoe. Signs of CNS impairment were staggered or stalking gait,
3 tremors, lying on the side, and narcosis. Symptoms were not differentiated with respect to the individual
4 exposure concentrations except that it was reported that narcosis was “slight” at the lowest concentration.

5 Shugaev (1969) reported that rats (strain, sex and number of animals not reported) inhaling
6 styrene for one hour at a concentration corresponding to the 4-hour LC₅₀ (reported to be 2761 ppm) were
7 in a state of deep narcosis at the end of the 1-hour exposure.

8 Effects on the nervous system (somnolence, tremors, and muscular seizures) that preceded
9 death were also reported by Bonnet et al. (1982). Lacrymation was not observed in styrene exposed
10 animals in this study.

11 Exposure of rats to 1300 ppm led to immediate irritation of eyes and nose with lacrymation,
12 salivation, and nasal discharge (Spencer et al. 1942, see 3.1.1 for further information). At this
13 concentration, no other signs of intoxication were noted until 12 hours of exposure when general
14 weakness and unsteadiness became apparent. These effects were more evident at 2000 ppm but more
15 pronounced signs of effects on the CNS with loss of consciousness were only seen in “some” animals after
16 24 – 30 hours. At 2500 ppm, rats showed definite CNS depression (weakness, stupor, incoordination, loss
17 of equilibrium, tremor, finally unconsciousness) after 10 – 12 hours. Animals were “usually” completely
18 unconscious within one hour exposure to 5000 ppm and even more rapid at 10,000 ppm. Unconsciousness
19 was preceded by loss of equilibrium, falling on the side, running leg movements, tremors and convulsions.
20 In addition to the immediate irritant action and the effects on the CNS, pulmonary changes were observed.
21 These varied from slight congestion to hemorrhages, edema, exudation, and leucocytic infiltration.
22 Generally, the severity of effects varied with the exposure concentration and duration. Marked pulmonary
23 lesions were seen at all concentrations when the exposure time was so long that at least some of the
24 exposed animals died following exposure. Regarding other organs, liver and kidney changes were seen in
25 “comparatively few animals”; these changes were most often recorded at 2500 ppm but less frequently at
26 higher concentrations.

27 Irritation during exposure also was observed in a subchronic study in which female and male
28 CD (Sprague-Dawley) rats (10 females, 10 males per group) were exposed to analytically (gas
29 chromatography) confirmed concentrations of 200, 500, 1000 and 1500 ppm styrene in 0.75 m³ inhalation
30 chambers for 6 hours/day, 5 days/week for 13 weeks (Cruzan et al. 1997b). Irritation was observed at all
31 concentrations during exposure. Signs ranged from closed eyes at 200 ppm to salivation and rubbing of
32 paws and chin on the cage at higher concentrations. Similar effects (salivation, restlessness, hunched
33 posture) were also observed in groups of 70 male and female CD rats each during exposure to 500 and
34 1000 ppm for 6 hours/day, 5 days/week for 104 weeks; generally, effects tended to decrease during each
35 week of exposure (Cruzan et al. 1998).

36 Salivation and reduced attention were observed in a subacute study in which 10 male Wistar
37 rats/group were exposed 6 hours/day on 5 consecutive days to an analytically confirmed concentration of
38 1500 ppm. At the beginning of the exposure period, signs of sensory irritation were also observed at 500
39 ppm but not at 150 ppm (Jarry et al. 2002).

40 Male Wistar rats were exposed to analytically (infrared spectrophotometry) confirmed con-
41 centrations of 0, 100, 300, or 600 ppm styrene 12 hours/day, 5 days/week for 4 weeks (Mäkitie et al.
42 2003). During the exposures, the animals were mostly recumbent, especially at 600 ppm. The authors saw
43 no clear signs of irritation of skin, eye or mucous membranes at the end of the daily exposures.

TABLE 4: SUMMARY OF ACUTE NON-LETHAL EFFECTS IN ANIMALS AFTER INHALATION EXPOSURE TO STYRENE				
Species (strain, sex, no./ group)^a	Concentration (ppm)	Exposure Duration	Effect	Reference
Rat (Wistar, m)	2000 ppm	5 hours	Loss of consciousness in “many of the test animals”	Withey and Collins 1979
Rat (nd; 18 f, 15 m)	1730 ppm	1 hour	Inability to suppress nystagmus	Niklasson et al. 1993
Rat (Wistar, 10 m)	1500 ppm 500 ppm	6 hours	Reduced attention, sensory irritation Sensory irritation at start of exposure	Jarry et al. 2002
Rat (nd)	4-hour LC ₅₀ (2760 ppm)	1 hour	State of deep narcosis	Shugaev 1969
Mouse (Swiss OF ₁ , 10 m)	549 ppm	4 hours	50 % decrease in immobility time in behavioral “despair swimming” test	de Ceaurriz et al. 1983
Mouse (Swiss Webster, m)	156 ppm	3 minutes	RD ₅₀	Alarie 1973
Mouse (Swiss OF ₁ , 6 m)	586 ppm	5 minutes	RD ₅₀	de Ceaurriz et al. 1981
Mouse (Swiss Webster, m)	980 ppm	10 minutes	RD ₅₀	Bos et al. 1992
Mouse (NMRI, 10 f, 10 m)	1420 ppm 2983 ppm 3766 ppm	4 hours	Staggered gait Apathy Narcosis	BASF 1979a

1

2 Effects of styrene on the vestibulo- and opto-oculo motor system effects were studied in a total

3 number of 18 female and 15 male “pigmented rats” (Niklasson et al. 1993). Each rat was used for an

4 initial control experiment with no solvent exposure and one or two subsequent experiments with exposure

5 to one or two styrene concentration levels. Exposure for each animal was separated by at least one week.

6 Animals were exposed in a dynamic exposure chamber to nominal concentrations (fluctuating within

7 about 15 % as confirmed analytically during all exposures) of 3600; 7400; 13,400; 17,300; and

8 21,800 mg/m³ of styrene (840, 1730, 3140, 4050, 5100 ppm). 10 minutes after initiation of exposure, a

9 few eye saccades were provoked and registered. Then, during continuous exposure, repeated vestibular

10 stimulations in darkness and combined vestibular and optokinetic stimulations were performed (lasting 35

11 minutes) followed by optokinetic stimulations (lasting 15 minutes). Optokinetic stimulation caused

12 nystagmus with a gain that was reduced by styrene exposure in a concentration-dependent manner. Effects

13 could be observed at the lowest concentration of styrene applied. Repeated vestibular stimulations in

14 darkness showed a prolongation of nystagmus at 4050 and 5100 ppm. The combined vestibular and

15 optokinetic stimulation caused no or little nystagmus in control experiments since the visual input

16 suppressed the vestibular reaction. Styrene exposure caused a concentration-dependent inability to

17 suppress the nystagmus at concentrations \geq 1730 ppm.

18 Pulmonary toxicity was studied in Sprague-Dawley rats (Green et al. 2001b). Groups of 5

19 female and 5 male animals were exposed “whole body” in 3.4 m³ chambers to analytically (gas

20 chromatography) controlled concentrations of 0 or 500 ppm styrene for 6 hours. No treatment-related

21 effects were observed in the lung of animals exposed to styrene for 1, 5, 6, or 10 days.

1 The serum activity of sorbitol dehydrogenase (SDH) was used as an indicator of liver damage
2 in a study with female Sprague-Dawley rats (Lundberg et al. 1986). Animals were exposed from 1/32 to 1/2
3 of the saturation concentration of styrene in air (33,200 mg/m³; 7769 ppm) for 4 hours and sacrificed
4 20 hours after the end of exposure. No increase in serum SDH-activity was observed at any concentration.

5 ***Studies with non-inhalation exposure***

6 In the study of Lundberg et al. (1986), female Sprague-Dawley rats were also treated by i.p.
7 injections of styrene in peanut oil at doses of 1/8, 1/16, and 1/32 of the LD₅₀ (898 mg/kg b.w.). The serum
8 activity of sorbitol dehydrogenase (SDH) was used as an indicator of liver damage; no increase was
9 observed at any of the concentrations.

10 ***Studies with repeated inhalation exposure***

11 The degeneration and regeneration of respiratory mucosa of the trachea and the nose following
12 subacute exposure of male Sprague-Dawley rats was studied by Ohashi et al. (1986). Groups of 10
13 animals each were exposed to analytically (gas chromatography) determined concentrations of 171 ± 21.8
14 ppm or 1108 ± 73.8 ppm of styrene or air in dynamic exposure chambers for 4 hours/day, 5 days/week for
15 3 weeks. On the first day of the post-exposure period, the ciliary activity of the tracheal mucosa showed
16 some deterioration in the 171-ppm group (80 % of control value). There was also an increased number of
17 dense bodies and small vacuoles in the epithelial cells and small compound cilia were observed but there
18 was no severe degeneration of epithelial cells. In the nasal mucosa, ciliary activity was reduced (41 % of
19 control) and morphological alterations (ballooning of cells, fewer ciliated cells, increase of dense bodies)
20 were seen. 12 weeks after the last exposure, the ciliar activity of the tracheal and nasal mucosa was normal
21 and cells with an increased number of dense bodies were only sporadically found in the trachea. At
22 1200 ppm, ciliar activity of the tracheal mucosa was poor (18 % of control) the first day after the last
23 exposure, and cells showed morphological changes (vacuolization, increased number of dense bodies,
24 cytoplasm protuberances). In the nasal mucosa, ciliary activity was disabled the first post-exposure day,
25 there were few ciliated cells and severe degeneration of epithelial cells. The effects in the trachea largely
26 resolved within the following 12 weeks but in the nasal mucosa reduced ciliary activity and morphological
27 alterations were still detectable.

28 In the nasal olfactory epithelium of female and male CD (Sprague-Dawley) rats,
29 histopathological changes were seen in a subchronic study after exposure to 500, 1000 and 1500 ppm for 6
30 hours/day, 5 days/week for 13 weeks. At 200 ppm, no effects were seen. In the same study, no styrene-
31 related effects were observed in the lungs at any concentration (Cruzan et al. 1997b).

32 Effects on serum prolactin and dopamine levels and on hypothalamic and striatal catecholamine
33 concentrations were studied in male Wistar rats (Jarry et al. 2002). Groups of 10 animals each were
34 exposed to analytically (gas chromatography) confirmed concentrations of 0, 150, 500, and 1500 ppm
35 styrene for 6 hours/day on 5 consecutive days. Parameters were measured immediately after the end of
36 exposure and after a recovery period of 24 hours. No significant changes in dopamine,
37 dihydroxyphenylacetic acid, noradrenaline, and homovanillic acid levels were observed in hypothalamus
38 and striatum of styrene-exposed rats compared to controls. Also, no change in prolactin level in serum was
39 observed. The dopamine level in peripheral blood was higher at 150 ppm and at 1500 ppm in the 24-hour
40 recovery group at 150 ppm, but no concentration-response was obvious; no change was seen immediate
41 after cessation of exposure.

42 Ototoxicity of styrene was investigated in several studies. When male Long-Evans rats were
43 exposed to concentrations between 500 ppm and 1500 ppm 6 hours/day, 5 days/week, for 4 weeks, a
44 permanent increase in auditory threshold was observed at mid frequency ranges in animals exposed to 850

1 and 1000 ppm. At higher concentrations, the threshold was increased in the mid-low, mid- and high
2 frequency (Loquet et al. 1999). In a further study, Long-Evans rats were exposed to 1000 ppm, 6
3 hours/day, for 5 days. Immediately after the end of exposure, cochlear function as tested by DPOAE
4 (distortion product otoacoustic emissions) showed no decrease in DPOAE amplitude compared to pre-
5 exposure. However, 2 and 4 weeks after the end of exposure, DPOAE indicated a disruption of auditory
6 function (Lataye et al. 2003). Histological lesions of the cochlea and worsening of the electrophysiological
7 results (evoked potentials from the inferior colliculus of the cochlea) after the end of exposure was also
8 described in another publication of the same group in which Long-Evans rats were exposed to 1000 ppm,
9 6 hours/day, 5 days/week, for up to 4 weeks (Campo et al. 2001). In male Wistar rats exposed to 100,
10 300, or 600 ppm styrene for 12 hours/day, 5 days/week, for 4 weeks, 100 and 300 ppm caused no hearing
11 impairment as measured by auditory brain response (ABR). At 600 ppm, a slight hearing loss (~ 3 dB)
12 was observed only at the highest test frequency of 8 kHz; cytochromeograms showed a substantial loss of
13 the outer hair cells. A synergism with exposure to noise (100 dB) was observed only when styrene was
14 applied in concentrations that were ototoxic without noise (Mäkitie et al. 2003).

15 3.2.3 Mice

16 10 female and 10 male NMRI mice per dose group were exposed to 680, 864, 1420, 1528, 2983
17 or 3766 ppm styrene for 4 hours (BASF 1979a, see 3.1.2). Symptoms (not reported separately for both
18 sexes) included hunched position at exposures exceeding 1420 ppm and rough fur at all concentrations.
19 Styrene was irritating to the respiratory tract and to the eyes (intermittent breathing at all concentrations,
20 rubbing of nose and mouth, secretion from nose and eyes, eyes closed at 2983 and 3766 ppm). Signs of
21 CNS impairment (staggered or stalking gait) were noted from 1420 ppm upwards and were more severe at
22 higher concentrations with apathy and narcosis occurring at 2983 and 3766 ppm.

23 In a subacute study, B6C3F1 and CD-1 mice (20 per sex and dose group) were exposed in
24 0.75 m³ inhalation chambers to analytically confirmed concentrations of 0, 14, 58, 250 or 519 ppm styrene
25 for 6 hours/day, 5 days/week for 14 days (Cruzan et al. 1997b). Mice exposed to all concentrations of
26 styrene showed signs of irritation. At 500 ppm, animals adopted a prone position during exposure.
27 Treatment related signs between exposures occurred in mice exposed to 250 or 519 ppm. These signs
28 included lethargy, shallow breathing, and unsteady gait. 250 and 500 ppm caused liver lesions with
29 centrilobular hepatocyte necrosis and associated changes. B6C3F1 mice were more susceptible than CD-1
30 mice. Mortality also occurred at these two highest concentrations (see 3.1.2).

31 Sensory irritation

32 Male Swiss OF₁ mice (six at each concentration) were exposed “head only” to at least 4
33 different analytically (gas chromatography) controlled concentrations of styrene in dynamic 200 L
34 inhalation test chambers for 5 minutes. For the determination of the reflex decrease in respiratory rate that
35 served as an index of sensory irritation, the animals were secured in individual body plethysmographs. An
36 RD₅₀ of 586 ppm (no confidence limits given) was determined (de Ceaurriz et al. 1981).

37 In a similar study, Swiss Webster mice were exposed to styrene for 3 minutes (Alarie 1973).
38 The test substance was solubilized in polyethylene glycol and aerosols were prepared. An RD₅₀ of
39 666 µg/l (156 ppm) (95 % conf. limit 574 – 758 µg/l; 134 – 177 ppm) was determined. In a further study
40 by the same author (cited in Bos et al. 1992), Swiss Webster mice were exposed for 10 minutes and an
41 RD₅₀ of 980 ppm (85 % conf. limit 826 – 1297 ppm) was determined.

42 Behavioral studies

1 Behavioral changes in a “despair swimming test” were studied in Swiss OF1 mice (de Ceaurriz
2 et al. 1983). Groups of 10 male animals were exposed to analytically (gas chromatography) confirmed
3 concentrations of 413, 610, 807, or 851 ppm styrene or air in 200-L chambers for 4 hours. Immediately
4 afterwards, total duration of immobility during a 3-minute period in a “despair swimming test” was
5 determined. Immobility was defined as cessation of struggling to get out of the water. Exposure to
6 solvents including styrene caused a dose-dependent decrease in duration of immobility as compared to the
7 corresponding controls. In case of styrene, the mean duration of immobility decreased significantly by 28,
8 60, 77, or 83 % of control at the concentrations noted above. An ID₅₀ (50 % decrease in immobility) of
9 549 ppm (95 % confidence interval 522 – 573 ppm) was calculated.

10 Immunological effects

11 It is reported that female BALB/c mice (6 per group) exposed to 300 ppm but not to 200 or
12 100 ppm styrene showed an increase in IgM response of lung-associated lymph nodes in an anti-SRBC
13 (sheep red blood cells) assay. Furthermore, the ex vivo release of γ -interferon from lung-associated lymph
14 nodes decreased with increasing concentration of styrene but was higher than control values at all styrene
15 concentrations. No effects were seen in the spleen (Ban et al. 2003). An evaluation of the results is not
16 possible since the duration of exposure is not reported.

17 *Studies with repeated inhalation exposure*

18 Pulmonary toxicity was studied in CD-1 mice (Green et al. 2001b). Groups of 5 female and 5
19 male mice were exposed “whole body” in 3.4 m³ chambers to analytically (gas chromatography)
20 controlled concentrations of 0, 40 or 160 ppm styrene for 6 hours. At 40 ppm, in mice killed immediately
21 after exposure, there was evidence of necrosis and loss of cells, believed to be Clara cells, from large
22 bronchioles, while Clara cells in the terminal bronchioles were not overtly affected. At 160 ppm, no
23 significant effect was seen at this time point. In animals killed 18 hours after exposure, minimal necrosis
24 but treatment-related focal loss of cytoplasm from non-ciliated cells was observed, predominantly at the
25 terminal bronchiolar area. Females seemed slightly more affected than males. The lesions observed at this
26 time point were similar at both styrene concentrations. In mice that had received 5-bromo-2-deoxyuridine
27 3 days prior to sacrifice, no evidence of an increase in cell replication in the alveoli, terminal or large
28 bronchioles was observed after one day of exposure to styrene.

29 In a further study of the authors, the toxicity of styrene to the nasal epithelium was studied in
30 male CD-1 mice. 20 mice per dose group were exposed to analytically (gas chromatography) confirmed
31 concentrations of 0, 40 or 160 ppm styrene for 6 hours/day for 3 days. Mice were killed 17 hours after the
32 last exposure. At 160 ppm, degenerative, mostly focal changes in the olfactory tissue were observed in all
33 mice. Most obvious was the presence of cellular and serious fluid exudate in the airways of the nasal
34 passages in the olfactory epithelium of the dorsal meatus. Atrophy of the olfactory mucosa with loss of
35 cellular organisation and focal decrease of Bowman’s glands were also observed. At 40 ppm, animals
36 were largely unaffected, only one mouse showed minimal atrophy of the olfactory mucosa (Green et al.
37 2001a).

38 Effects on the nasal passages and the lung were also investigated by Cruzan et al. (2001).
39 Groups of 55 male CD-1 mice were exposed to analytically (gas chromatography) confirmed
40 concentrations of 0, 40 or 80 ppm styrene in 2.43 m³ inhalation chambers for 6 hours/day, 5 days/week for
41 up to 13 weeks. A subgroup of 5 mice was terminated after one exposure (and further subgroups after
42 repeated exposures). In the nasal olfactory epithelium, single cell necrosis was found after a single
43 exposure to 80 ppm, but not to 40 ppm. No changes were observed in the lung at 40 or 80 ppm up to the
44 end of the 13th week.

1 **3.2.4 Guinea pigs**

2 In the study of Spencer et al. (1942), guinea pigs generally showed the same reactions to
3 styrene exposure than rats: irritation of mucous membranes, CNS-depression and pulmonary changes (see
4 3.2.2). The effects occurred at the same concentrations, however, it was reported that under comparable
5 conditions of exposure the pulmonary changes were more severe in guinea pigs than in rats.

6 *Studies with repeated inhalation exposure*

7 In a study on ototoxicity of styrene, pigmented guinea pigs were exposed to 1000 ppm, 6
8 hours/day, for 5 days. Cochlear function as tested by DPOAE (distortion product otoacoustic emissions)
9 was measured before exposure, immediately afterwards, and 2 and 4 weeks after exposure. In contrast to
10 the observations made in rats similarly exposed in the same study (see 3.2.2), no disruption of auditory
11 function was observed in guinea pigs (Lataye et al. 2003).

12 **3.2.5 Rabbits**

13 *Studies with repeated inhalation exposure*

14 In the study of Spencer et al. (1942), 2 rabbits (strain, sex, and further experimental details not
15 reported) received up to 126 exposures to 2000 ppm for 7.5 – 8 hours/day, 5 days/week. The rabbits were
16 reported not to be affected by these exposures. In contrast, rats and guinea pigs showed marked eye and
17 nose irritation during the exposures.

18 **3.3 Developmental/Reproductive Toxicity**

19 Data are available from studies with rats, mice, rabbits, and hamsters (for review, see Brown
20 1991; 2000; IARC 2002).

21 **3.3.1 Rats**

22 No studies were identified concerning the effects of a single inhalation exposure to styrene on
23 developmental or reproductive toxicity.

24 *Studies with non-inhalation exposure*

25 Sprague-Dawley rats were treated on the 11th day of gestation with a single dose of 300 mg/kg
26 styrene in corn oil by gavage (Daston et al. 1991). The dose led to maternal toxicity (decreased body
27 weight, reduced food intake) but no effects on pre- and postimplantation losses, malformations and
28 variations were observed on gestation day 20.

29 In a carcinogenicity study (Ponomarev and Tomatis 1978), female BD IV rats were given
30 1350 mg/kg b.w. styrene in olive oil by gavage on day 17 of gestation (followed by weekly treatment of
31 the offsprings with 500 mg/kg b.w. after weaning). Preweaning mortality in offsprings from styrene-
32 treated dams was non-significantly higher (10 %) than in the control group (2.5 %). There was no effect
33 on litter size at birth, postweaning survival, or body weight development.

34 *Studies with repeated inhalation exposure*

35 A “segment II” developmental toxicity study was conducted by Murray et al. (1978). Female
36 Sprague-Dawley rats were exposed to 0, 300 or 600 ppm for 7 hours/day during day 6 – 15 of gestation.

1 Both styrene concentrations were maternally toxic (decreased body weight gain and decreased food
2 consumption). A greater incidence of skeletal variations but no other embryo or fetal developmental
3 effects were observed in offsprings of styrene-treated dams compared to controls. The authors reported
4 that the observed incidence was within the range (number not reported) of historical controls.

5 Postnatal neurochemical changes, growth, and physical landmarks of development were studied
6 in offsprings of female Wistar rats that had been treated with 0, 50 or 300 ppm 6 hours/day during
7 gestation day 6 – 20 (Katakura et al. 2001). To adjust for nutritional effects, pair-fed and ad-libitum
8 controls were included. Food consumption of dams was decreased at 300 ppm, but maternal weight gain
9 was not significantly different from that of both control groups. Litter size, birth weight and sex ratio were
10 found to exhibit no effects within the variation range studied. At 300 ppm, an increased neonatal death
11 rate was observed compared to the pair-fed control group. Postnatal development (incisor eruption, eye
12 opening, air righting reflex) was also delayed at 300 ppm compared to both control groups. Furthermore,
13 neurochemical alterations were observed as indicated by a significantly decreased 5-hydroxytryptamine
14 concentration in the cerebrum at postnatal day 21 in offspring exposed in utero to 300 ppm styrene. These
15 results suggest that the offspring were susceptible to the effects of styrene on a few developmental
16 landmarks and the results support previous findings of alterations in postnatal development in offsprings
17 of styrene treated dams (Kishi et al. 1992; 1995).

18 ***Studies with non-inhalation exposure***

19 In the study of Murray et al. (1978) (see above), pregnant rats were also treated with 90 or
20 150 mg/kg b.w. styrene by gavage twice daily from the 6th to 15th day of gestation. Compared to non-
21 treated controls, maternal weight gain was reduced and the incidence of skeletal variation was higher in
22 styrene-exposed groups. However, the authors reported that the observed incidences were within the range
23 (numbers not reported) of historical controls.

24 In a further segment-II teratology study, albino rats were treated orally with 250 or 400 mg/kg
25 b.w. styrene in peanut oil on gestation days 6 – 15 (Srivastava et al. 1990). At 400 mg/kg b.w., maternal
26 toxicity (severe reduction in weight gain), increased pre- and postimplantation losses and reduction in fetal
27 weight was observed but no gross or structural defects. No maternal toxicity and embryo/fetotoxic or
28 developmental effects were seen at 250 mg/kg b.w.

29 Maternal toxicity (severe reduction in body weight, but no deaths) were also seen in a further
30 study in which Sprague-Dawley rats were administered 1147 mg/kg b.w. styrene on gestation day 6 – 15
31 (Chernoff et al. 1990). No differences compared to control were observed with respect to fetal weight,
32 embryo/fetal death, and skeletal or soft tissue malformations or variations.

33 Interactions of styrene exposure with protein malnutrition were studied by Khanna et al.
34 (1991). Rats were given a diet of 20 % casein or 8 % casein throughout pregnancy and lactation, with or
35 without 100 mg/kg b.w. of styrene given orally from day 6 of gestation onward. Low casein diet alone led
36 to a reduction in postnatal weight gain and a delay in development (eye opening, behavioral responses).
37 These effects were more pronounced in pups of dams that were treated with styrene and receiving the low
38 casein diet. These pups also showed a decrease in brain enzyme activities. No such effects were seen in
39 offsprings of dams that were given the normal casein diet.

40 In a three-generation reproductive toxicity study, female and male rats were continuously
41 exposed to 125 or 250 ppm styrene in drinking water (7 – 10 mg/kg b.w. or 14 – 21 mg/kg b.w.,
42 respectively). Water consumption was reduced in both groups. In high dose females, body weight gain
43 was slightly reduced but no consistent treatment-related effects on pup survival, pup body weights, or
44 developmental parameters could be observed (Beliles et al. 1985).

1 3.3.2 Mice

2 In a carcinogenicity study (Ponomarkov and Tomatis 1978), female O20 and C57Bl mice were
3 given styrene in olive oil by gavage on day 17 of gestation (O20: 1350 mg/kg b.w.; C57Bl: 300 mg/kg
4 b.w. each followed by weekly treatment of the offsprings with the same dose after weaning). In O20 mice,
5 the maximum tolerated dose was exceeded. There was no effect on litter size at birth or on body weight
6 gain but survival prior to weaning was decreased in the offspring of treated animals. In C57Bl mice, no
7 effects on maternal mortality, litter size or preweaning mortality was observed.

8 *Studies with repeated inhalation exposure*

9 Pregnant female BMR/T6T6 mice were exposed to an analytically (infrared spectrophotometry)
10 controlled concentration of 250 ppm styrene or air (control) for 6 hours/day from the 6th to the 16th day of
11 gestation and sacrificed the last day of exposure (Kankaanpää et al. 1980). The number of dead or
12 resorbed fetuses was higher in styrene exposed mice (26.9 %) compared to controls (18.2 %) but did not
13 reach statistical significance ($0.05 < p < 0.10$). Among 94 live fetuses in the styrene exposed group, 3
14 were malformed (rib fusion, extra rib), in the control group, among 76 live fetuses, one was malformed
15 (exteriorization of the liver). No statistical evaluation of these results was presented in the report, but it
16 seems unlikely that the effect would have been significant. In preliminary experiments with exposure to
17 500 and 750 ppm, high maternal mortality was observed (250 ppm: 2/6; 750 ppm: 3/5 died before
18 gestation day 16). Surviving mice carried a high number of dead and resorbed fetuses (fetal death rate at
19 250 ppm: 47 %; at 750 ppm: 95 %).

20 3.3.3 Rabbits

21 *Studies with repeated inhalation exposure*

22 A “segment II” developmental toxicity study was conducted by Murray et al. (1978). Female
23 New Zealand white rabbits were exposed to 0, 300 or 600 ppm for 7 hours/day during day 6 – 18 of
24 gestation. No maternal toxicity, no embryo-/fetotoxicity and no teratogenic effects were evident in styrene
25 exposed groups. Compared to the concurrent control, a higher incidence of a single skeletal variation was
26 observed at 600 ppm. However, the authors state that the observed incidence was within the range of
27 historical controls. It is reported (Brown et al. 2000) that styrene is not maternally toxic to rabbits at
28 concentrations up to 1000 ppm so the validity of the study seems to be limited.

29 3.3.4 Hamsters

30 *Studies with repeated inhalation exposure*

31 Pregnant Chinese hamsters were exposed to analytically (infrared spectrophotometry) controlled
32 concentrations of 300, 500, 750, and 1000 ppm styrene or air (control) for 6 hours/day from the 6th to the
33 18th day of gestation and sacrificed the last day of exposure (Kankaanpää et al. 1980). No
34 fetal/embryotoxic effects or malformations were seen at 300, 500, and 750 ppm. At 1000 ppm, the only
35 effect seen was a significantly increased number of dead or resorbed fetuses (66 %) compared to 26.2 % in
36 the control group.

37 3.4 Genotoxicity

38 A large number of studies have been published in which genotoxic effects (including DNA-
39 adducts) of styrene were investigated *in vitro* and *in vivo*. These studies have been extensively evaluated
40 and summarized in a number of reviews (ATSDR 1992; Cohen et al. 2002; IARC 1994; IARC 2002; Scott

1 and Preston 1994; Vodicka et al. 2002; WHO 1983; WHO 2000). Since a detailed description of the
2 findings from these studies is beyond the scope of this TSD, results described in these reviews are
3 summarized.

4 Styrene itself does not react with DNA or other nucleophiles *in vitro* in the absence of meta-
5 bolic activation. The genotoxic potential of styrene depends on the ability of the *in vitro* or *in vivo* system
6 to metabolize styrene to reactive electrophiles. The main primary metabolite of styrene in mammals is
7 styrene oxide (SO), an electrophilic epoxide that is able to form covalent adducts with nucleophiles such
8 as DNA. In accordance with this, SO binds to DNA and shows genotoxic activity *in vitro* and *in vivo*. The
9 potency of styrene in metabolically active test systems is dependent on a number of additional factors,
10 e.g., the ability to detoxify SO to non-reactive metabolites and to repair initial DNA-lesions.

11 In several studies with bacteria test systems (different strains of *Salmonella typhimurium*),
12 styrene was not mutagenic in the absence of exogenous metabolic activation system. In the presence of
13 such activation system, in some but not all studies, mutagenic effects were observed. Styrene induced
14 gene conversion and mitotic recombination in yeast cells *in vitro* and in a host-mediated assay using mice
15 as hosts. In *Drosophila melanogaster*, somatic mutations were only observed in insecticide resistant
16 strains that have a high bioactivation capacity.

17 In *in vitro* tests using rodent cells, styrene induced sister chromatid exchanges (SCE) in a study
18 using whole-blood rat lymphocyte cultures. An increase in SCE was also observed in several studies with
19 Chinese hamster ovary (CHO) cells, mostly in the presence of exogenous metabolic activation (S9 mix,
20 human erythrocytes), and a further increase was observed by the addition of cyclohexane epoxide, an
21 epoxide hydrolase inhibitor. Furthermore, styrene induced chromosomal aberrations (CA) in Chinese
22 hamster lung (CHL) cells in the presence but not in the absence of exogenous metabolic activation.

23 *In vivo* assays with rodents were performed with rats, mice, and hamsters. Chromosomal
24 aberrations (CA) and polyploidy, but not aneuploidy, in bone marrow were observed in one inhalation
25 study in which Wistar rats were exposed to 300 ppm styrene (6 hours/day, 5 days/week, 9 weeks). No
26 increase in CA was observed in other inhalation studies in bone marrow of Sprague-Dawley rats (600,
27 1000 ppm, 6 hours/day, 5 days/week, 12 months), in blood and spleen lymphocytes of B6C3F1 mice (124
28 – 491 ppm, 6 hours/day, 14 days), and in bone marrow of Chinese hamsters (300 ppm, 6 hours/day, 4 days
29 or 5 days/week for 3 weeks). Also, no increase in CA in bone marrow was observed following oral
30 administration of styrene in CD-1 mice (1000 mg/kg once; 500 mg/kg for 4 days, 200 mg/kg for 70 days)
31 or i.p. administration in C57/BL6 mice (50 – 1000 mg/kg). Induction of micronuclei (MN) in bone
32 marrow occurred following i.p. treatment of C57BL6 mice (250 – 1500 mg/kg), but not in blood
33 erythrocytes and spleen lymphocytes of B6C3F1 mice following inhalation exposure (124 – 491 ppm,
34 6 hours/day, 14 days) or in bone marrow of hamsters after i.p. administration (1000 mg/kg). Sister
35 chromatid exchanges (SCE) were not observed in blood lymphocytes of F344 rats after inhalation of
36 styrene (150 – 1000 ppm, 6 hours /day, 5 days/week, up to 4 weeks). In mice, however, an increase in
37 SCE in liver, bone marrow, alveolar macrophages, lung, blood and spleen lymphocytes was observed after
38 single (922 ppm, 6 hours) or repeated (387 ppm, 6 hours/day, 4 days) inhalation of styrene in BDF1 mice
39 and in C57/Bl6 and B6C3F1 mice after i.p. administration of styrene. In a recently published study that is
40 not included in the reviews mentioned above, no evidence of clastogenicity in bone marrow of NMRI
41 mice was observed following styrene inhalation exposure at 750 mg/m³ (175 ppm) or 1500 mg/m³ (350
42 ppm), 6 hours/day, for 1, 3, 7, 14, or 21 consecutive days (Engelhardt et al. 2003).

43 DNA strand breaks were detected in a comet assay in liver, kidney, lymphocytes, and bone
44 marrow of C57/Bl6 mice following single i.p. administration of 250 or 350 mg/kg b.w. styrene.

1 DNA-adducts of SO have been detected in several studies with rodents. In CD-1 mice and
2 Sprague-Dawley rats exposed by inhalation to 160 ppm ¹⁴C-styrene for 6 hours, an increase of N7-guanine
3 DNA-adducts was found in lung in liver of both species 42 hours later. More recent studies use ³²P-
4 postlabelling assays to detect and quantify different DNA-adducts. A dose respondent increase in N7- and
5 O⁶-guanine DNA-adducts of SO could be detected 3 hours after a single i.p. administration of styrene (up
6 to 450 mg/kg b.w.) to NMRI mice. The adduct level in the lungs was higher than that in liver. Similar
7 results were obtained in a further study with NMRI in which animals were exposed by inhalation to 175 or
8 350 ppm styrene, 6 hours/day, 7 days/week, for 1 – 21 days. The adduct levels increased linearly with
9 time.

10 Differences in adduct levels between rats and mice with respect to differences in
11 carcinogenicity between these two species were studied by Otteneider et al.(2002). In samples of liver
12 tissue from CD rats treated with styrene via inhalation for 2 years, levels of O⁶-SO-guanine adducts were
13 above the limit of detection only in the highest dose group (1000 ppm). It was concluded that rat liver is
14 able to tolerate a comparatively high level of styrene-derived DNA-adducts without a detectable increase
15 of the tumor rate. Further, CD-1 mice were exposed 6 hours/day, 5 days/week, 2 weeks, to 0, 40, or 160
16 ppm styrene, CD rats were exposed to 0 or 500 ppm. No increase in O⁶-SO-guanine adducts could be
17 detected in any of the lung samples despite the observation from carcinogenicity studies that styrene
18 increases the rate of lung tumors in mice but not in rats. The authors concluded that species- and site-
19 specific tumor formation by styrene is not reflected by DNA-adducts in tissues. However, this conclusion
20 has been questioned because the expected levels of O⁶-SO-guanine adducts may be far below the detection
21 limit (Vodicka et al. 2002).

22 **3.5 Carcinogenicity**

23 No carcinogenicity studies with single inhalation exposure of animals have been found in the
24 literature.

25 *Studies with non-inhalation exposure*

26 No increase in tumor incidence compared to “vehicle only” controls was observed in 40 female
27 and 40 male Sprague-dawley rats given a single subcutaneous dose of 50 mg styrene per animal in olive
28 oil or four i.p. doses of 50 mg per animal in olive oil over a period of 4 months (Conti et al. 1988).

29 *Studies with repeated inhalation exposure*

30 Carcinogenicity studies with repeated inhalation or oral exposure were performed with
31 different strains of rats (TABLE 5) and mice (TABLE 6). A detailed review with a critical comprehensive
32 evaluation has recently been published (Cohen et al. 2002).

33 *Rats*

34 Sprague-Dawley rats (initially 96 females, 96 males) were exposed to 0, 600 or 1000 -
35 1200 ppm styrene in air for 6 hours/day, 5 days/week for 20.7 months (females) or 18.3 months (males).
36 The higher concentration was reduced from 1200 ppm to 1000 ppm after 2 months because of excessive
37 treatment-related effects (decreased weight gain) in male rats (Jersey et al. 1978). The authors observed an
38 incidence (7/85 animals) of mammary adenocarcinoma at 600 ppm in females that was statistically higher
39 compared to the corresponding control (1/85) but was within the range of historical controls (0 – 9 %).
40 There was no significant association at 1000 ppm. The incidence of lymphosarcomas and leukemia in
41 females was identical at both styrene exposures and was not statistically higher than in the corresponding
42 control but exceeded that observed in historical controls.

TABLE 5: SUMMARY OF RESULTS ON STUDIES OF CANCER IN RATS TREATED WITH STYRENE *					
Strain	Exposure			Tumor incidence statistically elevated, type of tumor	Reference
	Route	Concentration or dose	Duration		
SD	Inhalation	600, 1000 - 1200 ppm	6 hours/day, 5 days/week f: 18.3 months, m: 20.7 months	Yes, for mammary adenocarcinoma	Jersey et al. 1978
SD	Inhalation	25, 50, 100, 200, 300 ppm	4 hours/day, 5 days/week 52 weeks	Yes, for combined mammary tumors and for malignant mammary tumors only	Conti et al. 1988
CD (SD-derived)	Inhalation	50, 200, 500, 1000 ppm	6 hours/day, 5 days/week 104 weeks	Yes, for testicular tumors	Cruzan et al. 1998
SD	Gavage	50, 250 mg/kg b.w.	4 or 5 days/week	No	Conti et al. 1988
SD	Drinking water	125, 250 ppm ^a	2 years	No	Beliles et al. 1985
SD	Drinking water	15 – 19 mg/animal x day	561 days	No	Oettel and Schulze 1962
F 344/N	Gavage	500 mg/kg b.w. 1000, 2000 mg/kg b.w.	5 days/week; 103 weeks 5 days/week, 78 weeks	No	NCI 1979b
F 344/N	Gavage	175, 350, 700 mg/kg b.w.	3 days/week, 79 weeks	No	NCI 1979a
BDIV	Gavage	500 mg/kg b.w.	once a week ^b	No	Ponomarkov and Tomatis 1978

1 * Table from Cohen et al. (2002), modified and supplemented;
 2 a: doses at 125 ppm were 7.7 mg/kg b.w. in males and 12 mg/kg b.w. in females, at 250 ppm, 14 mg/kg b.w. in
 3 males and 21 mg/kg b.w. in females;
 4 b: Dams were administered 1350 mg/kg b.w. styrene on day 17 of gestation, offspring received 500 mg/kg b.w. after
 5 weaning once weekly for lifetime.

6 In another inhalation study, Sprague-Dawley rats (30 females and 30 males) were exposed to
 7 25, 50, 100, 200 or 300 ppm styrene for 4 hours/day, 5 days/week for 52 weeks. The study was terminated
 8 when the survival rate reached 50% in at least one experimental group (Conti et al. 1988). Inhalation
 9 exposure to styrene was associated with a higher incidence of overall mammary tumors (benign and
 10 malignant combined, control: 57 %, exposed: 70 – 83 %) and of malignant mammary tumors alone
 11 (control: 10 %, exposed: 13 – 40 %). However, in the colony of rats used the incidence of mammary
 12 tumors was quite high and fluctuating and there was no clear concentration-response.

13 In the most recently conducted inhalation study, groups of 60 female and 60 male CD
 14 (Sprague-Dawley derived) rats were exposed to 0, 50, 200, 500 or 1000 ppm styrene for 6 hours/day, 5
 15 days/week for 104 weeks (Cruzan et al. 1998). In female rats, there was no increase of any tumor or in the

1 number of tumor-bearing rats in the exposed groups compared to controls; there was a decrease in
2 pituitary adenomas and mammary adenocarcinomas. In males, a significant trend for an increase in the
3 incidence of interstitial cell testicular adenomas was observed (control: 3.3 %, exposed 3.3 – 11.5 %).
4 However, all rates were within the range of historical controls (0 – 13.5 %), none of the incidences were
5 significantly different from controls by pairwise comparison, and no treatment-related increase in
6 histological alterations (cell hyperplasia, seminiferous tubular atrophy) typically associated with
7 chemically induced interstitial cell tumors was observed. Therefore, the authors judged the observed effect
8 to be incidental and not related to styrene exposure.

9 *Studies with non-inhalation exposure*

10 Six studies were performed in which rats were exposed orally by gavage or via drinking water
11 to styrene (Beliles et al. 1985; Conti et al. 1988; NCI 1979b; Oettel and Schulze 1962; Ponomarkov and
12 Tomatis 1978) or to a mixture of 70 % styrene and 30 % β -nitrostyrene (NCI 1979a). None of these
13 studies did show an association between exposure to styrene and the development of tumors. However, it
14 must be noted that none of these studies are fully acceptable under current standards (number of animals,
15 maximum tolerated dose not reached, low survival, exposure to mixture, or only weekly dosing).

16 *Mice*

17 With mice, only one carcinogenicity study was performed in which the animals were exposed
18 to styrene via inhalation. In this study, 50 female and 50 male CD-1 mice per group were exposed to 0, 20,
19 40, 80 or 160 ppm styrene for 6 hours/day, 5 days/week for 98 weeks (females) or 104 weeks (males). An
20 increased incidence for lung tumors was observed in male and female mice. The incidence of
21 bronchioalveolar adenomas was significantly increased in males at all except the lowest concentration of
22 styrene, and in females at 20, 40, and 160 ppm. In males, the incidence of bronchio-alveolar carcinomas in
23 the styrene-treated group was not significantly increased compared to the control. In females exposed to
24 160 ppm, the incidence of bronchio-alveolar carcinomas was higher than in controls. In interim sacrifices
25 after 12 and months, respectively, did not reveal lung tumors in male or female mice. Since the lung
26 tumors observed after 2 years in styrene-exposed and in control mice showed no difference in intensity of
27 immunostaining, tumor location and type of tumor, the authors concluded that styrene increased the
28 number of tumors seen spontaneously in this strain of mice (Cruzan et al. 2001a).

29 *Studies with non-inhalation exposure*

30 In three studies, mice were exposed orally by gavage to styrene (NCI 1979b; Ponomarkov and
31 Tomatis 1978) or to a mixture of 70 % styrene and 30 % β -nitrostyrene (NCI 1979a). It must be noted that
32 none of these studies is fully acceptable under current standards (number of animals too low, exposure to
33 mixture, or only weekly dosing).

34 In the NCI study with styrene (NCI 1979b), 50 female and 50 male B6C3F1 mice per styrene
35 dose group (20 females, 20 males for control receiving vehicle only) received 150 or 300 mg/kg b.w.
36 styrene in corn oil for 5 days/week for 78 weeks followed by a 27-week postexposure observation period.
37 No treatment-induced effect on the incidence of tumors was seen in female mice. In males, an increase in
38 the combined incidence of lung adenomas and carcinomas was observed. The incidence in the low-dose
39 group (13.6 %) was clearly higher than in the corresponding control (0 %) but about as high as in
40 historical controls (12 %, range 0 – 20 %). In the high-dose group, the incidence (20.9 %) exceeded that
41 observed in historical controls. In the NCI study using a mixture of styrene and β -nitrostyrene (NCI
42 1979a), no increase in the incidence of any tumor was observed.

1 In the study of Ponomarkov and Tomatis (1978), 29 pregnant O20 mice were treated with
 2 1350 mg/kg b.w. in olive oil on day 17 of gestation. Offsprings (39 females, 45 males) received
 3 1350 mg/kg b.w. in olive oil once a week for 16 weeks when exposure was ended due to high mortality
 4 with hepatic necrosis, lung congestion, and spleen hypoplasia (20 % of females and 50 % of males had
 5 died). Controls (22 females, 20 males) received vehicle only. Animals were sacrificed after 120 weeks.
 6 The combined incidence of lung adenomas and carcinomas was significantly higher in the group of
 7 styrene-treated animals. No treatment-related effects were described with respect to other tumors. It must
 8 be noted that the maximum tolerated dose had been exceeded.

9 Ponomarkov and Tomatis (1978) also exposed 15 pregnant C57 mice and their offspring (27
 10 females, 27 males) to styrene similarly as described above but to a lower dose of only 300 mg/kg b.w.
 11 There were no effects of styrene on survival, growth or the incidence of any tumor in this experiment.

12 In a further study with i.p. administration, groups of 25 female A/J mice received a total
 13 amount of 200 μ mol styrene (20.8 mg) in olive oil 3 times a week for a total of 20 injections (Brunnemann
 14 et al. 1992), 25 control animals received vehicle only. 20 weeks after the last dose, three treated animals
 15 and one control animal had lung adenoma, the difference was not statistically significant. No lung
 16 adenocarcinomas were found in any animal. It must be noted that the total dose applied was very low.

17 Taking together, these studies provide evidence of an increase of lung tumors in styrene-treated
 18 mice.

TABLE 6: SUMMARY OF RESULTS ON STUDIES OF CANCER IN MICE TREATED WITH STYRENE *

Strain	Exposure			Tumor incidence statistically elevated, type of tumor	Reference
	Route	Concentration or dose	Duration		
CD-1	Inhalation	20, 40, 80, 160 ppm	6 hours/day, 5 days/week f: 98 week, m: 104 weeks	Yes, for lung tumors	Cruzan et al. 2001a
O20	Gavage	1350 mg/kg b.w.	once a week ^a	Yes, for lung tumors	Ponomarkov and Tomatis 1978
C57	Gavage	300 mg/kg b.w.	once a week ^b	No	Ponomarkov and Tomatis 1978
B6C3F1	Gavage	150, 300 mg/kg b.w.	5 days/week, 78 weeks	Yes, for lung tumors	NCI 1979b
B6C3F1	Gavage	200, 400 mg/kg b.w.	3 days/week, 78 weeks ^c	No	NCI 1979a
A/J	I.p.	total: 200 μ mol (20.8 mg)	3 days/week, 20 injections	No	Brunnemann et al. 1992

19 * Table from Cohen et al. (2002), modified.

20 a: Dams were administered 1350 mg/kg b.w. styrene on day 17 of gestation, offspring received 1350 mg/kg b.w.
 21 after weaning once a week for lifetime.

22 b: Dams were administered 300 mg/kg b.w. styrene on day 17 of gestation, offspring received 300 mg/kg b.w. after
 23 weaning once a week for lifetime.

24 c: Mice were given a mixture of 70 % styrene with 30 % β -nitrostyrene.

1 3.6 Summary

2 Lethality data were available for rats, mice, and guinea pigs. Mice were much more sensitive
 3 than the other species as death in this but not in the other species was observed in a number of studies with
 4 single or short-term repeated 6-hour exposures to 250 and 500 ppm (Cruzan et al. 1997b; Mahler et al.
 5 1999; Morgan et al. 1993c; Morgan et al. 1993a; Sumner et al. 1997). In contrast, no death occurred in rats
 6 upon subchronic daily 6-hour exposures to 1500 ppm (Cruzan et al. 1997b). Guinea pigs could be more
 7 sensitive than rats as indicated by the lethality data provided by Stewart et al. (1942), but the data base is
 8 too limited to allow firm conclusions. Limited data for monkeys (4 animals, species not reported; Stewart
 9 et al. 1942) that were exposed in a subchronic study at 1300 ppm of styrene for 7-8 hours/day do not
 10 provide any evidence that monkeys may be more sensitive to styrene than rats.

11 In studies with rats, the reported lethality data (LC₀; LC₅₀; LC₁₀₀) show considerable
 12 differences between individual studies:

13	10,000 ppm	1 hour	LC ₀	(Spencer et al. 1942)
14	5000 ppm	1 hour	LC ₀	(Niklasson et al. 1993)
15	5000 ppm	2 hours	LC ₀	(Spencer et al. 1942)
16	10,000 ppm	3 hours	LC ₁₀₀	(Spencer et al. 1942)
17	2761 ppm	4 hours	LC ₅₀	(Shugaev 1969)
18	2700 ppm	4 hours	LC ₅₀	(Jaeger et al. 1974; abstract only)
19	6410 ppm	4 hours	LC ₅₀	(BASF 1979b)
20	7769 ppm	4 hours	LC ₀	(Lundberg et al. 1986)
21	1500 ppm	6 hours	LC ₀	(Cruzan et al. 1997; repeated exposure)
22	4618 ppm	6 hours	LC ₅₀	(Bonnet et al. 1982)
23	2500 ppm	8 hours	LC ₀	(Spencer et al. 1942)
24	7769 ppm	8 hours	"LC ₄₀ "	(Lundberg et al. 1986)
25	5000 ppm	8 hours	LC ₁₀₀	(Spencer et al. 1942)

26 Most notable, the 4-hour LC₅₀ reported in two studies (Jaeger et al. 1974; Shugaev, 1969) was
 27 lower than the LC₅₀ in a third study (BASF 1979b) and only 1/3 of the 4-hour LC₀ in another study
 28 (Lundberg et al. 1986). Also, it must be noted that these two "low" 4-hour LC₅₀ were even lower than the
 29 6-hour LC₅₀ in another study (Bonnet et al. 1982b) and similar to an 8-hour LC₀ in a further study
 30 (Spencer et al. 1942). Furthermore, the 4-hour LC₅₀ of BASF (1979b) and the 6-hour LC₅₀ are lower than
 31 the 8-hour concentration which caused death in 4/10 animals ("LC₄₀") (Lundberg et al. 1986).

32 Experimental differences between the studies are likely to have affected the outcomes of the
 33 studies. In the study of BASF (1979b), animals were observed for 14 days after the exposure, and delayed
 34 deaths that were observed up to 3 days after exposure were taken into account. In contrast, Lundberg et al.
 35 (1986) counted the number of deaths only 24 hours after start of the inhalation exposure but not at later
 36 time points. Therefore, delayed deaths will have been missed in this study. Niklasson et al. (1993)
 37 obviously observed no death during the neurological studies they performed in rats, but it cannot be
 38 deduced from their data whether the rats exposed to the highest concentration were observed for one week
 39 after exposure or not.

40 The data of Jaeger et al. (1974) only were published in an abstract lacking any experimental
 41 details. Shugaev (1969) also did not report important data, especially, the number of animals and of dose
 42 groups used were not given. In addition to data for rats, Shugaev (1969) also reported a 2-hour LC₅₀ of
 43 4914 ppm for an unspecified strain of mice. Interestingly, this value is much higher than the LC₅₀ for rats
 44 although it is clear from a vast number of studies that mice are more susceptible to styrene than rats.
 45 Furthermore, whereas the LC₅₀ reported by Shugaev (1969) for rats is much lower than the LC₅₀

1 determined in other studies, the opposite is true for the LC₅₀ for mice in Shugaev (1969); this value is
2 much higher than others reported in other studies, even when the different exposure times are taken into
3 account (BASF 1979a; Bonnet et al. 1979b; Izmerov et al. 1982). Although it cannot be ruled out that
4 differences in the susceptibility of different strains of mice to styrene could play some role, it is tempting
5 to speculate that the LC₅₀ for rats and mice could have been erroneously mixed up with each other in the
6 publication of Shugaev (1969).

7 In the study of Spencer et al. (1942), the concentration of 10,000 ppm may be doubted in view
8 of the observation of Lundberg et al. (1986) that 7769 ppm was the highest attainable (analytically
9 confirmed) vapor concentration of styrene. Therefore, it seems possible that in the study of Spencer et al.
10 (1942) some condensation of styrene vapor at the highest concentration used had occurred (leading to a
11 lower vapor concentration but possibly to additional dermal exposure).

12 The studies of BASF (1979b) and Bonnet et al. (1982a) both reported the experimental
13 conditions in detail (especially, number of animals and dose groups, analytically determined vapor
14 concentrations, and consideration of delayed deaths during post-exposure period). These studies thus
15 provide the most reliable and relevant acute lethality data for rats.

16 Following i.p. treatment of rats with styrene, no differences in LD₅₀ and the corresponding
17 confidence limits were observed when deaths were counted 24 days and 14 days after the injection
18 (Lundberg et al. 1986). This indicates that the delayed deaths observed after inhalation exposure are not
19 due to a systemic effect but probably are related to the local toxic effects that are observed in the lung of
20 animals dying some days after styrene exposure.

21 Very limited data from one study are available for styrene toxicity in monkeys (species not
22 reported) (Spencer et al. 1942). In this study, none of 4 animals died during subchronic exposure to
23 1300 ppm styrene, 7 – 8 hours/day, 5 days/week. It was further reported that there were no signs of
24 irritation or intoxication and no pathological findings in inner organs or in hematology compared to 3
25 control animals.

26 At non-lethal concentrations, rats showed CNS-depression. Animals were in state of deep
27 narcosis after 1 hour of exposure to the 4-hour LC₅₀ (reported to be 2761 ppm, but see discussion above)
28 (Shugaev 1969) and lost consciousness at 2000 ppm after 5 hours (Withey and Collins 1979). Reduced
29 attention was described to occur at 6-hours of exposure to 1500 ppm (Jarry et al. 2002), and an inability to
30 suppress nystagmus in an optokinetic test were seen at 1730 ppm after about 30 minutes of exposure
31 (Niklasson et al. 1993). Animals were mostly recumbent at 12 hours of exposure to 600 ppm (Mäkitie et
32 al. 2003), this may also indicate CNS-depression. In mice, signs of CNS-depression that occurred during a
33 4-hour exposure included staggered gait at 1420 ppm and apathy and finally narcosis at higher
34 concentrations (2983 and 3766 ppm) (BASF 1979a).

35 In rats, immediate sensory irritation occurred at 1300 ppm (Spencer et al. 1942). Cruzan et al.
36 (1997b, 1998) observed a concentration-dependent increase of irritation reaching from closed eyes at 200
37 ppm to salivation and rubbing of paws and chin at higher concentrations (500, 100, 1500 ppm). Signs of
38 sensory irritation were also observed at 500 ppm during initial exposure in one study (Jarry et al. 2002),
39 but in another study, no clear signs of eye, skin or mucous membrane irritation could be observed at
40 600 ppm (Mäkitie et al. 2003). In mice, RD₅₀ for sensory irritation of 156 ppm (3 minutes), 586 ppm (5
41 minutes) and 980 ppm (10 minutes) were reported (Alarie 1973; de Ceaurriz et al. 1981; Bos et al. 1992).

42 In rats, pulmonary lesions at acute exposure only were observed at concentrations that also
43 caused severe and mostly lethal CNS effects. Mice were more sensitive to styrene than rats. At 250 ppm
44 and 500 ppm, upper respiratory tract and lung toxicity, liver lesions and sometimes death were observed

1 following one or few exposures, and differences in sensitivity between strains were observed; B6C3F1
2 were most sensitive (Morgan et al. 1993a, c; Mahler et al. 1999; Cruzan et al. 1997; Sumner et al. 1997).

3 Ototoxicity of styrene was observed in rats after repeated exposure. Exposure for 6 hours/day,
4 5 days/week, for 4 weeks to 850 ppm and higher concentrations caused a permanent increase in auditory
5 threshold, at 500 ppm, no effect was observed (Loquet et al. 1999). In another study, no effect was seen
6 immediately after exposure to 1000 ppm, 6 hours/day, for 5 days, but tests indicated a disruption of
7 cochlear auditory function 2 and 4 weeks after the end of exposure. In the same study, no effects were
8 detected in similarly exposed guinea pigs (Lataye et al. 2003). Histological lesions of the cochlea and
9 worsening of the electrophysiological results after the end of exposure were also described in another
10 publication of the same group after exposure of rats to 1000 ppm, 6 hours/day, 5 days/week, for up to 4
11 weeks (Campo et al. 2001). No hearing impairment was detected in rats exposed to 100 or 300 ppm
12 styrene for 12 hours/day, 5 days/week, for 4 weeks; at 600 ppm, a hearing loss of ~ 3 dB was observed
13 only at the highest test frequency of 8 kHz, and cytochromeograms showed a substantial loss of the outer
14 hair cells of the cochlea from these animals (Mäkitie et al. 2003).

15 No studies were available concerning effects of a single inhalation exposure to styrene on
16 reproductive or developmental toxicity. A single oral administration of 300 mg/kg b.w. of styrene on day
17 11 of gestation caused maternal toxicity in rats, but had no developmental or fetotoxic effects (Daston et
18 al. 1991). In another study with rats and mice that were treated orally with styrene on gestation day 17,
19 1350 mg/kg b.w. styrene had no significant effect on preweaning mortality, litter size at birth, or body
20 weight development in BD IV rats. In O20 mice, survival prior to weaning was reduced after 1350 mg/kg
21 b.w., no effect was seen in C57Bl mice given 300 mg/kg b.w. (Ponomarev and Tomatis 1978).

22 Following repeated 6-hour exposure of rats to 300 ppm during gestation day 6 – 20, an
23 increased neonatal death rate was observed compared to pair-fed controls (that were included to control
24 for a styrene-induced reduction of food intake; maternal weight gain was not affected). Postnatal
25 development (incisor eruption, eye opening, air righting reflex) also was delayed. No effects were seen at
26 50 ppm (Katakura et al. 2001). These findings supported those from earlier studies in which similar effects
27 were described but no pair-fed controls were used (Kishi et al. 1992; 1995). In a study with hamsters, the
28 number of dead or resorbed fetuses was increased in the group exposed to 1000 ppm 6 hours/day from
29 gestation day 6 -18, but not at 750 ppm or lower concentrations (Kankaanpää et al. 1980). In other studies
30 with repeated oral or inhalation exposure of rats, mice, and rabbits, no significant developmental effects
31 were seen (Murray et al. 1978; Srivastava et al. 1990; Chernoff et al. 1990; Beliles et al. 1985;
32 Kankaanpää et al. 1980).

33 Styrene is genotoxic *in vitro*, provided there is sufficient activation to styrene oxide (SO), and
34 *in vivo*. Data from laboratory animals indicate that styrene exposure may lead to the formation of DNA-
35 adducts, sister chromatid exchange, and chromosomal aberrations.

36 With respect to carcinogenicity, no clear effect was observed in rats. In mice, the studies
37 provide evidence for an increase of lung tumors. IARC recently has re-evaluated the data on
38 carcinogenicity of styrene and concluded that there is “limited evidence” in experimental animals for the
39 carcinogenicity of styrene. In the overall evaluation, it was concluded that styrene is “possibly
40 carcinogenic to humans (Group 2B)” (IARC 2002). Styrene is being reassessed under the IRIS Program of
41 the US-EPA, no quantitative carcinogenicity assessment for lifetime exposure is currently proposed (US
42 EPA 1998). US-EPA’s Office of Research and Development has updated previous assessments on the
43 carcinogenic potential of styrene and concluded that styrene is appropriately classified as a Group C,
44 possible human carcinogen (US EPA 2003).

1 4 SPECIAL CONSIDERATIONS

2 4.1 Toxicokinetics

3 The toxicokinetics of styrene both in humans and laboratory animals has been reviewed (e.g.
4 ATSDR 1992; Bond 1989; Cohen et al. 2002; Engelhardt et al. 2003; Government Canada 1993; Linhart
5 2001; Sherrington and Routledge 2001; Sumner et al. 2001).

6 *Uptake and distribution*

7 In studies with human volunteers and occupationally exposed workers, retention of styrene was
8 about 70 % of the inhaled dose. E.g., in two studies on male healthy volunteers who were exposed to 300
9 mg/m³ (70 ppm) of styrene during light exercise, the average uptake of styrene was 68 % of the amount
10 supplied; the percentage of uptake was nearly constant during the whole exposure period (0 – 30 minutes:
11 71.0 %; 90 – 120 minutes: 66.7 % (Wigaeus et al. 1983; Wigaeus et al. 1984).


12 Experimental and simulation studies suggest a washin-washout effect for styrene in the upper
13 respiratory airways of humans (Jonsson and Johanson 2002). In rats and mice, styrene has been shown to
14 be taken up and metabolized in surgically isolated upper respiratory tract preparations; uptake amounted
15 to about 10 % of styrene at 200 ppm (Morris 2000).

16 For styrene, a high *in vitro* blood:air partition coefficient at equilibrium of 32 was reported by
17 Astrand (1975). Even higher coefficients of 40 for rats and mice and 52 for humans were reported by
18 Ramsey and Andersen (1984). In controlled human studies *in vivo*, the blood:air coefficient was found to
19 depend on the work load during exercise: At 50 and 150 ppm styrene, the coefficient of the concentration
20 of styrene in alveolar air:blood was 15 at rest and increased to 50, 85, and 105 at work loads of 50 W, 100
21 W, and 150 W during subsequent 30-minute exposure periods, respectively (Astrand 1975).

22 Concentrations of styrene determined in blood of humans and rats and in rat brain are
23 summarized in **TABLE 7**. In humans exposed to 69 ppm for two hours during light physical exercise
24 (50 W), the concentration of styrene in arterial blood rose steeply during the first 30 minutes and reached
25 a plateau at about 60 minutes (**FIGURE 3**) (Wigaeus et al. 1984). Controlled studies further show that the
26 concentration of styrene in blood depends on the intensity of physical work load. When volunteers were
27 exposed at 154 ppm styrene for consecutive 30-min periods with increasing intensity of physical exercise
28 (0, light exercise: 50 W, 100 W, heavy exercise: 150 W), the arterial blood concentration increased with
29 increasing exercise activity and was approximately 3fold higher at 50 W, 5fold higher at 100 W, and
30 10fold higher at 150 W than at rest (Astrand 1975). However, care must be taken when interpreting these
31 observations since a 30-minute exposure period (at 154 ppm) is not sufficient to reach a plateau level of
32 styrene in blood. Thus, the experimental condition in the study of Astrand (1975) leads to an
33 overestimation of the effect of work load.


34 At higher inhalation concentrations, no constant styrene concentration in blood is reached (data
35 for humans see **FIGURE 4**, Löf and Johanson 1993). In rats exposed to 520, 1274, and 2850 ppm styrene
36 by inhalation for up to 5 hours, the level of styrene in jugular venous blood rose continuously. After about
37 90 minutes, a nearly linear increase was observed at the three higher concentrations and no equilibrium
38 was reached during exposure. At 45 ppm, no marked increase with continuing exposure was observed
39 (**FIGURE 5**, Withey and Collins 1979).

40



1 **FIGURE 3: STYRENE CONCENTRATION IN ARTERIAL BLOOD OF HUMANS DURING**
 2 **AND AFTER A 2-HOUR EXPOSURE TO 69 PPM STYRENE IN AIR**
 3 (Human volunteers (n = 5) were exposed to 69 ppm styrene (open symbols) or a mixture of 70 ppm
 4 styrene and 520 ppm acetone (closed symbols) during a work load of 50 W (light exercise) (Graph from
 5 Wigaeus et al. 1984). 1 µM = 104 µg/l).


6



7

8 **FIGURE 4: OBSERVED (CIRCLES) AND SIMULATED CONCENTRATIONS OF STYRENE IN**
 9 **ARTERIALIZED CAPILLARY BLOOD FROM TWO HUMAN VOLUNTEERS**
 10 (2 hours of exposure during light (50 W) exercise. Continuous line: PBPK model simulation with a linear
 11 model (nonsaturable metabolism in liver); broken lines: same model with saturable metabolism. The study
 12 did not indicate which of the values were determined in the female and the male volunteer. Graph from
 13 Löf and Johanson (1993)).

1



2 **FIGURE 5: STYRENE CONCENTRATION IN BLOOD OF RATS DURING A 5-HOUR**
 3 **EXPOSURE TO DIFFERENT CONCENTRATIONS OF STYRENE IN AIR**

4 (Animals were exposed to the styrene vapor concentrations indicated and styrene was determined in blood
 5 from jugular vein at different time points by means of an indwelling cannula fixed prior to exposure.
 6 Graph from Withey and Collins 1979.)

7

8 Styrene is widely distributed throughout the body. From its high lipophilicity, the highest
 9 concentrations may be expected in lipid-rich tissues. However, it must be taken into account that the
 10 distribution of styrene is affected by its rapid metabolic clearance (see below). Thus, at low exposure
 11 concentrations (54 ppm), the concentration of styrene in rat brain was lower than in blood. At higher
 12 concentrations (≥ 470 ppm) where metabolic clearance approaches saturation (see below), the con-
 13 centration in rat brain was 1.17 – 1.89 fold higher than in blood. Similar effects were observed in heart,
 14 lung, liver, and spleen, but not in kidney where the styrene concentration was higher than in blood at all
 15 concentrations. Concentrations at least 10fold higher than in every other tissue were observed in perirenal
 16 fat (Withey and Collins 1979). In humans, the ratio between the styrene concentration in subcutaneous
 17 adipose tissue (from the gluteal region) and arterial blood reached 3 at the end of a 2-hour exposure to
 18 70 ppm styrene. This value is far below the value in equilibrium that can be calculated from the oil:air
 19 (about 5.5) and blood:air partition (52) coefficient of styrene indicating that styrene in adipose tissue does
 20 not reach equilibrium under the condition of the study. Taking into account the long half-life of styrene in
 21 subcutaneous adipose tissue (2.2 – 5.2 days), the authors further estimated that several days of continuous
 22 exposure would be necessary to reach 90 % of steady state (Wigaeus et al. 1983).

23

TABLE 7: EXPOSURE CONCENTRATIONS AND BLOOD LEVEL OF STYRENE IN HUMANS AND RATS				
Exposure time	Conc. in air (ppm)	Concentration in blood (mg/L) or brain(mg/kg)	Remarks	Reference
Humans				
50 min	87-139	2.7	Exposure at light physical exercise (50 W)	Ödkvist et al. 1982
55 min 1 h 55 min 3 h 30 min	51.4 116.7 116.7 99	0.2 – 0.7 (vb) 1.7 (vb) 2.7 (vb) 0.9 – 1.4 (vb)	Exposure at rest	Stewart et al. 1968
30 min 1 h 2 h	69	1.8 (ab) 2.1 2.2	Exposure with light physical exercise (50 W)	Wigaeus et al. 1983; 1984
30 min	154	~ 2 (ab) ~ 6 ~ 9 ~ 16	Exposure at rest 50 W exercise 100 W exercise 150 W exercise; all values estimated from figure	Astrand 1975
2 h	69	1.6 (ab)	Exposure with light physical exercise (50 W); study with occupationally exposed workers	Löf et al. 1984
6 h	80	0.92 (vb)	Exposure at rest	Ramsey et al. 1980
2 h	26 77 201 386	~ 0.7/ 0.7 (acb) ~ 2/ 3.1 ~ 6.2/ 8.3 ~ 15/ 21	Values for 2 volunteers exposed with light physical exercise (50 W); values estimated from figure	Löf and Johanson 1993
Rats				
2 h	520 1274 2850	~ 24 ~ 73 ~ 100	Values estimated from graph	Withey and Collins 1979
5 h	45 520 1274 2800	< 2 (vb) ~ 43 ~ 149 ~ 198	Values estimated from graph	Withey and Collins 1979
5 h	54 470 1018 1522 2144 2240	0.65 (vb)/ 0.2 (brain) ² 31.8 / 43 65.3 / 76 72.8 / 105 173.7 / 302 135.5 / 256		Withey and Collins 1979
		> 75 (ab)	i.v. exposure; effects on vestibular system as indicated by changes in nystagmus	Tham et al. 1982
6 h	80 1200	1.0 (wb) 63		Ramsey and Andersen

TABLE 7: EXPOSURE CONCENTRATIONS AND BLOOD LEVEL OF STYRENE IN HUMANS AND RATS				
Exposure time	Conc. in air (ppm)	Concentration in blood (mg/L) or brain(mg/kg)	Remarks	Reference
				1984
6 h	50 200 500 1000	0.43/ 0.29 (m/f) 2.8/ 1.95 12.5/ 9.5 33.2/ 29.7	Values determined in week 95 of chronic study	Cruzan et al. 1998
4 h 1 h	2760 * 2760 *	250 (brain) 218 (brain) 222 (brain) 177 (brain) 86 (brain) 0 - max. 44 (brain)	Exposure to LC ₅₀ End of exposure, animal in deep narcosis 15 min after end of exposure 30 min after end of exposure 60 min after end of exposure 90 min after end of exposure	Shugaev 1969
6 h + 4 h ¹	1750	37.5 (ab) 68 (brain)	At end of exposure	Campo et al. 1999

1 ab: arterial blood; acb: arterIALIZED capillary blood; vb: venous blood; wb: whole blood;
 2 m/f: values for males/females;
 3 1: 6 hours on 1st and 4 hours on 2nd day; 2: approximate concentration, calculated from values presented as brain
 4 concentration relative to blood in original reference.
 5 * see section 3.6 for discussion of validity of data from this study.

6

7 *Metabolism*

8 The metabolism of styrene was compared in male Sprague-Dawley rats and B6C3F1 mice. In
 9 both species, the rate of metabolism of inhaled styrene was found to increase linearly with concentration
 10 up to about 300 ppm. In this concentration range, delivery of styrene to the site of metabolism but not
 11 metabolic capacity was the rate-limiting step for metabolism. Above 300 ppm, the rate of metabolism at
 12 steady state became more and more limited by metabolic parameters. Metabolism approached nearly
 13 saturation at about 700 ppm in rats and 800 ppm in mice; exposure concentrations at half maximum rates
 14 of metabolism were 190 ppm in rats and 270 ppm in mice, respectively. Repeated exposure for 6
 15 hours/day on 5 consecutive days to 150 or 500 ppm caused no detectable changes in the rates of styrene
 16 metabolism (Filser et al. 1993). However, evidence for an induction of styrene metabolism in male rats
 17 following pre-exposure to styrene was observed in another study in which prior exposure to styrene (1000
 18 ppm, 6 hours/day, 4 days) increased V_{max} about twofold. Significant induction of styrene metabolism was
 19 observed in 24-hr continuous exposure to 400, 600, or 1200 ppm. Calculations using a physiological
 20 model of styrene inhalation kinetics to estimate the dynamics of the induction indicated that induction at
 21 1200 ppm began 4.6 hr after the start of exposure and reached 4.4 times the V_{max} of naive rats. No
 22 induction occurred in 48-hr exposure to 200 ppm (Andersen et al. 1984).


23 In humans, evidence from controlled studies indicates that saturation of metabolic capacity to
 24 clear styrene becomes noticeable at concentrations around 200 ppm. In one study, one female and one
 25 male volunteer were exposed to analytically confirmed concentrations of 26, 77, 201 and 386 ppm styrene
 26 vapor for 2 hours with light exercise (50 W). During the 2-h exposure, the concentration of styrene in
 27 blood reached a plateau at the lower concentrations in both individuals. At 386 ppm, the arterial styrene
 28 concentration only approached a plateau in one individual but continued to increase steadily in the other

1 **(Error! Reference source not found.**; it was not indicated in the study which of the values were
2 determined in the male and in the female volunteer). This non-linear relationship between the level of
3 exposure to styrene and the concentration of styrene in arterial blood (and also the 0 – 5 hours cumulative
4 excretion of mandelic acid, see below) indicated metabolic saturation. A physiologically based
5 pharmacokinetic model was used to estimate metabolic parameters. According to the model, transition to
6 metabolic saturation is seen at about 100 ppm (at 50 W physical activity) and at about 200 ppm at rest
7 (Löf and Johanson 1993). Previous studies also provided evidence that styrene metabolism in rats, mice
8 and humans becomes saturated at concentrations exceeding 200 ppm. At lower concentrations, the ratio of
9 styrene concentration in blood to inhaled air is controlled by perfusion limited metabolism, while at higher
10 concentrations, the ratio is controlled by the blood:air coefficient (Ramsey and Andersen 1984).

11 An overview of the pathways of styrene metabolism is presented in **FIGURE 6**. The major
12 metabolic pathway starts with the formation of styrene-7,8-oxide (SO) by cytochrome P450-dependent
13 monooxygenases. SO is either conjugated with glutathione (GSH) to finally produce mercapturic acids or it
14 is hydrolyzed by epoxide hydrolase to styrene glycol that is subsequently oxidized to mandelic and
15 phenylglyoxylic acid. Phenylacetic acid and benzoic acid or rather hippuric acid, its glycine conjugation
16 product, are also found in urine.

17 Different CYP isozymes are involved in the oxidation of styrene to SO. Based on *in vitro*
18 studies, CYP2B6 and CYP2E1 seem most important in liver and CYP2F2 in lung, but other isozymes also
19 seem to play a role. In mice devoid of CYP2E1 activity (Cyp2e1-null mice), the amount of metabolites
20 derived from SO was higher and that derived from phenylacetaldehyde was lower as compared to control
21 mice. The excretion of total urinary metabolites was higher in “null mice” than in wild-type controls.
22 These data indicate that CYP2E1 may not be a major isozyme involved in the metabolism of styrene to
23 SO in mice (Sumner et al. 2001). In humans with individual differences in xenobiotic metabolism capacity
24 determined with enzyme-specific substrates for CYP2E1, CYP1A2, and CYP2D6, no correlation was
25 found between the blood clearance of styrene and the metabolic capacity as measured by urinary excretion
26 of mandelic and phenylglyoxylic acid. Under the experimental conditions (24 and 84 ppm styrene, 1 hour
27 exposure, light exercise), the apparent blood clearance of styrene (1.4 l/min) was similar to the hepatic
28 blood flow (IARC 2002). These data further support the assumption that styrene metabolism at low
29 concentrations is limited by perfusion and not by the capacity of the metabolism.

30 Qualitatively, styrene metabolism is similar in humans and rodents (**FIGURE 6**), and in both,
31 humans and animals, more than 90 % of styrene taken up is metabolized. However, there are quantitative
32 differences between rats and humans, and, more pronounced, humans and mice. With respect to the
33 metabolism of styrene in the liver, the experimental data indicate that the order of the oxidation rate of
34 styrene to SO is mice > rats > humans, while the order for microsomal epoxide hydrolase activity of the
35 liver is humans > rats > mice (Mendrala et al. 1993). However, enzymatic activities in tissues other than in
36 liver may be different (Vodicka et al. 2002). In humans, conversion of SO preceeds predominantly via
37 oxidation to styrene glycol, whereas conjugation with GSH and formation of mercapturic acid is important
38 in mice and, to a much lesser extent, in rats. Furthermore, in mice up to 30 % of styrene metabolism leads
39 to the formation of phenylacetic acid. This pathway likely involves the formation of phenylacetaldehyde
40 as a reactive intermediate that is able to react with proteins. In rats and humans, this pathway is of minor
41 importance (rats: 5 %; humans: less than 5 %) (Sumner et al. 2001).



1 **FIGURE 6: PATHWAYS FOR THE METABOLISM OF STYRENE IN HUMANS AND**
 2 **RODENTS**

3 (modified from IARC 2002; main pathways are illustrated by thick arrows)

4 Nasal metabolism of styrene is thought to be related to olfactory epithelium toxicity that is
 5 pronounced in mice and less or marginal in rats (Cruzan et al. 2002). The metabolism of styrene in nasal
 6 epithelia of rats, mice, and humans was studied by Green et al. (2001a). Pretreatment of mice with 5-
 7 phenyl-1-pentyne, an inhibitor of CYP2F2 and CYP2E1, prevented the development of nasal lesions upon
 8 styrene exposure. Determination of enzyme activities *in vitro* in samples from respiratory and olfactory
 9 mucosa of rats and mice revealed that the rates of metabolic formation of SO from styrene in olfactory
 10 tissue of both species were similar and higher than in liver, whereas in preparations from respiratory tissue
 11 the rates were about half those in the olfactory region and comparable to samples from liver. However, SO
 12 is much more efficiently metabolized by both epoxide hydrolase and glutathione transferase in rat

1 olfactory tissue compared to respiratory tissue or to either region in the mouse. In a limited number of
2 nasal tissue fractions derived from 9 fresh human biopsies in which both respiratory and olfactory
3 epithelium was present in variable amounts, neither metabolism of styrene to styrene oxide nor GSH-
4 transferase activity could be detected. In contrast, epoxide hydrolase activity was detectable and
5 comparable to that in mice. Overall, with respect to the relation between SO-formation and SO-
6 metabolism in nasal epithelia, humans seem similar to rats as the rate of deactivation greatly exceeds
7 activation rates.

8 *Excretion*

9 In a study with human volunteers exposed to 80 ppm styrene, styrene was cleared from the
10 blood in a bi-phasic manner with calculated half-lives of 0.58 and 13 hours for the rapid and the slow
11 clearance phase, respectively (Ramsey et al. 1980). In humans and laboratory animals, very little styrene
12 (less than 5 %) is exhaled unchanged via the lungs. The majority of styrene (> 90 %) is oxidized to water
13 soluble metabolites that are excreted in urine. In humans, mandelic acid (MA) followed by
14 phenylglyoxylic acid (PGA) are the two predominant styrene metabolites that are excreted in urine. The
15 excretion of these metabolites is used as a biological exposure index to monitor exposure in
16 occupationally exposed workers (Schaller and Triebig 2000). Elimination of MA and PGA in urine also
17 follows bi-phasic kinetics with half-times of 4 – 9 and 17 – 26 hours determined for MA and of 10 and 26
18 hours for PGA (ACGIH 1997). At occupational exposure to average concentrations exceeding 150 ppm,
19 urinary excretion of MA and PGA determined at the end of the workshift appeared to reach a plateau
20 indicating saturation kinetics (Götell et al. 1972). In a controlled human study, cumulative excretion of
21 MA in urine 5 hours after onset of a 2-hour exposure leveled off when the exposure concentration was
22 increased from 201 to 386 ppm. However, cumulative 24-hour excretion of MA was proportional to
23 styrene exposure up to the highest concentration indicating that the metabolism to MA was delayed (Löf
24 and Johanson 1993).

25 **4.2 Mechanism of Toxicity**

26 Styrene has an acute CNS depressant action that is also observed with other alkyl and alkenyl
27 benzenes. This effect is likely related to the physico-chemical properties of the substance and the amount
28 of parent substance in the brain and is not dependent on styrene metabolism. In accordance with this, the
29 acute toxicity (as indicated by the LC₅₀) of styrene for rats falls within the range of LC₅₀ for xylenes and
30 toluene (Bonnet et al. 1982a). However, styrene is more irritant than the alkyl benzenes.

31 Other toxic effects of styrene have been attributed to the formation of reactive metabolites. The
32 main primary metabolite of styrene in mammals is styrene oxide (SO), an electrophilic epoxide that is able
33 to form covalent adducts with nucleophiles such as DNA, but also with proteins and glutathione. In
34 accordance with this, SO binds to DNA and shows genotoxic activity *in vitro* and *in vivo*. The respiratory
35 tract toxicity of styrene that is observed in mice also was shown to depend on the metabolism of styrene.

36 **4.3 Other relevant information**

37 **4.3.1 PBPK-Modelling**

38 Several physiology-based pharmacokinetic (PBPK) models have been developed to describe
39 toxicokinetics of styrene in animals and humans (Filser et al. 1993; Jonsson and Johanson 2002; Pierce et
40 al. 1998; Ramsey and Andersen 1984). In recent models, efforts have focussed on the description and
41 prediction of species-specific differences of styrene and styrene oxide metabolism in target organs,
42 especially the lung of mice (Csanady et al. 1994; Csanady et al. 2003; Filser et al. 1999; Filser et al. 2002;
43 Sarangapani et al. 2002; for review see Cohen et al. 2002).

1 4.3.2 Species variability

2 Mice are more sensitive to styrene than rats. Lethality was observed in mice, but not in rats,
3 following single or few exposures to 250 and 500 ppm. At these concentrations, lethality was related to
4 respiratory tract toxicity and hepatic lesions which are seen in mice, but not in rats.

5 In humans, no life threatening effects or long-lasting adverse health effects or death were
6 observed in controlled studies at single exposures up to 800 ppm for 4 hours. Also, no data describing
7 such effects following acute or short-term exposure were identified in occupational studies. Therefore, it is
8 considered that the higher susceptibility of mice is not relevant for the derivation of AEGL values.

9 The species difference between rats and mice with respect to respiratory tract and hepatic
10 toxicity and carcinogenicity is not only observed in case of styrene, but also with other epoxide-forming
11 chemicals and their epoxides, e.g. butadiene, isoprene, chloroprene, vinyl chloride, and ethylene oxide
12 (IARC 2002). In case of styrene, the general view is that the observed toxicity in respiratory tract and liver
13 and the genotoxic and tumorigenic effects are related to the activation of styrene to styrene-7,8-epoxide
14 (SO). This view is supported by studies in rats and mice which showed that inhibition of styrene
15 metabolism prevents the development of histological lesions. However, systemic SO concentrations
16 cannot explain the observed species differences: In rats exposed to 1000 ppm styrene, the SO
17 concentration in blood was two orders of magnitude lower than that in mice exposed to 20 – 40 ppm, but
18 tumors developed in the lung of mice, while no increase in tumors were observed in rats. It is discussed
19 that either differences in target-cell specific toxicokinetics or in toxicodynamics or both play a role for the
20 observed species differences in carcinogenicity (IARC 2002).

21 4.3.3 Susceptible populations

22 Individuals with a high level of physical activity during exposure may be considered more
23 susceptible than individuals at rest because the concentration of styrene in blood is strongly affected by
24 physical activity. Subjects with high physical activity during exposure will take up more styrene and thus
25 have a higher concentration of styrene in blood than subjects at rest. The influence of physical activity
26 can be explained by physiological models taking into account the blood:air partition efficient and the
27 effect of physical activity on basic physiological parameters (alveolar ventilation, cardiac output, hepatic
28 perfusion) and (Csanady and Filser 2001). In controlled studies, the observed increase of styrene in
29 arterial blood at exposure to about 150 ppm styrene was approximately 3fold when the physical activity
30 was increased from rest to light exercise (50 W), 5fold at moderate exercise (100 W), and 10fold at heavy
31 exercise (150 W). These values are conservative estimates since – as outlined above (see section 4.1) – the
32 experimental conditions lead to an overestimation of the effect.

33 Individual cases of respiratory or skin sensitization to styrene have been described (Hayes et al.
34 1991; Moscato et al. 1987; Sjöborg et al. 1982). Taking into account the wide use of styrene both in
35 industry and in consumer products, sensitization seems to be a rare event. However, sensitized individuals
36 may not be able to tolerate styrene concentrations that are without effect in non-sensitized individuals and
37 may not be protected by the AEGL-levels developed for styrene in this TSD.

38 4.3.4 Concurrent exposure issues

39 In rats, acetone potentiated the lung toxicity of styrene (Elovaara et al. 1990). No data were
40 available for humans with respect to acute toxic interactions of styrene and other chemicals.

1 In humans, the toxicokinetics of styrene was not affected by co-exposure with acetone,
2 methanol, or toluene. However, co-administration of ethanol was found to decrease the excretion of
3 mandelic acid and phenylglyoxylic acid in urine (IARC 2002).

4 **5 DATA ANALYSIS AND PROPOSED AEGL-1**

5 AEGL-1 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which
6 it is predicted that the general population, including susceptible individuals, could experience notable
7 discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling
8 and are transient and reversible upon cessation of exposure.

9 **5.1 Summary of Human Data Relevant to AEGL-1**

10 In humans, the effects associated with acute inhalation exposure are irritation of eyes and
11 mucous membranes and central nervous system depression.

12 In a study on psychological reactions related to chemosensory irritation, ratings for odor and
13 annoyance increased similarly with increasing styrene concentrations ranging from 0.5 – 40 ppm, while
14 there was only a marginal increase for irritation. Effects sizes comparing the ratings between exposure to
15 20 ppm and pre-exposure were higher for odor, irritation, and annoyance. Effects sizes were also higher
16 compared to “clean air only”-exposure. However, the ratings for irritation indicated only marginal effects
17 in this respect (Seeber et al. 2002). No increase in irritation or headaches compared to control was noted at
18 20 ppm in a further study (Hake et al. 1983). Subjective signs and symptoms of irritation and CNS effects
19 were not negatively influenced during a 6-hour exposure at 25 or 50 ppm or at 50 ppm with 4 peak
20 exposures of 15 minutes at 100 ppm (Ska et al. 2003; Vyskocil et al. 2002a,b). At 50 ppm, a further study
21 indicated a slight increase in subjective symptoms ratings for eye and nose irritation, headache, and
22 fatigue (Oltromare et al. 1974). At 100 ppm, Oltromare et al. (1974) reported that signs of irritation and of
23 mild subjective CNS effects (headaches, fatigue, poor concentration, sleepiness) were felt more often than
24 at 50 ppm. Complaints of mild eye and throat irritation at 99 ppm in one test but not in another at 116 ppm
25 were reported by Stewart et al. (1968). Complaints of eye and nose irritation were frequent at about 200
26 ppm (Oltromare et al. 1974; Stewart et al. 1968) and the severity increased with a further increase in
27 concentration to 376 ppm. 300 – 400 ppm caused immediate lacrymation, and previously non-exposed
28 subjects reported that they could not withstand 500 – 800 ppm for more than 1 – 2 minutes (Götell et al.
29 1972).

30 **5.2 Summary of Animal Data Relevant to AEGL-1**

31 The RD₅₀ as a measure of sensory irritation in mice varied – depending on the exposure
32 duration – between 156 ppm (3 minutes), 586 ppm (5 minutes), and 980 ppm (10 minutes) (Alarie 1973;
33 de Ceaurriz et al. 1981, Bos et al. 1992). In rats, closed eyes at exposure to 200 ppm possibly indicate eye
34 irritation (Cruzan et al. 1997b). Other signs of irritation were salivation (500 ppm), lacrymation
35 (1300 ppm), and rubbing of paws and chin (1500 ppm) (Cruzan et al. 1997b; Stewart et al. 1942; Jarry et
36 al. 2002).

37 **5.3 Derivation of AEGL-1**

38 In an evaluation of reactions related to chemosensory irritation in humans, the ratings for
39 irritation at 20 ppm indicated only marginal effects in this respect. No increase in irritation or headaches
40 compared to control was noted at 20 ppm in a further study. At 50 ppm, a marginal increase in subjective
41 symptoms ratings for eye and nose irritation, headache, and fatigue was described in one, but not in a
42 second study. At 100 ppm, signs of irritation and of mild subjective CNS effects were reported in some

1 studies, but no such effects were seen in others. Complaints of eye and nose irritation were more frequent
2 at about 200 ppm and the severity increased with a further increase in concentration.

3 Therefore, 20 ppm were selected to derive AEGL-1. Because this concentration represents a
4 NOAEL for local as well as CNS effects and in other studies effects at 50 and 100 ppm were only weak or
5 absent, an intraspecies factor of 1 is applied. The value of 20 ppm was used for all timepoints since slight
6 irritation and subjective discomfort that were reported at higher concentrations did not increase within
7 several hours of exposure.

8 The derived values are listed below.

TABLE 8: AEGL-1 VALUES FOR STYRENE					
AEGL Level	10-Minute	30-Minute	1-Hour	4-Hour	8-Hour
AEGL-1	20 ppm	20 ppm	20 ppm	20 ppm	20 ppm

9
10 The level of distinct odor awareness (LOA) for styrene is 0.54 ppm. The LOA derivation
11 follows the guidance as described (Van Doorn et al. 2002). The LOA represents the concentration above
12 which it is predicted that more than half of the exposed population will experience at least a distinct odor
13 intensity, about 10 % of the population will experience a strong odor intensity. The LOA should help
14 chemical emergency responders in assessing the public awareness of the exposure due to odor perception.
15 The derived LOA is considered to have warning properties, but it must be noted that accommodation to odor
16 usually occurs within minutes.

17 **6 DATA ANALYSIS AND PROPOSED AEGL-2**

18 AEGL-2 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which
19 it is predicted that the general population, including susceptible individuals, could experience irreversible
20 or other serious, long-lasting adverse health effects, or an impaired ability to escape.

21 **6.1 Summary of Human Data Relevant to AEGL-2**

22 As outlined above, the effects in humans associated with acute inhalation exposure are irritation
23 and central nervous system depression.

24 Nasal and mild eye irritation were reported by volunteers exposed to 376 ppm (Stewart et al.
25 1968). Local irritation was nearly absent when the odor was masked (Gamberale and Hultengren 1974). In
26 their study of styrene exposed workers, Götell et al. (1972) reported that they themselves suffered from
27 lacrymation and irritation of the nasopharynx immediately when exposed to 300 – 400 ppm. Con-
28 centrations of 500 – 800 ppm caused irritation that was intolerable to the investigators within 1 or 2
29 minutes. Strong eye and nasal irritation was also reported by volunteers exposed to concentrations
30 ≥ 600 ppm (Carpenter et al. 1944; Wolf et al. 1956).

31 With respect to CNS-depression, at 99 ppm intermittent difficulties in performing a modified
32 Romberg test were observed in 3/6 subjects exposed for 7 hours with a 30-minute break in between. Other
33 tests on coordination and on manual dexterity were normal, and no effects were noted at the end of
34 exposure. No CNS effects were seen in another experiment with 116 ppm exposure for 2 hours or
35 216 ppm for 1 hour in the same study (Stewart et al. 1968). In another study, 6 hour exposure at 50 ppm
36 with 4 repeated 15-minute peaks at 100 ppm had no negative influence on performance to

1 neuropsychological tests (Vyskocil et al. 2002a,b). Headaches, but no effects on equilibrium and cognitive
2 function tests were noted in male and female volunteers at repeated exposures to 100 and 125 ppm for at
3 least one hour (Hake et al. 1983). Oltramare et al. (1974) noted that slight difficulties in balance
4 performance at 50 – 200 ppm (1.5 hours), but there was no concentration-response, and slight difficulties
5 in balance performance at 200 ppm (1 hour), but the variation of data was large. No effects on simple and
6 choice reaction time was seen following exposure to 250 ppm for 30 minutes. However, when the
7 concentration was raised to 350 ppm for 30 minutes directly afterwards, both simple and choice reaction
8 time were increased (Gamberale and Hultengren 1974). More pronounced effects were observed during
9 exposure to 376 ppm for one hour: One subject complained of nausea that persisted one hour after the end
10 of exposure, 2 subjects had a feeling of being inebriated, 3 of 5 subjects exposed were unable to normally
11 perform the modified Romberg test, and also 3 subjects (unclear, if the same 3 subjects) had significant
12 decrements in other tests of coordination and manual dexterity (Stewart et al. 1968).

13 In a toxicokinetic study, 2 subjects were exposed to 386 ppm styrene for 2 hours while
14 performing light physical exercise of 50 W (Löf and Johanson 1993). In that study, no information was
15 presented as to the presence or absence of subjective or objective signs of intoxication or irritation.
16 However, it may reasonably be assumed that no severe effects will have occurred in such a study.

17 At higher concentrations, the irritation becomes very strong (see above), and only one
18 controlled study was located that was conducted at this level (Carpenter et al. 1944). In this study, 2
19 subjects exposed to 800 ppm for 4 hours suffered from listlessness, drowsiness, impairment of balance,
20 and, after cessation of exposure, muscular weakness and unsteadiness with inertia and depression. A
21 “steadiness test” (measuring manual dexterity) indicated a marked decreased of performance compared to
22 pre-exposure level. Besides CNS-depression, the subjects complained of eye and throat irritation.

23 Limited data from studies in workers do not provide evidence that styrene exposure leads to
24 lesions of the upper respiratory tract or will impair the sense of smell. In a cross-sectional study, no
25 differences in histological characteristics of the mucosa from the nasal inferior turbinates could be
26 observed in biopsies from styrene exposed workers and matched controls (Ödkvist et al. 1985). In a
27 controlled study, the olfactory threshold for styrene was 32-fold higher in styrene-exposed workers than in
28 age-matched controls. However, the odor threshold for the olfactory standard phenyl ethylalcohol was not
29 altered nor was the ability to identify 20 different aroma compounds in an odor identification test (Dalton
30 et al. 2003).

31 **6.2 Summary of Animal Data Relevant to AEGL-2**

32 Limited data from one study are available for styrene toxicity in monkeys (species not
33 reported) (Spencer et al. 1942). In this study, no death occurred in animals during subchronic exposure to
34 1300 ppm styrene, 7 – 8 hours/day, 5 days/week. It was further reported that there were no signs of
35 irritation or intoxication and no pathological findings in inner organs or in hematology.

36 Rats exposed to 2760 ppm for one hour were in a state of deep narcosis (Shugaev 1969). Also,
37 “many” rats lost consciousness during exposure to 2000 ppm for 5 hours (Withey and Collins 1979). In
38 rats exposed to concentrations \geq 2983 ppm, signs of CNS impairment (staggered or staling gait, tremors,
39 lying on the side, and narcosis) were observed. In mice, signs of CNS-depression that occurred during a 4-
40 hour exposure also included staggered gait at 1420 ppm and apathy and finally narcosis at higher
41 concentrations (2983 and 3766 ppm) (BASF 1979a).

42 At 1500 ppm, reduced attention was described to occur during 6-hours of exposure in rats
43 (Jarry et al. 2002), and an inability to suppress nystagmus in an optokinetic test were seen at 1730 ppm

1 after about 30 minutes of exposure (Niklasson et al. 1993). Rats were mostly recumbent at 12 hours of
2 exposure to 600 ppm (Mäkitie et al. 2003), this may also indicate weak CNS-depression.

3 Behavioral changes were observed in a “despair swimming test” in mice (de Ceaurriz et al.
4 1983). The mean duration of immobility decreased by 28 – 83 % of control after a 4-hour exposure to 413
5 – 851 ppm styrene. An ID₅₀ (50 % decrease in immobility) of 549 ppm was calculated.

6 Ototoxicity of styrene with an increase of the auditory threshold in functional tests and a
7 substantial loss of the outer hair cells of the cochlea was observed in rats after repeated exposure at
8 600 ppm and higher concentrations, but not at 500 ppm (6 hours/day, 5 days/week, 4 weeks) (Mäkitie et
9 al. 2003; Loquet et al. 1999; Lataye et al. 2003 Campo et al. 2001); no effects were detected in similarly
10 exposed guinea pigs (Lataye et al. 2003). No studies were available in which ototoxicity was investigated
11 after a single exposure, so the relevance of these effects with respect to a single exposure of humans is not
12 known. Therefore, these results will not be used for the derivation of AEGL-2.

13 In rats, pulmonary lesions following acute inhalation exposure only were observed at
14 concentrations that also caused severe and mostly lethal CNS effects. Mice were more sensitive to styrene
15 than rats. At 250 ppm and 500 ppm, upper respiratory tract and lung toxicity, liver lesions and sometimes
16 death were observed following one or few exposures, and differences in sensitivity between strains were
17 observed; B6C3F1 were most sensitive (Morgan et al. 1993a, c; Mahler et al. 1999; Cruzan et al. 1997;
18 Sumner et al. 1997). At similar concentrations, no such effects have been observed in humans in
19 controlled studies and in numerous studies on occupationally exposed workers with long-term exposure to
20 styrene. Obviously, the high susceptibility of mice with respect to liver and respiratory tract lesions is
21 species- (and strain-) specific and these data are not relevant for the derivation of AEGL.

22 No developmental toxicity was observed in rats following single oral administration of a
23 maternall toxic dose on day 11 of gestation in one study (Daston et al. 1991) and on gestation day 17 in
24 another (Ponomarkov and Tomatis 1978). In O₂₀ mice, survival prior to weaning was reduced after a
25 maternally toxic dose given orally on gestation day 17, no effect was seen in C57Bl mice given a lower
26 dose (Ponomarkov and Tomatis 1978). Following repeated 6-hour exposure to 300 ppm, but not to
27 50 ppm, during gestation day 6 – 20, an increased neonatal death rate was observed and delayed postnatal
28 development was observed (Katakura et al. 2001). In hamsters, the number of dead or resorbed fetuses
29 was increased at exposure to 1000 ppm 6 hours/day from gestation day 6 -18, but not at 750 ppm
30 (Kankaanpää et al. 1980). In other studies with repeated oral or inhalation exposure of rats, mice, and
31 rabbits, no significant developmental effects were seen (Murray et al. 1978; Srivastava et al. 1990;
32 Chernoff et al. 1990; Beliles et al. 1985; Kankaanpää et al. 1980). The relevance of an exposure duration
33 of about half the gestation period in rodents to a less than one day exposure in humans is questionable.
34 Therefore, these results will not be used for the derivation of AEGL-2.

35 **6.3 Derivation of AEGL-2**

36 The AEGL-2 is based on the CNS effects observed in humans following exposure to 376 ppm
37 for one hour: nausea in one subject; feeling of being inebriated in two, and inability to normally perform
38 the modified Romberg test and significant decrements in other tests of coordination and manual dexterity
39 in three of five subjects (Stewart et al. 1968). The effects described address a level of CNS depression that
40 seems still below a level for an impairment of the ability to escape and therefore a concentration of 376
41 ppm is considered a NOAEL. However, this concentration is close to the range where irritation in humans
42 becomes intolerable: Exposed subjects reported immediate lacrymation at 300 – 400 ppm and described
43 the irritation above 500 or 600 ppm as very strong or even intolerable after 1 or minutes. Clearly, such
44 irritating levels may limit the ability to escape and thus are above AEGL-2.

1 Generally, for volatile substances with CNS-depressant effects an intraspecies factor of 3 is
2 applied to account for sensitive individuals because the effective concentration range does not differ more
3 than 2-3fold between individuals. In case of styrene, it must be taken into account that physical activity
4 has a marked effect on the uptake of styrene and its level in blood. In the studies used to derive AEGL-2,
5 the subjects were at rest. In controlled studies, the observed increase of styrene in arterial blood at ex-
6 posure to about 150 ppm styrene was approximately 3fold when the physical activity was increased from
7 rest to light exercise (50 W), 5fold at moderate exercise (100 W), and 10fold at heavy exercise (150 W)
8 (Astrand 1975). These values are conservative estimates since – as outlined above (see section 4.1) – the
9 experimental conditions lead to an overestimation of the effect.

10 Therefore, it could be argued that an intraspecies uncertainty factor of 10 to account for
11 sensitive subgroups would be necessary to protect individuals at heavy physical exercise. Application of a
12 factor of 10 would lead to a 1-hour AEGL-2 of 38 ppm and similar values at longer time periods. On the
13 other hand, the following two points which indicate that a factor of 3 is justified, are believed to outweigh
14 the above rationale.

15 Firstly, due to physiological limitations, heavy physical exercise (150 W) cannot be performed
16 continuously for longer periods of time. Therefore, it is unrealistic to consider an exposure scenario with
17 heavy exercise for one or several hours. In contrast, light exercise (50 W) may be performed over a longer
18 period of time. In this case, the increase of the styrene concentration in blood will be about 3fold which is
19 within the range of an uncertainty factor of three.

20 Secondly, an AEGL-2 value in the range of 38 ppm as mentioned above would be in conflict
21 with styrene exposure data at occupational workplaces. At workplaces, such concentrations are or were
22 frequently observed (IARC 2002) without workers showing signs of CNS depression that would have
23 limited their ability to escape.

24 Therefore, an intraspecies uncertainty factor of 3 is considered adequate to protect sensitive
25 subgroups including groups exposed to styrene during longer periods of light exercise. This leads to a
26 value of 130 ppm as AEGL-2 for 1 hour.

27 This experimentally derived exposure value was scaled to shorter periods of time using the
28 equation $c^n \times t = k$ (Ten Berge et al. 1986). As outlined in NRC (2001), a default of $n = 3$ for shorter
29 periods of time (30 minutes and 10 minutes) was applied, due to the lack of suitable experimental data for
30 deriving the concentration exponent. The “n” value of 1.2 used for calculations of AEGL-3 (see below)
31 was not used for AEGL-2 for following reasons: Firstly, the exponent was derived from lethality studies
32 in which delayed mortality was observed that was not related to narcotic effects on the CNS (which are
33 relevant for AEGL-2) but probably to pulmonary lesions observed at these very high concentrations (in
34 addition to CNS effects which are the major cause of death). Secondly, toxicokinetics at high exposure
35 concentrations over several hours of exposures (as in the lethality studies) is different from that at lower
36 concentrations for shorter time periods.

37 Toxicokinetic studies with humans exposed to styrene concentrations at 70 – 200 ppm show
38 that most of the increase of the styrene concentration in blood is seen during the first 30 minutes of
39 exposure and that there is no or very little increase at 1 – 3 hours at these concentrations (Löf and
40 Johanson 1993; Ramsey et al. 1980; Wigaeus et al. 1983). Therefore, no additional extrapolation is
41 necessary and the AEGL-2 of 130 ppm derived for 1 hour is applied to longer periods of time.

42 The derived values are listed below.

TABLE 9: AEGL-2 VALUES FOR STYRENE					
AEGL Level	10-Minute	30-Minute	1-Hour	4-Hour	8-Hour
AEGL-2	230 ppm	160 ppm	130 ppm	130 ppm	130 ppm

1

2 As outlined above, ototoxicity was observed in short-term studies with rats. At present, the
 3 relevance of these findings for acute exposure in humans cannot be assessed. However, taking into
 4 account that the NOEL of 500 ppm is derived from a subacute study (6 hours/day, 5 days/week, 4 weeks),
 5 the derived AEGLs are considered to be protective against ototoxic effects.

6 Individual cases of respiratory sensitization to styrene were described (Hayes et al. 1991;
 7 Moscato et al. 1987). Taking into account the wide use of styrene both in industry and in do-it-yourself
 8 products, sensitization seems to be an exceptionally rare event. Although the risk of sensitization
 9 following a single exposure at AEGL-2 is considered negligible, individuals already sensitized may not be
 10 able to tolerate styrene concentrations that are without effect in non-sensitized individuals and may not be
 11 protected by the AEGL developed for styrene in this TSD.

12 **7 DATA ANALYSIS AND PROPOSED AEGL-3**

13 AEGL-3 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which
 14 it is predicted that the general population, including susceptible individuals, could experience life-
 15 threatening health effects or death.

16 In lethality studies with rats (see below), most animals died of CNS-depression but delayed
 17 death was observed in some rats. These animals showed pulmonary edema and hemorrhages. Since no
 18 reports of death in humans following exposure to styrene were located in the literature, it is not known if
 19 pulmonary lesions may occur in humans at high, acute life-threatening exposure, but this cannot be
 20 excluded.

21 **7.1 Summary of Human Data Relevant to AEGL-3**

22 No studies were located in which it was reported that styrene exposure has caused death in
 23 humans.

24 **7.2 Summary of Animal Data Relevant to AEGL-3**

25 At high concentrations, CNS-depression progresses to loss of consciousness and finally death.
 26 Furthermore, delayed deaths were observed that seem to be related to pulmonary lesions. As outlined in
 27 section 3.6, the most reliable data for lethal toxicity in rats are those of BASF (1979b) and Bonnet et al.
 28 (1982). In these studies, delayed deaths which were seen in some animals were included in the
 29 determination of the LC₅₀. Other lethality studies did not include such observations or lack important
 30 experimental details.

31 Limited data are available for nonhuman primates. In one study with monkeys (species not
 32 reported), no death was observed at repeated exposures to 1300 ppm, 7 – 8 hours/day, 5 days/week for at
 33 least 7 months (Spencer et al. 1942).

34 Mice were more sensitive to styrene than rats. At 250 ppm and 500 ppm, upper respiratory tract
 35 and lung toxicity, liver lesions and sometimes death were observed following one or few exposures, and

1 differences in sensitivity between strains were observed; B6C3F1 were most sensitive (Morgan et al.
2 1993a, c; Mahler et al. 1999; Cruzan et al. 1997; Sumner et al. 1997). At similar concentrations, no such
3 effects were observed in humans in controlled studies and in numerous studies on occupationally exposed
4 workers with long-term exposure to styrene. Obviously, the high susceptibility of mice with respect to
5 liver and respiratory tract lesions is species- (and strain-) specific and these data are not relevant for the
6 derivation of AEGL.

7 Developmental toxicity including embryoletality data are summarized above (see 6.2). For the
8 same reason as outlined there, these results will not be used for the derivation of AEGL-2.

9 **7.3 Derivation of AEGL-3**

10 In rats, exposure to high concentrations of styrene leads to progressive CNS depression with
11 narcosis and, finally, death. Pulmonary lesions were also described in these studies but only at
12 concentrations leading to severe or lethal CNS effects.

13 In humans, the acute effects on the CNS are also well known. However, no reports were
14 identified describing lethal intoxication of humans following styrene exposure. Therefore, it is not known
15 if the pulmonary lesions observed in rats may also occur in humans exposed to life-threatening or
16 potentially lethal concentrations of styrene.

17 For a conservative approach, data from studies with rats taking into account delayed deaths
18 with pulmonary lesions were taken to derive AEGL-3. From the data of the 4-hour exposure study of
19 BASF (1979b), a benchmark calculation was performed with the lethality data using different models.
20 Calculations were performed for males/females combined and for both sexes separately. According to
21 these calculations, female rats could be slightly more susceptible than male rats as indicated by the higher
22 mortality at lower concentrations. Therefore, a BMDL05 for female rats of 3409 ppm (rounded to 3400
23 ppm) was used as a starting point to derive AEGL-3.

24 A total uncertainty factor of 10 was applied. This total factor may formally be split up into an
25 interspecies factor of 3 and an intraspecies factor also of 3.

26 For volatile solvents like styrene with a CNS-depressant effect, an interspecies uncertainty
27 factor of 3 has been applied in the derivation of AEGL for several substances. This is based on the
28 similarity of effects manifested in rodents compared to humans.

29 In case of styrene, limited data indicate no gross differences in the concentration of styrene in
30 blood between rats and humans. According to a toxicokinetic model, at concentrations exceeding 200 ppm
31 styrene in air, the non-steady-state concentration of styrene in blood of humans (calculated for 6 hours of
32 exposure) will always be lower than that in blood of rats since (Ramsey and Andersen 1984). Styrene
33 levels in human blood were in accordance with this model up to 376 ppm in air, however, no experimental
34 human data are available at higher concentrations.

35 An intraspecies uncertainty factor of 3 was applied to account for sensitive individuals since
36 the threshold for CNS impairment is not expected to vary much among individuals. As in case of the
37 derivation of AEGL-2 (see 6.3), an intraspecies uncertainty factor of 3 is considered adequate to protect
38 sensitive subgroups including groups exposed to styrene during longer periods of light exercise.

39 The experimentally derived exposure values were scaled to AEGL time frames using the
40 equation $c^n \times t = k$ (Ten Berge et al. 1986). An exponent of $n = 1.2$ which was used for extrapolation to all

1 time points was derived from the 4-hour and 6-hour LC₅₀ for rats obtained by BASF (1979b) and Bonnet
2 et al. (1982a; see Appendix B).

3 The derived values are listed below.

TABLE 10: AEGL-3 VALUES FOR STYRENE					
AEGL Level	10-Minute	30-Minute	1-Hour	4-Hour	8-Hour
AEGL-3	4800 ppm *	1900 ppm *	1100 ppm	340 ppm	190 ppm

4 *: The lower explosive limit (LEL) of styrene in air is 1.1 % (11,000 ppm). The AEGL-3 value of
5 4800 ppm (8090 mg/m³) for 10 minutes and the AEGL-3 value of 1900 ppm (8090 mg/m³) are higher than 1/10 of
6 the LEL. Therefore, safety considerations against hazard of explosion must be taken into account.

7 The derived values can be interpreted to the effect that the average population might be
8 exposed to a concentration 3fold higher than susceptible subgroups without experiencing AEGL-3 effects.
9 Taking this into account, limited data from controlled human studies support the derived AEGL-3 values.
10 Especially, Carpenter et al. (1944) observed marked CNS depression (and severe irritation) but no life-
11 threatening effects in 2 resting volunteers exposed to 800 ppm for 4 hours.

12 **8 SUMMARY OF PROPOSED AEGLS**

13 **8.1 AEGL Values and Toxicity Endpoints**


14

TABLE 11: SUMMARY/RELATIONSHIP OF PROPOSED AEGL VALUES ^a					
Classification	10-Minute	30-Minute	1-Hour	4-Hour	8-Hour
AEGL-1 (Nondisabling)	20 ppm	20 ppm	20 ppm	20 ppm	20 ppm
AEGL-2 (Disabling)	230 ppm	160 ppm	130 ppm	130 ppm	130 ppm
AEGL-3 (Lethal)	4800 ppm *	1900 ppm *	1100 ppm	340 ppm	190 ppm

15 *: The lower explosive limit (LEL) of styrene in air is 1.1 % (11,000 ppm). The AEGL-3 value of
16 4800 ppm (20,450 mg/m³) for 10 minutes and the AEGL-3 value of 1900 ppm (8090 mg/m³) are higher than 1/10 of
17 the LEL. Therefore, safety considerations against hazard of explosion must be taken into account.

18

19



1 **FIGURE 7: CATEGORICAL REPRESENTATION OF STYRENE INHALATION DATA**
 2

1 8.2 Comparison with Other Standards and Guidelines

2 Other standard and guidance levels for workplace and community are listed in **TABLE 12**.

Guideline	Exposure duration					
	10 min	30 min	1 h	4 h	8 h	24 h
AEGL-1	20 ppm	20 ppm	20 ppm	20 ppm	20 ppm	20 ppm
AEGL-2	230 ppm	160 ppm	130 ppm	130 ppm	130 ppm	
AEGL-3	4800 ppm *	1900 ppm *	1100 ppm	340 ppm	190 ppm	
ERPG-1 (AIHA 1995) ^a			50 ppm			
ERPG-2 (AIHA 1995) ^a			250 ppm			
ERPG-3 (AIHA 1995) ^a			1000 ppm			
IDLH (NIOSH 1996) ^b		700 ppm				
PEL-TWA (OSHA, 1989) ^e					100 ppm	
Acceptable peak (OSHA) ^f	600 ppm [5 min]					
REL-TWA (NIOSH) ^g					50 ppm	
STEL-NIOSH	100 ppm [15 min]					
TLV-TWA (ACGIH 1997) ^h					20 ppm	
TRGS 900 (Germany) ⁱ						
TRGS 900 (Germany) Spitzenbegrenzung ^l						
MAK (DFG 1987, Germany) ^k					20 ppm	
MAK (DFG, Germany) Kurzzeitkategorie ^l					II,1	
Einsatztoleranzwert ^m				40 ppm		

3 *: The lower explosive limit (LEL) of styrene in air is 1.1 % (11,000 ppm). The AEGL-3 value of 4800 ppm
 4 (20,450 mg/m³) for 10 minutes and the AEGL-3 value of 1900 ppm (8090 mg/m³) are higher than 1/10 of the LEL.
 5 Therefore, safety considerations against hazard of explosion must be taken into account.

6

- 1 a **ERPG** (Emergency Response Planning Guidelines, American Industrial Hygiene Association)
- 2 The ERPG-1 is the maximum airborne concentration below which nearly all individuals could be exposed
- 3 for up to one hour without experiencing or developing effects more serious than mild irritation, other mild
- 4 transient health effects, or perception of a clearly objectionable odor. The ERPG-1 for styrene is based on
- 5 the observation that controlled exposure to 50 ppm for 1 hour or more does not produce any adverse health
- 6 effects except mild to moderate odor perception.
- 7 The ERPG-2 is the maximum airborne concentration below nearly all individuals could be exposed for up
- 8 to one hour without experiencing or developing irreversible or other serious adverse health effects or
- 9 symptoms that could impair an individual's ability to take protective action. The ERPG-2 for styrene is
- 10 derived on the basis that simple reaction time was increased after 30 minutes exposure at 350 ppm, but not
- 11 at 250 ppm and exposure to 200 ppm was well-tolerated.²
- 12 The ERPG-3 is the maximum airborne concentration below which it is believed nearly all individuals could
- 13 be exposed for up to one hour without experiencing or developing life-threatening health effects. The
- 14 ERPG-3 for styrene of 1000 ppm is derived on the basis that this value is well below lethality levels
- 15 observed in acute animal studies, exposure to 2 human volunteers at 800 ppm caused only irritation and
- 16 CNS depression, and that repeated exposures to 1300 ppm are well-tolerated in animal species.
- 17 b: **IDLH** (Immediately Dangerous to Life and Health, National Institute of Occupational Safety and Health)
- 18 Basis for revised IDLH: Acute inhalation toxicity data in humans (drowsiness, nausea, headache, fatigue,
- 19 and dizziness reported to occur in workers exposed to 200 – 700 ppm; AIHA 1959) (NIOSH 1996).
- 20 e: **OSHA PEL-TWA** (Occupational Health and Safety Administration, Permissible Exposure Limits - Time
- 21 Weighted Average) for 8 hours (OSHA). Additionally, in 1996, the styrene industry agreed to establish a
- 22 voluntary compliance program, the objective of which is to encourage all facilities to comply with PEL
- 23 established for styrene during the 1989 rulemaking; that is, inhalation exposures that do not exceed 50 ppm
- 24 on an 8-hour TWA, and a 100 ppm 15-minute ceiling (OSHA 2003).
- 25 f: **Acceptable Peak OSHA** (Occupational Health and Safety Administration, Permissible Exposure Limits; OSHA).
- 26 g: **REL-TWA NIOSH** (National Institute of Occupational Safety and Health, Recommended Exposure Limits -
- 27 Time Weighted Average) (NIOSH), is defined analogous to the ACGIH-TLV-TWA.
- 28 h: **ACGIH TLV-TWA** (American Conference of Governmental Industrial Hygienists, Threshold Limit Value -
- 29 Time Weighted Average) (ACGIH, 1999):
- 30 The time-weighted average concentration for a normal 8-hour workday and a 40-hour workweek, to which
- 31 nearly all workers may be repeatedly exposed, day after day, without adverse effect.
- 32 k: **MAK** (Maximale Arbeitsplatzkonzentration [Maximum Workplace Concentration], Deutsche Forschungs-
- 33 gemeinschaft [German Research Association], Germany.
- 34 is defined analogous to the ACGIH-TLV-TWA.
- 35 l: **MAK Spitzenbegrenzung** (Kategorie II, 1) (Peak Limit Category II, 1) (DFG 2000): 5 times MAK
- 36 constitutes the maximum average concentration for substances with a half-life of less than two hours to
- 37 which workers may be exposed for a period up to 30 minutes (mean value) no more than 4 times per
- 38 workshift.
- 39 n: **Einsatztoleranzwert** (Buff and Greim 2000)
- 40 Einsatztoleranzwert (Action Tolerance Levels), Vereinigung zur Förderung des deutschen Brandschutzes e.
- 41 V. (Federation for the Advancement of German Fire Prevention) constitutes a concentration to which
- 42 unprotected firemen and the general population can be exposed to for up to 4 hours without any health risk.
- 43

² The rationale, however, also stated that there was a loss of balance in volunteers exposed for 1 – 3 hours to 200 ppm or more.

1 **8.3 Data Adequacy and Research Needs**

2 The data base on humans includes controlled clinical studies and studies at the workplace.
3 These studies showed that styrene is irritating to eyes and mucous membranes of the upper respiratory
4 tract. Effects on the central nervous system were observed in controlled human studies, in studies on
5 workers occupationally exposed to styrene, and in accidents following exposure to higher but unknown
6 concentrations. Toxicokinetic studies are also available. The derived AEGL-1 and -2 values are based on
7 well-described controlled human studies.

8 Studies with acute to subacute exposure of animals – mostly rats and mice, and very limited
9 data for other species (monkeys, guinea pigs, hamsters, rabbits) – addressed irritation, effects on the
10 central nervous system including behavior, ototoxicity, and lethality. Developmental toxicity, genotoxicity
11 and carcinogenicity studies are also available. Species differences observed between rats and mice were
12 observed with respect to respiratory toxicity and carcinogenicity. Toxicokinetic studies indicate that the
13 higher susceptibility of mice compared to rats with respect to pulmonary toxicity and carcinogenicity is
14 related to differences in the metabolic activation and detoxification of styrene. The derived AEGL-3
15 values are based on a well-conducted and -described lethality study with rats.

16

17 **9 REFERENCES**

- 18 ACGIH. 1997. Styrene, monomer. In: Documentation of the Threshold Limit Values and Biological
19 Exposure Indices. Supplement ed., pp. 1 - 16. American Conference of Governmental Industrial
20 Hygienists, Cincinnati, Ohio.
- 21 AIHA. 1959. Styrene monomer. In: Hygienic guide series. American Industrial Hygiene Association
22 (AIHA), Akron, OH.
- 23 AIHA. 1995. Emergency response planning guidelines (ERPG): Styrene. American Industrial Hygiene
24 Association (AIHA), Fairfax, VA.
- 25 Alarie, Y. 1973. Sensory irritation of the upper airways by airborne chemicals. *Toxicol Appl. Pharmacol*
26 24: 279-297.
- 27 Amoores, J.E. and E. Hautala. 1983. Odor as an aid to chemical safety: odor thresholds compared with
28 threshold limit values and volatilities for 214 industrial chemicals in air and water dilution. *J.*
29 *Appl. Toxicol.* 3: 272-290.
- 30 Andersen, M.E., M.L. Gargas, and J.C. Ramsey. 1984. Inhalation pharmacokinetics: evaluating systemic
31 extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene
32 in rats based on arterial blood:inhaled air concentration ratios. *Toxicol. Appl. Pharmacol.* 73: 176-
33 187. Cited from abstract in MEDLINE (<http://gateway.nlm.nih.gov/gw/Cmd>).
- 34 Arnedo-Pena, A., J. Bellido-Blasco, J.L. Villamarin-Vazquez, J.L. Aranda-Mares, N. Font-Cardona, F.
35 Gobba, and M. Kogevinas. 2003. Acute health effects after accidental exposure to styrene from
36 drinking water in Spain. *Environ Health* 2: 1-6. Cited from abstract in MEDLINE
37 (<http://gateway.nlm.nih.gov/gw/Cmd>).
- 38 Astrand, I. 1975. Uptake of solvents in the blood and tissues of man. A review. *Scand. J. Work Environ*
39 *Health* 1: 199-218.

- 1 ATSDR. 1992. Toxicological profile for styrene. U.S. Department of Health and Human Services. Public
2 Health Service. Agency for Toxic Substances and Disease Registry, Atlanta, Georgia.
- 3 Ban, M., D. Hettich, and P. Bonnet. 2003. Effect of inhaled industrial chemicals on systemic and local
4 immune response. *Toxicology* 184: 41-50.
- 5 BASF. 10-12-1979a. Bericht über die Bestimmung der akuten Inhalationstoxizität LC50 von Styrol als
6 Dampf bei 4stündiger Exposition an NMRI-Mäusen. Unveröffentlichte Untersuchung. BASF
7 AG, Ludwigshafen, Germany.
- 8 BASF. 10-12-1979b. Bericht über die Bestimmung der akuten Inhalationstoxizität LC50 von Styrol als
9 Dampf bei 4stündiger Exposition an Sprague-Dawley-Ratten. Unveröffentlichte Untersuchung.
10 BASF AG, Ludwigshafen, Germany.
- 11 Beliles, R.P., J.H. Butala, C.R. Stack, and S. Makris. 1985. Chronic toxicity and three-generation
12 reproduction study of styrene monomer in the drinking water of rats. *Fundam. Appl. Toxicol* 5:
13 855-868. Cited in Brown (2000) and Cohen et al. (2002).
- 14 Bonassi, S., F. Montanaro, M. Ceppi, and A. Abbondandolo. 1996. Is human exposure to styrene a cause
15 of cytogenetic damage? A re-analysis of the available evidence. *Biomarkers* 1: 217-225.
- 16 Bond, J.A. 1989. Review of the toxicology of styrene. *Crit Rev. Toxicol* 19: 227-249.
- 17 Bonnet, P., Y. Morele, G. Raoult, D. Zissu, and D. Gradiski. 1982a. Détermination de la concentration
18 léthales50 des principaux hydrocarbures aromatiques chez le rat. *Arch. Mal. Prof.* 43: 261-265.
- 19 Bonnet, P., G. Raoult, and D. Gradiski. 1979b. Concentrations léthales 50 des principaux hydrocarbures
20 aromatiques. *Arch. Mal. Prof.* 40: 805-810.
- 21 Bos, P., A. Zwart, P.G.J. Reuzel, and P.C. Bragt. 1992. Evaluation of the Sensory Irritation Test for the
22 Assessment of Occupational Health Risk. *Crit. Rev. Toxicol.* 21: 423-450.
- 23 Brown, N.A. 1991. Reproductive and developmental toxicity of styrene. *Reprod. Toxicol.* 5: 3-29.
- 24 Brown, N.A., J.C. Lamb, S.M. Brown, and B.H. Neal. 2000. A review of the developmental and
25 reproductive toxicity of styrene. *Regul. Toxicol. Pharmacol* 32: 228-247.
- 26 Brunnemann, K.D., A. Rivenson, S.C. Cheng, V. Saa, and D. Hoffmann. 1992. A study of tobacco
27 carcinogenesis. XLVII. Bioassays of vinylpyridines for genotoxicity and for tumorigenicity in A/J
28 mice. *Cancer Lett.* 65: 107-113. Cited in Cohen (1992).
- 29 Buff, K. and H. Greim. 2000. Der Einsatztoleranzwert als Instrument der raschen Gefahrenbewertung am
30 Brandort und beim Gefahrstoffeinsatz. In: Bundesamt für Zivilschutz (ed.): Zivilschutz-
31 Forschung. 45., 46. und 48. Jahrestagung der Schutzkommission beim Bundesminister des Innern
32 - Vorträge. Schriftenreihe der Schutzkommission beim Bundesminister des Innern. Neue Folge
33 Band 42, p. 221-228. Medienhaus Froitzheim AG, Bonn, Berlin.
- 34 Campo, P., R. Lataye, G. Loquet, and P. Bonnet. 2001. Styrene-induced hearing loss: a membrane insult.
35 *Hear. Res.* 154: 170-180. Cited from abstract in MEDLINE
36 (<http://gateway.nlm.nih.gov/gw/Cmd>).

- 1 Campo, P., G. Loquet, V. Blachere, and M. Roure. 1999. Toluene and styrene intoxication route in the rat
2 cochlea. *Neurotoxicol. Teratol.* 21: 427-434.
- 3 Carpenter, C.P., H.F.Jr. Smyth, and D.C. Pozzani. 1944. Studies on the inhalation of 1:3-butadiene; with a
4 comparison of its narcotic effect with benzol, toluol, and styrene, and a note on the elimination of
5 styrene by the human. *J. Ind. Hyg. Toxicol.* 26: 69-78.
- 6 Chernoff, N., R.W. Setzer, D.B. Miller, M.B. Rosen, and J.M. Rogers. 1990. Effects of chemically
7 induced maternal toxicity on prenatal development in the rat. *Teratology* 42: 651-658. Cited in
8 Brown et al. (2000).
- 9 Cohen, J.T., G. Carlson, G. Charnley, D. Coggon, E. Delzell, J.D. Graham, H. Greim, D. Krewski et al.
10 2002. A comprehensive evaluation of the potential health risks associated with occupational and
11 environmental exposure to styrene. *J. Toxicol Environ Health B Crit Rev.* 5: 1-265.
- 12 Conti, B., C. Maltoni, G. Perino, and A. Ciliberti. 1988. Long-term carcinogenicity bioassays on styrene
13 administered by inhalation, ingestion and injection and styrene oxide administered by ingestion in
14 Sprague-Dawley rats, and para-methylstyrene administered by ingestion in Sprague-Dawley rats
15 and Swiss mice. *Ann. N. Y. Acad. Sci.* 534: 203-234. Cited in Cohen et al. (2002) and IARC
16 (2002).
- 17 Cruzan, G., G.P. Carlson, K.A. Johnson, L.S. Andrews, M.I. Banton, C. Bevan, and J.R. Cushman. 2002.
18 Styrene respiratory tract toxicity and mouse lung tumors are mediated by CYP2F-generated
19 metabolites. *Regul. Toxicol Pharmacol* 35: 308-319.
- 20 Cruzan, G., J.R. Cushman, L.S. Andrews, G.C. Granville, K.A. Johnson, C. Bevan, C.J. Hardy, D.W.
21 Coombs et al. 2001a. Chronic toxicity/oncogenicity study of styrene in CD-1 mice by inhalation
22 exposure for 104 weeks. *J. Appl. Toxicol.* 21: 185-198.
- 23 Cruzan, G., J.R. Cushman, L.S. Andrews, G.C. Granville, K.A. Johnson, C.J. Hardy, D.W. Coombs, P.A.
24 Mullins et al. 1998. Chronic toxicity/oncogenicity study of styrene in CD rats by inhalation
25 exposure for 104 weeks. *Toxicol Sci.* 46: 266-281.
- 26 Cruzan, G., J.R. Cushman, L.S. Andrews, G.C. Granville, R.R. Miller, C.J. Hardy, D.W. Coombs, and
27 P.A. Mullins. 1997b. Subchronic inhalation studies of styrene in CD rats and CD-1 mice. *Fundam.*
28 *Appl. Toxicol* 35: 152-165.
- 29 Csanady, G.A. and J.G. Filser. 2001. The relevance of physical activity for the kinetics of inhaled gaseous
30 substances. *Arch. Toxicol.* 74: 663-672.
- 31 Csanady, G.A., W. Kessler, H.D. Hoffmann, and J.G. Filser. 2003. A toxicokinetic model for styrene and
32 its metabolite styrene-7,8-oxide in mouse, rat and human with special emphasis on the lung.
33 *Toxicol Lett.* 138: 75-102.
- 34 Csanady, G.A., A.L. Mendrala, R.J. Nolan, and J.G. Filser. 1994. A physiologic pharmacokinetic model
35 for styrene and styrene-7,8-oxide in mouse, rat and man. *Arch. Toxicol.* 68: 143-157.
- 36 Dalton, P., B. Cowart, D. Dilks, M. Gould, P.S. Lees, A. Stefaniak, and E. Emmett. 2003. Olfactory
37 function in workers exposed to styrene in the reinforced-plastics industry. *Am. J. Ind. Med.* 44: 1-
38 11.

- 1 Daston, G.P., G.J. Overmann, M.W. Taubeneck, L.D. Lehman-McKeeman, J.M. Rogers, and C.L. Keen.
2 1991. The role of metallothionein induction and altered zinc status in maternally mediated
3 developmental toxicity: comparison of the effects of urethane and styrene in rats. *Toxicol Appl.*
4 *Pharmacol* 110: 450-463.
- 5 de Ceaurriz, J., J.P. Desiles, P. Bonnet, B. Marignac, J. Muller, and J.P. Guenier. 1983. Concentration-
6 dependent behavioral changes in mice following short-term inhalation exposure to various
7 industrial solvents. *Toxicol Appl. Pharmacol* 67: 383-389.
- 8 de Ceaurriz, J.C., J.C. Micillino, P. Bonnet, and J.P. Guenier. 1981. Sensory irritation caused by various
9 industrial airborne chemicals. *Toxicol Lett.* 9: 137-143.
- 10 DFG. 1987. Styrol. In: Greim, H. (ed.): *Gesundheitsschädliche Arbeitsstoffe. Toxikologisch-*
11 *arbeitsmedizinische Begründungen von MAK-Werten*, 13. Lieferung. Wiley-VCH, Weinheim,
12 Germany.
- 13 Edling, C. and K. Ekberg. 1985. No acute behavioural effects of exposure to styrene: a safe level of
14 exposure? *Br. J. Ind. Med.* 42: 301-304.
- 15 Elovaara, E., H. Vainio, and A. Aitio. 1990. Pulmonary toxicity of inhaled styrene in acetone-,
16 phenobarbital- and 3-methylcholanthrene-treated rats. *Arch. Toxicol.* 64: 365-369.
- 17 Engelhardt, G., A. Gamer, P. Vodicka, I. Barta, H.D. Hoffmann, and G. Veenstra. 2003. A re-assessment
18 of styrene-induced clastogenicity in mice in a subacute inhalation study. *Arch. Toxicol.* 77: 56-61.
- 19 Filser, J.G., W. Kessler, and G.A. Csanady. 2002. Estimation of a possible tumorigenic risk of styrene
20 from daily intake via food and ambient air. *Toxicol Lett.* 126: 1-18.
- 21 Filser, J.G., H.R. Oberste-Frielinghaus, M. Dhawan-Robl, T.H. Faller, W. Kessler, and G.A. Csanady.
22 1999. A physiological toxicokinetic model for styrene and styrene-7,8-oxide in mouse,
23 rat and human considering metabolism in the lung. GSF Institute of Toxicology, Neuherberg, Germany,
24 Cited in Cohen et al. (2002).
- 25 Filser, J.G., U. Schwegler, G.A. Csanady, H. Greim, P.E. Kreuzer, and W. Kessler. 1993. Species-specific
26 pharmacokinetics of styrene in rat and mouse. *Arch. Toxicol.* 67: 517-530.
- 27 Gamberale, F. and M. Hultengren. 1974. Exposure to styrene. II. Psychological functions. *Work Environ*
28 *Health* 11: 86-93.
- 29 Götell, P., O. Axelson, and B. Lindelöf. 1972. Field Studies on Human Styrene Exposure. *Work,*
30 *Environment and Health* 9: 76-83.
- 31 Government Canada. 1993. Canadian Environmental Protection Act (CEPA). Priority substances list
32 assessment report. Styrene. Environment Canada/Health Canada. Minister of Public Works and
33 Government Services, <http://www.hc-sc.gc.ca/hecs-sesc/exsd/cepa/styrene.pdf>.
- 34 Gradiski, D., P. Bonnet, G. Raoult, and J.L. Magadur. 1978. Toxicité aiguë comparée par inhalation des
35 principaux solvants aliphatiques chlorés. *Arch. Mal. Prof.* 39: 249-257.

- 1 Green, T., R. Lee, A. Toghil, S. Meadowcroft, V. Lund, and J. Foster. 2001a. The toxicity of styrene to
2 the nasal epithelium of mice and rats: studies on the mode of action and relevance to humans.
3 Chem. Biol. Interact. 137: 185-202.
- 4 Green, T., A. Toghil, and J.R. Foster. 2001b. The role of cytochromes P-450 in styrene induced
5 pulmonary toxicity and carcinogenicity. Toxicology 169: 107-117.
- 6 Greim, H. 2003. Mechanistic and toxicokinetic data reducing uncertainty in risk assessment. Toxicol Lett.
7 138: 1-8.
- 8 Hahn, A., H. Michalak, A. Engler, K. Preußner, G. Heinemeyer, and U. Gundert-Remy. 2000. Ärztliche
9 Mitteilungen bei Vergiftungen nach §16e Chemikaliengesetz. Bericht der "Zentralen
10 Erfassungsstelle für Vergiftungen, gefährliche Stoffe und Zubereitungen, Umweltmedizin" für das
11 Jahr 1999. Bundesinstitut für gesundheitlichen Verbraucherschutz und Veterinärmedizin, Berlin,
12 Germany.
- 13 Hake, C.L., R.D. Stewart, A. Wu, S. Graff, H.V. Forster, W.H. Keeler, A.J. Lebrun, P.E. Newton, and R.J.
14 Soto. 1983. Styrene - Development of a Biologic Standard for the Industrial Worker by Breath
15 Analysis. NIOSH-MCOW-ENVM-STY-77-2. Medical College of Wisconsin, Milwaukee. Cited
16 in NIOSH (1983).
- 17 Hayes, J.P., L. Lambourn, J.A. Hopkirk, S.R. Durham, and A.J. Taylor. 1991. Occupational asthma due to
18 styrene. Thorax 46: 396-397. Cited in Sherrington and Routledge (2001).
- 19 Hoshika, Y., T. Imamura, G. Muto, L.J. van Gemert, J.A. Don, and J.I. Walpot. 1993. International
20 comparison of odor threshold values of several odorants in Japan and in The Netherlands. Environ
21 Res. 61: 78-83.
- 22 IARC. 1994. Styrene. IARC Monogr Eval. Carcinog. Risks Hum. 60: 233-320.
- 23 IARC. 2002. Some Traditional Herbal Medicines, some Mycotoxins, Naphthalene and Styrene. Summary
24 of Data Reported and Evaluation. IARC Monographs on the Evaluation of Carcinogenic Risks to
25 Humans 82, p. 437-550. IARC (International Agency for Research on Cancer), WHO (World
26 Health Organization), Lyon, France.
- 27 Izmerov, N.F., I.V. Sanotsky, and K.K. Sidorov. 1982. Toxicometric parameters of industrial toxic
28 chemicals under single exposure. UNEP-IRPTC, Centre for International Projects, GKNT,
29 Moscow.
- 30 Jaeger, R.J., R.B. Conolly, and S.D. Murphy. 1974. Toxicity and biochemical changes in rats after
31 inhalation exposure to 1,1-dichloroethylene, bromobenzene, styrene, acrylonitrile or 2-
32 chlorobutadiene (Abstract for Thirteenth Annual Meeting of the Society of Toxicology,
33 Washington, DC, March 10-14, 1974.). Toxicol Appl. Pharmacol 29: 81.
- 34 Jarry, H., M. Metten, A.O. Gamer, and W. Wuttke. 2002. Effects of 5-day styrene inhalation on serum
35 prolactin and dopamine levels and on hypothalamic and striatal catecholamine concentrations in
36 male rats. Arch. Toxicol. 76: 657-663.
- 37 Jersey, G.C., M.F. Balmer, J.F. Quast, C.N. Park, D.J. Schuetz, J.E. Beyer, K.J. Olson, S.B. McCollister,
38 and L.W. Rampy. 1978. Two-year chronic inhalation toxicity and carcinogenicity study on

- 1 monomeric styrene in rats - final report. Dow Chemical USA, Midland, MI. Cited in Cohen et al.
2 (2002) and ATSDR (1992).
- 3 Jonsson, F. and G. Johanson. 2002. Physiologically based modeling of the inhalation kinetics of styrene in
4 humans using a bayesian population approach. *Toxicol Appl. Pharmacol* 179: 35-49.
- 5 Kankaanpää, J.T.J., E. Elovaara, K. Hemminki, and H. Vainio. 1980. The effect of maternally inhaled
6 styrene on embryonal and foetal development in mice and Chinese hamsters. *Acta pharmacol. et*
7 *toxicol.* 47: 127-129.
- 8 Katakura, Y., R. Kishi, T. Ikeda, and H. Miyake. 2001. Effects of prenatal styrene exposure on postnatal
9 development and brain serotonin and catecholamine levels in rats. *Environ Res.* 85: 41-47.
- 10 Khanna, V.K., R. Husain, J.P. Hanig, and P.K. Seth. 1991. Increased neurobehavioral toxicity of styrene
11 in protein-malnourished rats. *Neurotoxicol. Teratol.* 13: 153-159. Cited in Brown et al. (2000).
- 12 Kishi, R., B.Q. Chen, Y. Katakura, T. Ikeda, and H. Miyake. 1995. Effect of prenatal exposure to styrene
13 on the neurobehavioral development, activity, motor coordination, and learning behavior of rats.
14 *Neurotoxicol. Teratol.* 17: 121-130.
- 15 Kishi, R., Y. Katakura, T. Ikeda, B.Q. Chen, and H. Miyake. 1992. Neurochemical effects in rats
16 following gestational exposure to styrene. *Toxicol Lett.* 63: 141-146. Cited in Brown et al. (2000).
- 17 Lataye, R., P. Campo, B. Pouyatos, B. Cossec, V. Blachere, and G. Morel. 2003. Solvent ototoxicity in the
18 rat and guinea pig. *Neurotoxicol. Teratol.* 25: 39-50.
- 19 Leonardos, G., D. Kendall, and N. Barnard. 1969. Odor threshold determinations of 53 odorant chemicals.
20 *J. Air Pollut. Control Assoc.* 19: 91-95.
- 21 Linhart, I. 2001. Stereochemistry of styrene biotransformation. *Drug Metab Rev.* 33: 353-367.
- 22 Löf, A. and G. Johanson. 1993. Dose-dependent kinetics of inhaled styrene in man. *IARC Sci. Publ.* 89-
23 99.
- 24 Löf, A., E. Lundgren, E.-M. Nydahl, P.H. Näslund, and M. Byfält Nordqvist. 1984. The kinetics of
25 styrene in occupationally exposed volunteers. In: ICOST (International Conference on Organic
26 Solvent Toxicity). Abstract Book. pp. 11 - . Astrand, I. (ed.). Stockholm.
- 27 Loquet, G., P. Campo, and R. Lataye. 1999. Comparison of toluene-induced and styrene-induced hearing
28 losses. *Neurotoxicol. Teratol.* 21: 689-697.
- 29 Lundberg, I., M. Ekdahl, T. Kronevi, V. Lidums, and S. Lundberg. 1986. Relative hepatotoxicity of some
30 industrial solvents after intraperitoneal injection or inhalation exposure in rats. *Environ Res.* 40:
31 411-420.
- 32 MacFarlane, I.A., R. Wilkinson, and J.M. Harrington. 1984. Severe postural hypotension following home
33 canoe construction from polyester resins. *Postgrad. Med. J.* 60: 497-498. Cited from abstract in
34 MEDLINE (<http://gateway.nlm.nih.gov/gw/Cmd>).

- 1 Mahler, J.F., H.C. Price, Jr., R.W. O'Connor, R.F. Wilson, S.R. Eldridge, M.P. Moorman, and D.L.
2 Morgan. 1999. Characterization of hepatocellular resistance and susceptibility to styrene toxicity
3 in B6C3F1 mice. *Toxicol. Sci.* 48: 123-133.
- 4 Mäkitie, A.A., U. Pirvola, I. Pyykko, H. Sakakibara, V. Riihimaki, and J. Ylikoski. 2003. The ototoxic
5 interaction of styrene and noise. *Hear. Res.* 179: 9-20.
- 6 Mendrala, A.L., P.W. Langvardt, K.D. Nitschke, J.F. Quast, and R.J. Nolan. 1993. In vitro kinetics of
7 styrene and styrene oxide metabolism in rat, mouse, and human. *Arch. Toxicol.* 67: 18-27.
- 8 Morgan, D.L., J.F. Mahler, J.A. Dill, H.C. Price, Jr., R.W. O'Connor, and B. Adkins, Jr. 1993a. Styrene
9 inhalation toxicity studies in mice. II. Sex differences in susceptibility of B6C3F1 mice. *Fundam.*
10 *Appl. Toxicol.* 21: 317-325.
- 11 Morgan, D.L., J.F. Mahler, J.A. Dill, H.C. Price, Jr., R.W. O'Connor, and B. Adkins, Jr. 1993b. Styrene
12 inhalation toxicity studies in mice. III. Strain differences in susceptibility. *Fundam. Appl. Toxicol.*
13 21: 326-333.
- 14 Morgan, D.L., J.F. Mahler, M.P. Moorman, R.E. Wilson, H.C. Price, Jr., J.H. Richards, and R.W.
15 O'Connor. 1995. Comparison of styrene hepatotoxicity in B6C3F1 and Swiss mice. *Fundam.*
16 *Appl. Toxicol.* 27: 217-222.
- 17 Morgan, D.L., J.F. Mahler, R.W. O'Connor, H.C. Price, Jr., and B. Adkins, Jr. 1993c. Styrene inhalation
18 toxicity studies in mice. I. Hepatotoxicity in B6C3F1 mice. *Fundam. Appl. Toxicol.* 20: 325-335.
- 19 Morris, J.B. 2000. Uptake of styrene in the upper respiratory tract of the CD mouse and Sprague-Dawley
20 rat. *Toxicol. Sci.* 54: 222-228. Cited in IARC (2002).
- 21 Moscato, G., G. Biscaldi, D. Cottica, F. Pugliese, S. Candura, and F. Candura. 1987. Occupational asthma
22 due to styrene: two case reports. *J. Occup. Med.* 29: 957-960. Cited in Sherrington and Routledge
23 (2001).
- 24 Murray, F.J., J.A. John, M.F. Balmer, and B.A. Schwetz. 1978. Teratologic evaluation of styrene given to
25 rats and rabbits by inhalation or by gavage. *Toxicology* 11: 335-343. Cited in Brown (1991) and
26 WHO (1983).
- 27 NCI. 1979a. Bioassay of a solution of β -nitrostyrene and styrene for possible carcinogenicity. NCI-CG-
28 TR-170. National Cancer Institute (NCI), U.S. Department of Health, Education, and Welfare,
29 Public Health Service, National Institutes of Health, Bethesda, MD. Cited in Cohen et al. (2002).
- 30 NCI. 1979b. Bioassay of styrene for possible carcinogenicity. NCI-CG-TR-185. National Cancer Institute
31 (NCI), U.S. Department of Health, Education, and Welfare, Public Health Service, National
32 Institutes of Health, Bethesda, MD. Cited in Cohen et al. (2002).
- 33 Niklasson, M., R. Tham, B. Larsby, and B. Eriksson. 1993. Effects of toluene, styrene, trichloroethylene,
34 and trichloroethane on the vestibulo-and opto-oculo motor system in rats. *Neurotoxicol. Teratol.*
35 15: 327-334.
- 36 NIOSH. 1983. Criteria for a Recommended Standard - Occupational Exposure to Styrene. DHHS
37 (NIOSH) Report. 83-119. National Institute for Occupational Safety and Health (NIOSH),
38 Cincinnati, OH.

- 1 NIOSH. 1996. Styrene. IDLH documentation. U.S. Department of Health and Human Services, Public
2 Health Service, Center for Disease Control, National Institute for Occupational Safety and Health,
3 Division of Standards Development and Technology Transfer, Technical Information Branch,
4 Cincinnati, OH, <http://www.cdc.gov/niosh/100425.htm>.
- 5 NRC. 2001. Standing Operating Procedure for Developing Acute Exposure Guideline Levels for
6 Hazardous Chemicals. National Research Council (NRC), Committee on Toxicology. National
7 Academy of Science, National Academy Press, Washington, D.C.
- 8 Ödkvist, L.M., C. Edling, and H. Hellquist. 1985. Influence of vapours on the nasal mucosa among
9 industry workers. *Rhinology* 23: 121-127.
- 10 Ödkvist, L.M., B. Larsby, R. Tham, H. Ahlfeldt, B. Andersson, B. Eriksson, and S.R. Liedgren. 1982.
11 Vestibulo-oculomotor disturbances in humans exposed to styrene. *Acta Otolaryngol.* 94: 487-493.
- 12 OEHHA. 1999. Chronic toxicity summary. Styrene. Determination of acute reference exposure levels for
13 airborne toxicants. Office of Environmental Health Hazard Assessment (OEHHA), California
14 Environmental Protection Agency, State of California.
- 15 Oettel, H. and E. Schulze. 1962. Bericht der med.-biol. Forschungslaboratorien. BASF, Ludwigshafen,
16 Germany. Cited in DFG (1987).
- 17 Ohashi, Y., Y. Nakai, H. Ikeoka, H. Koshimo, J. Nakata, Y. Esaki, S. Horiguchi, and K. Teramoto. 1986.
18 Degeneration and regeneration of respiratory mucosa of rats after exposure to styrene. *J. Appl.*
19 *Toxicol* 6: 405-412.
- 20 Oltramare, M.E., E. Desbaumes, C. Imhoff, and W. Michiels. 1974. Toxicologie du styrene monomere
21 [Toxicology of Monomeric Styrene - Experimental and Clinical Studies on Man.]. Editions
22 Medicine et Hygienique. Geneva, Switzerland. Cited in NIOSH (1983) and WHO (1983).
- 23 OSHA. 2003. Letter (January 30, 1996): Styrene Permissible Exposure Level. Voluntary Compliance
24 Program. <http://www.osha.gov/SLTC/styrene/styrene.html>.
- 25 Otteneder, M., U. Lutz, and W.K. Lutz. 2002. DNA adducts of styrene-7,8-oxide in target and non-target
26 organs for tumor induction in rat and mouse after repeated inhalation exposure to styrene. *Mutat.*
27 *Res.* 500: 111-116.
- 28 Parkki, M.G. 1978. The role of glutathione in the toxicity of styrene. *Scand. J. Work Environ Health* 4
29 *Suppl* 2: 53-59.
- 30 Pierce, C.H., C.E. Becker, T.N. Tozer, D.J. Owen, and Y. So. 1998. Modeling the acute neurotoxicity of
31 styrene. *J. Occup. Environ. Med.* 40: 230-240.
- 32 Ponomarkov, V. and L. Tomatis. 1978. Effects of long-term oral administration of styrene to mice and
33 rats. *Scand. J. Work Environ Health* 4 *Suppl* 2: 127-135. Cited in Brown et al. (2000) and Cohen
34 et al. (2002).
- 35 Ramsey, J.C. and M.E. Andersen. 1984. A physiologically based description of the inhalation
36 pharmacokinetics of styrene in rats and humans. *Toxicol. Appl. Pharmacol.* 73: 159-175.

- 1 Ramsey, J.C., J.D. Young, R.J. Karbowski, M.B. Chenoweth, L.P. McCarty, and W.H. Braun. 1980.
2 Pharmacokinetics of inhaled styrene in human volunteers. *Toxicol. Appl. Pharmacol.* 53: 54-63.
- 3 Ruth, J.H. 1986. Odor thresholds and irritation levels of several chemical substances: a review. *Am. Ind.*
4 *Hyg. Assoc. J.* 47: A142-A151.
- 5 Sarangapani, R., J.G. Teeguarden, G. Cruzan, H.J. Clewell, and M.E. Andersen. 2002. Physiologically
6 based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in
7 rodents and humans. *Inhal. Toxicol* 14: 789-834.
- 8 Schaller, K.H. and G. Triebig. 2000. Zweites Addendum zu Styrol. In: Deutsche Forschungsgemeinschaft
9 (DFG) (ed.): *Biologische Arbeitsstoff-Toleranzwerte (BAT-Werte) und Expositionsäquivalente*
10 *für krebserzeugende Arbeitsstoffe (EKA) - Arbeitsmedizinisch-toxikologische Begründungen*, 9.
11 *Lieferung p. 27-37.* Wiley-VCH, Weinheim, Germany.
- 12 Scott, D. and R.J. Preston. 1994. A re-evaluation of the cytogenetic effects of styrene. *Mutat. Res.* 318:
13 175-203.
- 14 Seeber, A., C. van Thriel, K. Haumann, E. Kiesswetter, M. Blaszkewicz, and K. Golka. 2002.
15 Psychological reactions related to chemosensory irritation. *Int. Arch Occup. Environ Health* 75:
16 314-325.
- 17 Sherrington, E.J. and P.A. Routledge. 2001. The toxicity of styrene monomer. *Adverse Drug React.*
18 *Toxicol. Rev.* 20: 9-35.
- 19 Shugaev, B.B. 1969. Concentrations of hydrocarbons in tissues as a measure of toxicity. *Arch. Environ.*
20 *Health* 18: 878-882.
- 21 Sjöborg, S., I. Dahlquist, S. Fregert, and L. Trulsson. 1982. Contact allergy to styrene with cross reaction to
22 vinyltoluene. *Contact Dermatitis* 8: 207-208.
- 23 Ska, B., A. Vyskocil, R.G. Tardif, G. Carrier, R. Thuot, K. Muray, and C. Viau. 2003. Effects of peak
24 concentrations on the neurotoxicity of styrene in volunteers. *Hum. Exp. Toxicol.* 22: 407-415.
- 25 Spencer, H.C., D.D. Irish, E.M. Adams, and et al. 1942. The response of laboratory animal to monomeric
26 styrene. *J. Ind. Hyg. Toxicol.* 24: 295-301.
- 27 Srivastava, S., S.P. Srivastava, and P.K. Seth. 1990. Embryo/fetotoxicity of styrene in rats. *J. Environ.*
28 *Biol.* 11: 73-77. Cited in Brown et al. (2000).
- 29 Stewart, R.D., H.C. Dodd, E.D. Baretta, and A.W. Schaffer. 1968. Human exposure to styrene vapor.
30 *Arch Environ Health* 16: 656-662.
- 31 Sumner, S.C., R.C. Cattley, B. Asgharian, D.B. Janszen, and T.R. Fennell. 1997. Evaluation of the
32 metabolism and hepatotoxicity of styrene in F344 rats, B6C3F1 mice, and CD-1 mice following
33 single and repeated inhalation exposures. *Chem. Biol. Interact.* 106: 47-65.
- 34 Sumner, S.C., G. Cruzan, G. Johanson, B.I. Ghanayem, and T.R. Fennell. 2001. Styrene metabolism in
35 rats, mice, and humans. *CIIT Activities* 21: 1-8.

- 1 Ten Berge, W.F., A. Zwart, and L.M. Appelman. 1986. Concentration-time mortality response
2 relationship of irritant and systemically acting vapours and gases. *J. Haz. Mat.* 13: 301-309.
- 3 Tham, R., B. Larsby, B. Eriksson, I. Bunnfors, L.M. Ödkvist, and C. Liedgren. 1982.
4 Electronystagmographic findings in rats exposed to styrene or toluene. *Acta Otolaryngol.* 93: 107-
5 112. Cited from abstract in MEDLINE (<http://gateway.nlm.nih.gov/gw/Cmd>) and from Ödkvist et
6 al. 1982.
- 7 Tornero-Velez, R. and S.M. Rappaport. 2001. Physiological modeling of the relative contributions of
8 styrene-7,8-oxide derived from direct inhalation and from styrene metabolism to the systemic
9 dose in humans. *Toxicol Sci.* 64: 151-161. Cited from abstract in MEDLINE
10 (<http://gateway.nlm.nih.gov/gw/Cmd>).
- 11 Triebig, G., S. Lehl, D. Weltle, K.H. Schaller, and H. Valentin. 1989. Clinical and neurobehavioural
12 study of the acute and chronic neurotoxicity of styrene. *Br. J. Ind. Med.* 46: 799-804. Cited from
13 abstract in MEDLINE (<http://gateway.nlm.nih.gov/gw/Cmd>).
- 14 Truchon, G., C. Ostiguy, D. Drolet, D. Mergler, D. Campagna, S. Bélanger, F. Larribe, and G. Huel. 1992.
15 Surveillance des effets neurotoxiques de l'exposition au styrène en milieu de travail. I. Évaluation
16 environnementale et surveillance biologique de l'exposition. *Travail et Santé* 8: S11-S14. Cited in
17 IARC (2002).
- 18 US EPA. 1998. IRIS Substance file - Styrene, CASRN 100-42-5. U.S. Environmental Protection Agency,
19 Washington, D.C., <http://www.epa.gov/iris/subst/0104.htm>.
- 20 US EPA. 2003. Technology Transfer Network Air Toxics Website. Styrene. Air Toxics Website. U.S.
21 Environmental Protection Agency, Washington, DC.
22 <http://www.epa.gov/ttn/atw/htlhef/styrene.htm>.
- 23 Van Doorn, R., M.W. Ruijten, and T. van Harreveld. 2002. Guidance for the Development of a Level of
24 Odor Annoyance in Chemical Emergency Response. Version 2.1, August, 29., 2002. Presented at
25 the NAC/AEGL-meeting September 2002, Washington DC.
- 26 Vodicka, P., M. Koskinen, M. Arand, F. Oesch, and K. Hemminki. 2002. Spectrum of styrene-induced
27 DNA adducts: the relationship to other biomarkers and prospects in human biomonitoring. *Mutat.*
28 *Res.* 511: 239-254.
- 29 Vyskocil, A., B. Ska, R.G. Tardif, G. Carrier, R. Thuot, and C. Viau. 2002a. Neurotoxic effects of peak
30 exposure to styrene in volunteers. 40th Congress of Eurotox, Budapest, Hungary .
- 31 Vyskocil, A., R.G. Tardif, C. Viau, G. Carrier, R. Thuot, B. Ska, A. Rossner, J.-P. Farant, and A. Turcot.
32 2002b. Effets des pics de concentration sur la neurotoxicité du styrène dans l'industrie de
33 plastique renforcé de fibre de verre - Phase I. R-309. Institut de recherche Robert-sauvé en santé et
34 en sécurité du travail, Montreal, Canada. www.irsst.qc.ca.
- 35 Weast, R.C. 1973. Handbook of chemistry and physics. 54th ed. CRC Press, Cleveland, Ohio.
- 36 WHO. 1983. Styrene. Environmental Health Criteria (EHC) 26. International Programme on Chemical
37 Safety (IPCS); World Health Organization, Geneva, Switzerland.

- 1 WHO. 2000. Air Quality Guidelines for Europe; second Edition. WHO Regional Publications, European
2 Series. 91. WHO (World Health Organization) Regional Office for Europe, Copenhagen,
3 Denmark.
- 4 Wigaeus, E., A. Lof, R. Bjurström, and M.B. Nordqvist. 1983. Exposure to styrene. Uptake, distribution,
5 metabolism and elimination in man. *Scand. J. Work Environ Health* 9: 479-488.
- 6 Wigaeus, E., A. Lof, and M.B. Nordqvist. 1984. Uptake, distribution, metabolism, and elimination of
7 styrene in man. A comparison between single exposure and co-exposure with acetone. *Br. J. Ind.*
8 *Med.* 41: 539-546.
- 9 Withey, J.R. and P.G. Collins. 1979. The distribution and pharmacokinetics of styrene monomer in rats by
10 the pulmonary route. *J. Environ Pathol. Toxicol* 2: 1329-1342.
- 11 Wolf, J.R., V.K. Rowe, D.D. McCollister, R.L. Hollingsworth, and F. Oyen. 1956. Toxicological studies
12 of certain alkylated benzenes and benzene. Experiments on laboratory animals. *Arch. Ind. Health*
13 14: 387-398.
14
15

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8

APPENDIX A: DERIVATION OF AEGL VALUES

1
2**Derivation of AEGL-1**

Key study:	Seeber et al. 2002
Toxicity endpoint:	NOAEL for slight irritation: 20 ppm
Scaling:	None
Uncertainty/ modifying factors	None
Calculations	The 20 ppm concentration is used for all exposure durations.
<u>10-minute AEGL-1</u>	20 ppm (85 mg/m ³)
<u>30-minute AEGL-1</u>	20 ppm (85 mg/m ³)
<u>1-hour AEGL-1</u>	20 ppm (85 mg/m ³)
<u>4-hour AEGL-1</u>	20 ppm (85 mg/m ³)
<u>8-hour AEGL-1</u>	20 ppm (85 mg/m ³)

3
4

1
2**Derivation of AEGL-2**

Key study:	Gamberale and Hultengren 1974; Stewart et al. 1968
Toxicity endpoint:	CNS effects (impairment of reaction time, difficulties in balance performance test, decrement in coordination test, nausea, feeling of inebriation) in humans exposed to 350 ppm for 30 minutes or 376 ppm for 1 hour.
Uncertainty/ modifying factors	3 for intraspecies variability
Scaling:	$C^3 \times t = k$ for extrapolation to shorter time points $k = 376^3 \text{ ppm}^3 \times 1 \text{ h} = 5.31574 \times 10^7 \text{ ppm}^3 \text{ h}$ Applying the uncertainty factor of 3 results in a concentration at which toxicokinetic data indicate that the blood level of styrene does not or only very slightly increase after 1 hour. Therefore, 1-hour AEGL-2 = 4-hour AEGL-2 = 8-hour AEGL-2.

Calculations

<u>10-minute AEGL-2</u>	$C^3 \times 0.167 \text{ h} = 5.31574 \times 10^7 \text{ ppm}^3 \text{ h}$ $C = 683 \text{ ppm}$ 10-min AEGL-2 = $683 \text{ ppm}/3 = 230 \text{ ppm}$ (980 mg/m ³)
<u>30-minute AEGL-2</u>	$C^3 \times 0.5 \text{ h} = 5.31574 \times 10^7 \text{ ppm}^3 \text{ h}$ $C = 473 \text{ ppm}$ 30-min AEGL-2 = $473 \text{ ppm}/3 = 160 \text{ ppm}$ (680 mg/m ³)
<u>1-hour AEGL-2</u>	$C = 376 \text{ ppm}$ 1-hour AEGL-2 = $376 \text{ ppm}/3 = 130 \text{ ppm}$ (550 mg/m ³)
<u>4-hour AEGL-2</u>	4-hour AEGL-2 = 1-hour AEGL-2 4-hour AEGL-2 = 130 ppm (550 mg/m ³)
<u>8-hour AEGL-2</u>	8-hour AEGL-2 = 1-hour AEGL-2 8-hour AEGL-2 = 130 ppm (550 mg/m ³)

3

1
2**Derivation of AEGL-3**

Key study:	BASF 1979b
Toxicity endpoint:	BMDL05 = 3400 ppm for female rats, 4-hour exposure, acute toxicity study
Scaling:	$C^{1.2} \times t = k$ for extrapolation to all time points $k = 3400^{1.2} \text{ ppm}^{1.2} \times 4 \text{ h} = 6.91568 \times 10^4 \text{ ppm}^{1.2} \text{ h}$
Uncertainty/ modifying factors	Combined uncertainty factor of 10 3 for interspecies variability 3 for intraspecies variability

Calculations

<u>10-minute AEGL-3</u>	$C^{1.2} \times 0.167 \text{ h} = 6.91568 \times 10^4 \text{ ppm}^{1.2} \text{ h}$ $C = 48045 \text{ ppm}$ 10-min AEGL-3 = 48045 ppm/10 = 4800 ppm (20450 mg/m ³)
<u>30-minute AEGL-3</u>	$C^{1.2} \times 0.5 \text{ h} = 6.91568 \times 10^4 \text{ ppm}^{1.2} \text{ h}$ $C = 19233 \text{ ppm}$ 30-min AEGL-3 = 19233 ppm/10 = 1900 ppm (8090 mg/m ³)
<u>1-hour AEGL-3</u>	$C^{1.2} \times 1 \text{ h} = 6.91568 \times 10^4 \text{ ppm}^{1.2} \text{ h}$ $C = 10794 \text{ ppm}$ 1-hour AEGL-3 = 10794 ppm/10 = 1100 ppm (4690 mg/m ³)
<u>4-hour AEGL-3</u>	$C^{1.2} \times 4 \text{ h} = 6.91568 \times 10^4 \text{ ppm}^{1.2} \text{ h}$ $C = 3400 \text{ ppm}$ 4-hour AEGL-3 = 3400 ppm/10 = 340 ppm (1450 mg/m ³)
<u>8-hour AEGL-3</u>	$C^{1.2} \times 8 \text{ h} = 6.91568 \times 10^4 \text{ ppm}^{1.2} \text{ h}$ $C = 1908 \text{ ppm}$ 8-hour AEGL-3 = 1908 ppm/10 = 190 ppm (810 mg/m ³)

3

1
2
3
4
5
6
7
8
9
10

**APPENDIX B:
DERIVATION OF EXPONENTIAL FUNCTION FOR TEMPORAL SCALING**

1

2

Concentration-Time Mortality Response Relationship for Rats

3

Data source: BASF 1979b; Bonnet et al. 1982a

4

Time (min)	Conc. (ppm)	lg Time	lg Conc.
240	6410	2.3802	3.8069
360	4618	2.5563	3.66445

5


6

n = 1.2

7

k = 1.224 x 10⁷

8

Best Fit Concentration x Time Curve

9

1
2
3
4
5
6
7
8

**APPENDIX C:
BENCHMARK CALCULATIONS FOR STYRENE**

1 **Benchmark calculations on styrene using BMDS Version 1.3.2 (US-EPA)**

2 Calculations are based on lethality data for rats (BASF 1979b) and were performed with data
3 for male and female rats separately and with the combined data set.

4 Overview of different calculations; best fit for each data set indicated gray. All values
5 presented in ppm.

Sex	Model	BMD ₀₅	BMDL ₀₅	BMD ₀₁	LC ₅₀	Remark
Male	Weibull	4895	4121	4026	6688	
	Gamma	4250	3832	3513	6455	
	Logprobit	4884	4213	4344	6477	LC ₅₀ (BASF): 6480
Female	Logprobit	4221	3409	3571	6317	LC ₅₀ (BASF): 6310
	Gamma	4153	3273	3417	6366	
	Weibull	3769	2817	2673	6525	
Male and female	Weibull	4269	3671	3244	6621	
	Gamma	4222	3863	3490	6411	
	Logprobit	4551	4036	3950	6405	LC ₅₀ (BASF): 6410

6

7 **Calculation of BMDL₀₅ for female rats**

8

9 Probit Model \$Revision: 2.1 \$ \$Date: 2000/02/26 03:38:53 \$

10 Input Data File: C:\BMDS\STYRENE-LET-BASF.(d)

11 Gnuplot Plotting File: C:\BMDS\STYRENE-LET-BASF.plt

12 Sat Aug 09 14:52:49 2003

13

14 BMDS MODEL RUN

15

16 The form of the probability function is:

17 $P[\text{response}] = \text{Background} + (1 - \text{Background}) * \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Log}(\text{Dose})),$

1 where CumNorm(.) is the cumulative normal distribution function.
 2 Dependent variable = Let_femal
 3 Independent variable = ppm
 4 Background parameter is set to zero
 5 Slope parameter is restricted as slope ≥ 1
 6 Total number of observations = 7
 7 Total number of records with missing values = 0
 8 Maximum number of iterations = 250
 9 Relative Function Convergence has been set to: 1e-008
 10 Parameter Convergence has been set to: 1e-008
 11 User has chosen the log transformed model
 12 AIC: 68.4993

13

14 Goodness of Fit

15

Scaled

16

Dose	Est._Prob.	Expected	Observed	Size	Residual
------	------------	----------	----------	------	----------

17

18

2983.0000 0.0011 0.011 0 10 -0.1051

19

3766.0000 0.0174 0.174 0 10 -0.4212

20

4814.0000 0.1339 1.339 1 10 -0.3145

21

5911.0000 0.3933 3.933 6 10 1.338

22

6621.0000 0.5761 5.761 6 10 0.1531

23

7218.0000 0.7068 7.068 5 10 -1.437

24

8407.0000 0.8782 17.564 18 20 0.2979

25

Chi-square = 4.25 DF = 5 P-value = 0.5134

26

1 **Benchmark Dose Computation**


2 Specified effect = 0.05

3 Risk Type = Extra risk

4 Confidence level = 0.95

5 BMD = 4220.71

6 **BMDL = 3408.98**



7 14:52 08/09 2003

8

9

10

11

12

13

14

1
2
3
4
5

**APPENDIX D:
DERIVATION SUMMARY FOR STYRENE AEGLS**

**ACUTE EXPOSURE GUIDELINE LEVELS
FOR STYRENE**

DERIVATION SUMMARY

AEGL-1 VALUES				
10 minutes	30 minutes	1 hour	4 hours	8 hours
20 ppm	20 ppm	20 ppm	20 ppm	20 ppm
Key References: Seeber, A., C. van Thriel, K. Haumann, E. Kiesswetter, M. Blaszkewicz, and K. Golka. 2002. Psychological reactions related to chemosensory irritation. Int. Arch Occup. Environ Health 75: 314-325.				
Test Species/Strain/Number: 16 or 24 human subjects; 4 subjects/group				
Exposure Route/Concentrations/Durations: : Inhalation 0.5 ppm (4 hours), 20 ppm (3 hours), 40 ppm (30 minutes, interim peak exposures during exposure to 0.5 ppm)				
Effects: Increase of ratings for odor and annoyance, but only marginally for irritation. Effects sizes comparing ratings during exposure to 20 ppm and during pre-exposure higher for odor, annoyance, and irritation, and also higher compared to "clean air only", however, verbally rated as "hardly at all".				
Endpoint/Concentration/Rationale: NOAEL for slight irritation/subjective discomfort at 20 ppm				
Uncertainty Factors/Rationale: Interspecies: 1, test subjects were humans Intraspecies: 1, intensity of irritation is not expected to vary greatly among the general population.				
Modifying factor: NA				
Animal to Human Dosimetric Adjustment: NA				
Time Scaling: Not applied, complaints about discomfort were reported not to increase during several hours of exposure.				
Confidence and Support for AEGL values: Values are based on data from well-described controlled human study and are supported by data from other controlled human studies.				

5

1

AEGL-2 VALUES				
10 minutes	30 minutes	1 hour	4 hours	8 hours
230 ppm	160 ppm	130 ppm	130 ppm	130 ppm
<p>Key References: Stewart, R.D., H.C. Dodd, E.D. Baretta, and A.W. Schaffer. 1968. Human exposure to styrene vapor. Arch Environ Health 16: 656-662. Gamberale, F. and M. Hultengren. 1974. Exposure to styrene. II. Psychological functions. Work Environ Health 11: 86-93.</p>				
Test Species/Strain/Number:		1 - 5 human subjects/dose (Stewart et al. 1968) 12 human subjects/dose (Gamberale and Hultengren 1974)		
<p>Exposure Route/Concentrations/Durations: Inhalation 51 ppm (1 h), 99 ppm (2 x 3.5 h), 117 ppm (2 h), 216 ppm (1 h), 376 ppm (1 h) (Stewart et al. 1968) 50 ppm, 150 ppm, 250 ppm, 350 ppm (30 minutes) (Gamberale and Hultengren 1974)</p>				
<p>Effects: 376 ppm: difficulties in balance performance tests, decrement in manual dexterity tests, nausea, inebriation, headaches (Stewart et al. 1968); 250 ppm: no effect; 350 ppm: increase in simple and choice reaction time (Gamberale and Hultengren 1974).</p>				
Endpoint/Concentration/Rationale: NOAEL for CNS depression impairing ability to escape: 376 ppm (1 hour)				
<p>Uncertainty Factors/Rationale: Interspecies: 1, test subjects were humans Intraspecies: 3, CNS effects not expected to vary greatly within the general population.</p>				
Modifying factor: NA				
Animal to Human Dosimetric Adjustment: NA				
<p>Time Scaling: Extrapolation was made to the relevant AEGL time points using the relationship $C^n \times t = k$ with a default value of $n = 3$ for extrapolation to shorter time periods. Toxicokinetic studies with humans exposed to styrene concentrations at 70 – 200 ppm show that most of the increase of the styrene concentration in blood is seen during the first 30 minutes of exposure and that there is no or very little increase at 1 – 3 hours at these concentrations. Therefore, no additional extrapolation is necessary and the AEGL-2 of 130 ppm derived for 1 hour is applied to longer periods of time.</p>				
Confidence and Support for AEGL values: Values are derived from controlled human studies reported in sufficient detail, supporting studies available addressing irritation, CNS-effects, and toxicokinetics.				

2

1

AEGL-3 VALUES				
10 minutes	30 minutes	1 hour	4 hours	8 hours
4800 ppm	1900 ppm	1100 ppm	340 ppm	190 ppm
Key References: BASF. 10-12-1979b. Bericht über die Bestimmung der akuten Inhalationstoxizität LC ₅₀ von Styrol als Dampf bei 4stündiger Exposition an Sprague-Dawley-Ratten. Unveröffentlichte Untersuchung. [Report on the determination of the acute inhalation toxicity LC ₅₀ of styrene as vapor at a 4-hour exposure on Sprague-Dawley rats. Unpublished study.] BASF AG, Ludwigshafen, Germany. [In German].				
Test Species/Strain/Number: Rats/ Sprague-Dawley/ Groups of 10 (20) males (m) and 10 (20) females (f)				
Exposure Route/Concentrations/Durations: Inhalation 2983, 3766, 4814, 5911, 6621, 7218, 8407 ppm, 4 hours				
Effects: 18/20 f, 20/20 m, 38/40 m + f died 5/10 f, 8/10 m, 13/20 m + f died 6/10 f, 3/10 m, 9/20 m + f died 6/10 f, 1/10 m, 7/20 m + f died 1/10 f, 2/10 m, 3/20 m + f died 0/10 f, 0/10 m, 0/20 m + f died 0/10 f, 0/10 m, 0/20 m + f died				
Endpoint/Concentration/Rationale: Death (due to CNS depression and additionally to pulmonary lesions at concentrations causing severe to lethal CNS-effects). Benchmark calculation of BMDL ₀₅ for female rats: 3400 ppm				
Uncertainty Factors/Rationale: Interspecies: 3; no gross interspecies differences expected for substances with acute CNS-depression Intraspecies: 3; CNS effects not expected to vary greatly within the general population.				
Modifying factor: NA				
Animal to Human Dosimetric Adjustment: NA				
Time Scaling: Extrapolation was made to the relevant AEGL time points using the relationship $C^n \times t = k$ with a value of $n = 1.2$ which was derived from extrapolation of the LC ₅₀ in rats for 4- and 6 hours (BASF 1979b; Bonnet et al. 1982a).				
Confidence and Support for AEGL values: Well conducted study, described in sufficient detail, data supported from other acute toxicity studies with rats.				

2

1
2
3
4
5
6
7

**APPENDIX E:
DERIVATION OF THE LEVEL OF DISTINCT ODOR AWARENESS**

1 The level of distinct odor awareness (LOA) represents the concentration above which it is
2 predicted that more than half of the exposed population will experience at least a distinct odor intensity,
3 about 10% of the population will experience a strong odor intensity. The LOA should help chemical
4 emergency responders in assessing the public awareness of the exposure due to odor perception. The LOA
5 derivation follows the guidance given Van Doorn et al. (2002).

6 Van Doorn et al. (2002) present results of odor threshold determinations for styrene that were
7 a) measured by olfactometry methods considered compatible with a precursor of the NVN2820 and
8 EN13725 method or b) were measured by TNO in the Netherlands using a precursor of the NVN2820 and
9 EN 13725 methods, with a mean n-butanol threshold of 25 ppb. Results of both were converted to the
10 reference agreed in EN13725 of 400 ppb n-butanol by using a factor of $40:25 = 1.6$. Thereby, odor
11 thresholds of 0.049 ppm and 0.025 ppm, respectively, were obtained. Taking into account the threshold
12 value of 0.033 ppm obtained by the Japanese method (Hoshika et al. 1993), Van Doorn et al. (2002)
13 calculated an n-butanol corrected mean odor threshold of 0.0345 ppm for styrene.

14 Corrected odor detection threshold (OT_{50}) for styrene (Van Doorn et al. 2002): 0.0345 ppm

15 The concentration (C) leading to an odor intensity (I) of distinct odor awareness (I=3) is
16 derived using the Fechner function:

$$17 \quad I = k_w * \log (C / OT_{50}) + 0.5$$

18 For the Fechner coefficient, the default of $k_w = 2.33$ will be used due to the lack of chemical-
19 specific data:

$$20 \quad 3 = 2.33 * \log (C / 0.0345) + 0.5 \quad \text{and}$$

$$21 \quad C = 0.41 \text{ ppm}$$

22 The resulting concentration is multiplied by an empirical field correction factor. It takes into
23 account that in everyday life factors, such as sex, age, sleep, smoking, upper airway infections and allergy
24 as well as distraction, increase the odor detection threshold by a factor of 4. In addition, it takes into
25 account that odor perception is very fast (about 5 seconds) which leads to the perception of concentration
26 peaks. Based on the current knowledge, a factor of $1/3$ is applied to adjust for peak exposure. Adjustment
27 for distraction and peak exposure lead to a correction factor of $4 / 3 = 1.33$

$$28 \quad LOA = C * 1.33 = 0.41 \text{ ppm} * 1.33 = 0.54 \text{ ppm}$$

29 The LOA for styrene is set to 0.54 ppm.